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Abstract  
Hypoxic signaling is involved in homeostatic and developmental angiogenic and 
neurogenic proliferation and differentiation as well as modulating many disease 
processes that result in or from restricted blood flow.  A better understanding of this 
pathway and how other pathways interact with it is important for progression towards 
targeted therapeutics.   
Von Hippel Lindau (vhl-/-) zebrafish embryos demonstrated hypoxic phenotypes such 
as hyperventilation, polycythemia and an altered vascular network (van Rooijen et al., 
2009).  The fih-/- embryos showed no morphological phenotype and the adults are 
fully viable and fertile.  By combining the two lines it was possible to investigate the 
effect of a double knock out of these genes and the effect this had on downstream 
targets.  The first hypothesis to test, the first observation to make, was to assess the 
effect of the loss of fih on both wild type embryos and on vhl null embryos.  Given the 
roles of fih and vhl are independent of each other in regulating HIF function (FIH 
regulating HIF function, while VHL regulates HIF turnover), the hypothesis in this case 
would be that the loss of fih alone may not show dramatic phenotypes, however in the 
context of the loss of vhl it may alter or exacerbate phenotypes observed in the 
organisms where vhl was lost.  
This was proved to be correct when it came to assessment of global and morphological 
phenotypes.  The loss fih resulted in no significant changes compared with wild type 
embryos in initial observations; however the loss of both fih and vhl altered the known 
vhl-/- phenotype, which indicated a role for fih, under conditions of de-regulated 
hypoxia inducible factor (HIF), in enhancing hypoxic signaling.  Expression levels of Hif 
targets, phd3 and vegfa, were assessed and showed that these were elevated in the 
vhl-/- zebrafish line and further elevated in fih-/-;vhl-/- embryos, by in situ 
hybridisation.   Further analyses of the downstream effects of the loss of fih were 
assessed using microarray analysis and further validated using qRT-PCR.  Preliminary 
results suggested that on a transcriptional level, fih in isolation was not influencing 
expression and that fih functioned mainly through HIF. 
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Vascular branching was altered in the vhl-/- zebrafish line compared to wild-type 
siblings, and this was exacerbated in the fih-/-;vhl-/- embryos.  This correlated with 
increased vegf expression and a corresponding increase in endothelial cell numbers.   
The fih-/-;vhl-/- embryos exhibited decreased blood flow along the aorta, which ceased 
at 5dpf  despite continuation of the heart beat.  The fih-/- embryos exhibited an 
increase in blood velocity along the aorta with a corresponding increase in heart rate 
at the same stage.  Our data suggested that Fih had an essential role in the regulation 
of heart rate in the zebrafish and, in combination with vhl; it influenced formation and 
functionality of blood vessels by affecting the hypoxic signaling pathway. 
Also investigated were correlations between the zebrafish model of fih loss and those 
published in the mouse, and several connections and corroborations were made.  
However there was also scope, in the zebrafish, for the proposal of a potential 
mechanism of action which was not proposed in the mouse model.  Microarray 
analysis revealed that, specifically in the fih null embryos, two key genes in the renin 
angiotensin system were down regulated.  Since this is a mechanism by which fluid 
dynamics are regulated, and since there have been observations of altered blood flow 
dynamics in double mutants, further investigation as to the potential role of this 
homeostatic mechanism and its potential regulation by fih are needed to further 
investigate these findings.   
A second hypothesis that was proposed was that lead by a study by Lee et al, which 
proposed a model whereby the three proteins, FIH, VHL and HIF are required to bind 
together with VHL acting as a functional bridge in order to result in downstream 
effects (Lee et al., 2003).  In this case a loss of vhl would disrupt the hydroxylation of 
HIF-α by fih as well.  The hypothesis in this case would therefore be that the loss of fih 
as well, in an individual that had lost vhl function, would result in no alteration in the 
phenotypes observed.  This hypothesis was shown not to be supported by the data 
and further investigation into possible interactions between the proteins would need 
to be assessed in order to ascertain the discrepancy. 
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ESV End-Systolic Volume 
EXO Exonuclease 
FABP Fatty Acid Binding Protein  
FGA Factor I - Fibrinogen 
FII Factor II - Thrombin 
FIII Factor III - Tissue Factor 
FV Factor V - Proaccelerin, Labile Factor 
FVIIi Factor Viii - Proconvertin Stable Factor 
FVIII Factor VIII - Antihemophilic Factor A 
FIX Factor IX - Antihemophilic Factor B, Christmas Factor 
FX Factor X - Stuart-Prower Factor 
FXIIIal Factor Xiiia Like 
FIH Factor Inhibiting HIF 
FLI1 Friend-Leukaemia Integration 1 Transcription Factor 
FLIM Fluorescence Lifetime Imaging Microscopy 
FNG Fibrinogen I 
FLT1 Fms-Related Tyrosine Kinase 1 (VEGFR1) 
FLT4 Fms-Related Tyrosine Kinase 4 (VEGFR3) 
FRET Fluorescence Resonance Energy Transfer 
G6Pase Glucose 6-Phosphatase 
GALR Galactin Receptor 
GAPDH Glyceraldehydes-3-Phosphate Dehydrogenase 
GATA Transcription Factor Specific To ‘GATA’ Sequences 
GCGA Glucagon A 
GCGR Glucagon Receptor 
GCK Glucokinase 
GCSF Granulocyte Stimulating Factor 
GF Growth Factors 
GFP Green Fluorescent Protein 
GlUT1 Glucose Transporter 1 (Slc2a) 
GM-CSF Granulocyte Macrophage-Colony Stimulating Factor 
GO Gene Ontology 
GOF Gain Of Function 
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GOI Gene Of Interest 
GPIB Phosphoglucose Isomerase 
HAS Hif Ancillary Sequence 
HDAC Histone Deacetlylase 
HDL High Density Lipoprotein 
HER  Epidermal Growth Factor Receptor Family 
HES Hairy And Enhancer Of  Protein Family 
HEY Hes-Related Repressor Protein Family 
HFD High Fat Diet 
HIF Hypoxia Inducible Factor 
HK1 Hexokinase1 
HO-1/Hmox Heme-Oxygenase 
HPX/HK Hemopexin 
HRE Hypoxia Response Element 
ICAM-1 Intercellular Adhesion Molecule 1 
ICD Intracellular Domain 
IGF Insulin Growth Factor 
IGFBP Insulin Growth Factor Binding Protein 
IGFR Insulin Growth Factor Receptor 
iHOP Information Hyperlinked Over Proteins 
IκB Inhibitor Of Kappa B 
IKBKG Inhibitor Of Kappa Light Polypeptide Gene Enhancer In B-Cells, Kinase Gamma 
IL Interleukin 
INS Preproinsulin 
ISV Intersegmental Vessel 
ISWI Imitation Switch 
JMJC Jumonjic 
KDA Kila Dalton 
KDM Lysine (K)-Specific Demethylase 
KDR Kinase Insert Domain Receptor (VEGFR2) 
KKS Kallikrein-Kinin System 
KNGI Kininogen 1 
L-685458 (5S)-(T-Butixycarbon-Ylamino)-6-Phenyl-(4R)Hydroxy-(2R)Benzylhexanoyl)-L-Leu-L-
Pheamide 
LCM Laser Capture Micro-Dissection 
LDH Lactate Dehydrogenase 
LDL/VLDL Low Density Lipoprotein/Very Low Density Lipoprotein 
LOF Loss Of Function 
LPHN Latrophillin 
MCA Middle Cerebral Artery 
MCL1 Myeloid Cell Leukaemia Sequence 1 
MCP-1 Monocyte Chemoattractant Protein 1 
MEF Mouse Embryonic Fibroblast 
MMP Matrix Metalloproteinases 
MPH Methylphenidate/Ritalin 
NAD(P)H Nicotinamide Adenine Dinucleotide Phosphate 
NCARE Negative Calcium-Response Element 
NICD Notch Intracellular Domain 
NID Nidogen 
NFΚB Nuclear Factor Of Kappa B 
NFKBIA Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer Of B-Cells Inhibitor 
Alpha 
NLS Nuclear Localisation Sequence 
NOS Nitric-Oxide Synthase 
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NRARP Notch Regulated Ankyrin Repeat Domain Protein 
NRP Neuropillin 
NTC Non-Template Control 
ODDD Oxygen-Dependent Degradation Domain 
P300 300kd Co-Activator Protein 
PAI-1 Plasminogen Activator Inhibitor-1 
PAPASS 3’-Phosphoadenosine 5’-Phosphosulfate Synthase 
PARP Poly (ADP-Ribose) Polymerase Family 
PAS Per/Arnt/Sim 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
PDGF Platelet-Derived Growth Factor 
PEPCK Phosphoenolylyruvate Carboxykinase 
PER Period 
PFA Para-Formaldehyde 
PFKFB 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 
PGC-1A Peroxisome Proliferator Activated Receptor Gamma Co-Activator Gene 
PGK1 Phosphoglycerate Kinase 
PGAM1 Phosphoglycerate Mutase 1 
PGM1 Phosphoglucomutase 1 
PHD Prolyl Hydroxylase Domain 
PKMA Phosphofructokinase  
PKM2A Pyruvate Kinase 
PKCΖ Protein Kinase C Ζ 
PKM Pyruvate Kinase 
PLG Plasminogen 
PPARG Peroxisome Proliferator Activated Receptor 
PRCP Polylcarboxypeptidase/Angiotensinase 
PROC Protein C 
PTH1A Parathyroid Hormone 1a 
PYGL Phosphorylase - Liver Glycogen 
QRT-PCR Quantitative Real-Time Polymerase Chain Reaction 
RAAS Renin-Angiotensin Aldosterone System 
RBC Red Blood Cell 
RBPJ Recombination Signal Binding Protein For Immunoglobulin Kappa J 
RBPSUH Recombining Protein Suppressor Of Hairless 
RCC Renal Cell Carcinoma 
RUNX1 Runt Related Transcription Factor 
SAP Shrimp Alkaline Phosphatase 
SCLC Small Cell Lung Cancer 
SDF Stromal Cell Derived Factor 
SERPINDI Heparin Cofactor II 
SEI/SNF Switch/Sucrose Nonfermentable 
SHH Sonic Hedgehog 
SIM Single-Minded 
SIRNA Small Interfering RNA 
SM Smooth Muscle 
SMARC SWI/SNF, Matrix Associated, Actin Dependent Regulator Of Chromatin  
STAT Signal Transducer And Activator Of Transcription 
STIL Tal1 (Scl) Interrupting Locus 
TAD-N/TAD-C N- And C-Terminal Transactivtation Domain 
TAC Tachykinin 
TACR Tachykinin Receptor 
TAL T-Cell Acute Lymphocityic Leukaemia 
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TAM Tumour-Associated Macrophages 
TCA Total Coagulation Assay 
TF Tissue Factor 
TG Triglycerides 
TGF Transforming Growth Factor 
TIE Tyrosine Kinase Receptor 
TILLING Targeting Induced Local Lesions In Genome 
TNFΑ Tumour Necrosis Factor Α 
TNNT Troponin-T 
TPI1 Triosephosphate Isomerase 
UCP Uncoupling Protein 
UPAR Urokinase Plasminogen Activator Receptor 
VEGF Vascular Endothelial Growth Factor 
VEGFR Vascular Endothelial Growth Factor Receptor 
VHL Von Hippel Lindau 
VLP/VHLH VHL-Like Protein 
VPF Vascular Permeability Factor 
VSMC Vascular Smooth Muscle Cell 
VVO Vesicular-Vacuolar Organelles 
WT Wild Type 
XIAP X-Linked Inhibitor Of Apoptosis 
XSU(H) Suppressor Of Hairless 
ZGC Zebrafish Gene Collection 
Table 1:  Abbreviations 
 
Gene Homozygous wild type Heterozygous mutant Homozygous mutant 
fih +/+ +/- -/- 
Table 2:  Notation of Genotype 
 
Species Gene Protein 
Zebrafish Fih Fih 
Human FIH FIH 
Mouse Fih FIH 
Table 3:  Notation Gene and Protein abbreviations for different species 
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1 General Introduction 
1.1 Causes and Consequences of Hypoxia 
Decreases in environmental oxygen, or disruption of local metabolism by an imbalance 
between oxygen supply and consumption (Nangaku and Eckardt, 2007), can all cause 
hypoxia.  The latter can have a variety of reasons; hypoventilation, restriction of 
ventilatory systems, reduced alveolar surface size or diffusion barriers (Uenoyama et 
al., 2010).  In mammalian species, these changes in environmental oxygen are 
detected by the carotid body, which picks up acute changes in arterial blood oxygen 
levels and initiates systemic cardiac, vascular and respiratory responses to these 
changes (Prabhakar and Semenza, 2012).  The carotid bodies are bilateral sensory 
organs located at the bifurcation of the common carotid artery (Prabhakar, 2000).  
They are made up of glomus type 1 chemoreceptor cells which, upon challenge with 
hypoxia, release neurotransmitters that set the level of electrical activity in the 
afferent fibers of the carotid sinus nerve (Rocher et al., 1988).  The response to 
decreases in environmental oxygen is a highly regulated process that plays a role in 
normal physiology and initially leads to increased ventilation and cardiac output.  In 
addition to these metabolic physiological adaptations, hypoxia prompts cells to induce 
vascular growth and haematopoiesis in order to maximise the body’s access to 
available oxygen during hypoxia.  
Systemic hypoxia is defined as an inadequate oxygenation of blood and tissues when 
demand exceeds supply leading to the need for corrective measure (Fahling and 
Persson, 2012).  Distinct types of hypoxia can be defined by different manifestations of 
the process and different tissues in which it occurs.  Anemic hypoxia occurs in 
response to reductions in hemoglobin levels or when hemoglobin is abnormal and 
cannot bind oxygen.  This results in a reduction of oxygen-carrying capacity (Kertscho 
et al., 2012).  The mechanism for detecting the difference between normal arterial 
oxygen and lowered venous oxygen that occurs in these cases is unknown (Fahling and 
Persson, 2012).  Ischemic hypoxia can be the result of limited flow to a particular tissue 
or organ that means insufficient oxygen/blood supply is available, and this type of 
hypoxia can be associated with several disease processes, but also more simply with a 
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response to exercise (Edvinsson and Povlsen, 2011, Thijssen et al., 2011).  This can 
result in limited glucose delivery and accumulation of metabolites that can also then 
go on to affect the cellular response (Fahling and Persson, 2012).  Histotoxic hypoxia 
could indicate problems in peripheral gas exchange, meaning that cells can’t absorb or 
utilize oxygen and carbon monoxide or cyanide poisoning could each be causes for this 
(Choi et al., 2010).   
Molecular sensors to detect these changes in oxygen availability need to have low 
oxygen affinity and the method employed can be different under the different hypoxic 
conditions discussed (Bunn and Poyton, 1996).  These can be potassium channels, 
mitochondria, members of the NAD(P)H oxidase family and prolyl hydroxylases 
(Fahling and Persson, 2012).  On a cellular level hypoxia induces a systematic signaling 
cascade known as the hypoxic signaling pathway, leading to stabilisation of hypoxia 
inducible factor α (HIF-α) as the central transcription factor.  This results in the 
activation of transcription of genes, which initiate the body’s response to the reduced 
oxygen availability.  This signaling pathway, along with downstream effects such as 
angiogenesis, plays a role in many vascular diseases in humans, including ischemic 
heart disease, stroke and cancer.  For example, in cases such as in ischemic heart 
disease where a blockage has occurred in a vessel (Semenza, 2004), developing 
collateral vessels to remodel the blood vessels surrounding the blockage to re-route 
the supply can be seen to be beneficial.  However, if HIF-α levels are allowed to 
accumulate, inappropriately in the heart, this can lead to these responses occurring 
aberrantly, which can lead to defective cardiac homeostasis and cardiomyopathy 
(Holscher et al., 2012). 
Several studies have shown that vascular response can be enhanced by an increase in 
vascular endothelial growth factor (VEGF) mRNA expression, a hypoxic signaling target, 
with increased hypoxia inducible factor 1α (HIF-1) activity (Sung et al., 2005, Alidoosti 
et al., 2011, Ong and Hausenloy, 2012).  To name a few examples, it has also been 
shown that HIF-1 was accumulated following renal ischemia and also in reperfusion 
in human proximal tubule cells after hypoxia/reperfusion (H/R), in rat kidneys after 
ischemia/reperfusion (I/R) and in human biopsies after transplants.   This induction of 
HIF-1α expression was reported to be crucial for proxial tubule epithelial cell survival 
and recovery (Conde et al., 2012).  Other reports describe the various effects of 
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stabilisation of HIF-1α on angiogenesis in skeletal muscle (Pajusola et al., 2005) and 
hind limb ischemia (e.g.((Patel et al., 2005b)). 
 
 
Figure 1 Dominant active HIF results in increased branching angiogenesis in the 
hind limbs of rabbits 
Taken from (Li et al., 2011a) to demonstrate the stimulating effect of dominant active 
HIF-1α expression (Ad-HIF-1a-Trip) on angiogenesis in ischemic hind limbs evaluated by 
vascular casting.  A) Shows the representative vascular casts of the hind limbs of 
rabbits in Saline (mock), Ad-Null (empty adenovirus vector) or Ad-Hif-1a-Trip (without 
the full target sites of PHD and the specific target site of FIH-1) on day 28 following 
transfection, where the lines indicate the location of the femoral artery stump.  B) 
Shows the quantification of the normalized vascular area of the ischemic hind limbs, 
*P<0.05 vs. saline. Mean values and SEM are shown and each group had 3 rabbits.  
Reprinted with permission from Elsevier, also Lancet special credit with permission 
from Elsevier 
 
Findings from Li et al., 2011 (Figure 1) demonstrate that the animals transfected with 
functionally dominant active form HIF-1α, which possesses both stability and effective 
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transcriptional activity under normoxic conditions, showed the best re-vascularisation 
response to the induced hind limb ischemia (Li et al., 2011a).  This suggests that the 
induction of HIF signaling and the consequence of inducing downstream transcription 
of vascular inducing genes such as VEGF are involved in collateral vessel formation 
following ischemia.   
According to the British Heart Foundation figures from 2010 1.5 million people had a 
myocardial infarction, with over 900,000 of these being under the age of 75.  Similarly 
1.2 million people in the UK had a stroke, with around 600,000 of these being under 
the age of 75 (BHF, 2010).  The incidence of new cases of cancer was around 309,500 
in 2011 (excluding non-melanoma skin cancer) according to Cancer Research UK 
(CRUK, 2011).  Statistics such as these make it easy to visualise the impact that 
diseases of these kinds have on the human population worldwide and demonstrate 
how important a better understanding of the underlying mechanisms are to the way 
that we tackle them. 
In cancer HIF signaling is associated with several characteristics of solid tumour, 
allowing them to expand and become a threat.  These effects include; 1) expansion of 
cancer cells, which depends on enhanced glucose transport and glycolysis (the 
Warburg effect).  2) Tumours can’t grow larger than several mm3 without 
angiogenesis, and the degree of vascularisation has been inversely correlated with 
patient survival.  3) The probability of invasion, metastasis and death are positively 
correlated with the degree of intra-tumoural hypoxia, regulated by 
immature/defective microcirculation so that cells adjacent to neo-vessels can still be 
hypoxic.  4) Tumour hypoxia has been associated with resistance to chemotherapy, 
immuno-therapy and radiotherapy, and therefore associated with tumour survival 
(Zhong et al., 1999).   Several solid tumours have been shown to be angiogenesis 
dependent (Folkman, 1985, Sugimachi et al., 2002) and will co-opt the body’s own 
mechanisms of blood vessel development and re-modelling for its own gains at the 
expense of the patient, using HIF activation to induce expression of VEGF, stromal-cell 
derived factor (SDF1), Angiopoietin etc (Fahling and Persson, 2012, Isobe et al., 2012).   
Many studies have been performed in order to assess levels of HIF-1α protein as a 
predictive tool across several different carcinomas (Yohena et al., 2009, Semenza, 
2010, Zhong et al., 1999).  In a review in 2010, Semenza identified a largely positive 
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correlation between levels of HIF-1α with clinico-pathological factors and the 
subsequent influence on prognosis.  Semenza also compiled a list of xenograft models 
looking at HIF-1 and HIF-2 loss of function (LOF) and gain of function (GOF) models in 
various tissues have shown that LOF correlates with decreased growth of the 
xenograft, while GOF xenografts demonstrate the opposite effect (Semenza, 2010).  
Over-expression of HIF-1α in a human PCA (prostate cancer) cell line derived from 
bone metastasis was found in normoxic culture conditions (Zhong et al., 1999).  
Semenza suggested that in certain tumours (breast, cervical, endometrial), high levels 
of HIF might be used as an indicator for more aggressive therapy in patients (Semenza, 
2010).  
 
1.2 Overview of the Hypoxic Signaling Pathway 
The cellular response to hypoxia is a highly regulated process that plays a role in 
normal physiology and is driven by the HIF family of transcription.  These responses to 
hypoxia are conserved across metazoans from worms to humans, aiming to increase 
glycolysis to compensate for energy loss and improve oxygenation through 
erythropoiesis and angiogenesis (Fong and Takeda, 2008).  The human response to 
hypoxia is also initially to increase pulmonary ventilation, cardiac output and heart rate 
(Semenza, 2004).  
Active HIF is a heterodimer-complex of HIF-α and HIF-β, which together regulate the 
transcription of a large number of effector genes (Wenger et al., 2005, Manalo et al., 
2005).  HIF-1 was identified as a hypoxia-inducible nuclear factor that bound to the 3’ 
hypoxia-response enhancer element (HRE) of the Epo gene (Semenza and Wang, 1992, 
Marti, 2004, Semenza et al., 1991, Smith et al., 2008), which has been characterised as 
a haematopoietic factor (Krantz, 1991) that is produced in response to tissue hypoxia 
(Jelkmann, 1992).  Since then, three HIF-α isoforms have been identified in humans, 
HIF-1α, HIF-2α and the relatively uncharacterised HIF-3α (Heikkila et al., 2011), 
although the latter, in fact, may have an inhibitory role  in HIF signaling (Makino et al., 
2007).  For this section, these will be referred to collectively as HIF-α.   
In a normoxic environment there are several control mechanisms on the activation of 
the hypoxic signaling pathway (for a review (Masson and Ratcliffe, 2003) and see 
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Figure 2).  Prolyl hydroxylase domain containing proteins (PHDs) hydroxylate two 
specific proline residues on the HIF-α protein and this hydroxylation leads to Hypoxia-
Inducible Factor (HIF)-α recognition and ubiquitination by von Hippel Lindau protein 
(VHL) complex (VHL, elonginC, elonginB, cullin2, rbx1) and subsequent degradation by 
the proteasome.  Factor inhibiting HIF (FIH) hydroxylates HIF-α at a specific asparagine 
residue (Asn803 on HIF-1α), a residue within the binding site for HIF complex co-
activators in the nucleus, impairing the activity of the HIF-α protein. 
 
Figure 2 HIF signaling pathway in normoxia 
In normoxia HIF- levels are regulated by hydroxylation. PHDs hydroxylate specific 
residues inducing the recognition by an ubiquitination complex including VHL, targeting 
it for proteasomal degradation.  Simultaneously FIH hydroxylates a distinct residue in a 
key region necessary for the binding of co-activators, such as p300.    
 
In hypoxia the hydroxylation events that regulate HIF-α levels and activity in normoxia 
don’t occur.  This ensures the VHL complex is not triggered to and ubiqutinate HIF-α, 
allowing HIF-α to accumulate and translocate into the nucleus, where it binds with HIF-
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β, to form an active transcription complex, including p300 and CBP co-activators, see 
Figure 3.  
 
 
Figure 3 HIF signaling pathway in hypoxia 
In hypoxia the hydroxylase enzymes (PHDs and FIH) are inhibited, HIF- is not 
hydroxylated and the levels accumulate. It then translocates into the nucleus where it 
forms a transcriptional active complex with HIF- and co-activators p300 and CBP. This 
complex binds to HREs in the genome, activating transcription.  A negative feedback 
loop also exists where PHD2 & 3 are both known targets of HIF-activated transcription, 
once up-regulated they can then regulate levels of HIF-. 
 
Normal and or pathological activation of the HIF pathway results in a variety of effects, 
some examples have been illustrated in Figure 4. 
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Figure 4 Distinct phenotypes of increasing hypoxia and/or HIF-signaling are 
observed in the branch points of blood vessels, the expression of VEGF and by 
assessing the hemoatocrit.   
A) Increased branching angiogenesis in adult Tg(Fli1;eGFP) zebrafish (a GFP reporter 
line tagged to the friend-leukemia factor transcription factor, which labels the 
endothelium (Lawson and Weinstein, 2002b)), where the hypoxic group were exposed 
to 10% air saturation for 12 days.  Taken from Figure 1 of (Cao et al., 2008). B) Vegf 
mRNA isolated from lymphocytes taken from venous blood from Chuvash Polycythemia 
(CP) (see main text) patients as well as normal control participants was incubated at 
eight different levels of oxygen tension prior to RNA isolation.  The expression of Vegf 
at different oxygen tensions, from 0.1% (where Vegf mRNA is highest) to 20% (where 
Vegf mRNA is lowest) was compared against CP patients, who exhibit higher levels of 
Vegf mRNA compared to normal control patient samples at each of the oxygen 
tensions tested (Smith et al., 2006). C) Polycythemia (illustrated by an increase in 
hemoatocrit (HCT)) exhibited in R/R mice (Vhl mutation in mice that models Chuvash 
Polycythemia). Loss of 1 allele of Hif-2α but not Hif-1α resulted in HCT levels reverting 
to WT levels in R/R mice (Hickey et al., 2010).   
 
Some of these phenotypes have been shown to be phenotypes in HIF-2α gain of 
function (GOF) mutants and Chuvash Polycythemia (CP) models, which is a heritable 
autosomal-recessive disease caused by germline homozygosity for the 598C-T 
mutation in exon3 of von Hippel Lindau (VHL), which mutation causes inappropriate 
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activation of HIF signaling (Formenti et al., 2011, Hickey et al., 2007).  The common 
phenotypes observed in CP patients and HIF-2α GOF suggest a role for HIF-signaling in 
controlling these phenotypes (Formenti et al., 2011).  CP patients differ from those 
with VHL disease, as these patients are not predisposed to cancers (highly vascularised 
tumours and cysts including thrombosis, haemangioblastomas, pheochromocytomas 
and clear cell renal cell carcinoma (CCRCC)) (van Rooijen et al., 2009, Gordeuk et al., 
2004).   Instead, phenotypes of CP include increased hemoglobin and hematocrit 
levels, with patients also exhibiting elevated respiratory and pulmonary vascular 
regulation along with elevated responses to acute hypoxia.  Patients experience 
cerebral vascular events or peripheral thrombosis, which leads to premature mortality 
(van Rooijen et al., 2009, Gordeuk et al., 2004).   
 
1.3 Hypoxia-Inducible Factor (HIF) 
The HIF heterodimer along with cofactors (p300 and CBP) forms a complex that acts as 
a transcription factor, initiating expression of target genes, containing HREs (Wenger et 
al., 2005, Kaluz et al., 2008).  The human HIF-1 consensus sequence has been described 
by the DNA motif 5’-TACGTGCT’3’ (Varma and Cohen, 1997, Wang and Semenza, 1995) 
and many genes with these sequences in their enhancer regions have been shown to 
be involved in adaptation to the hypoxic environment, including those involved in 
pathways such as angiogenesis, haematopoiesis and the glycolytic pathway. 
Protein sequence homology was found between the Drosophila Melanogaster period 
(Per) single-minded (Sim) and the mammalian aryl hydrocarbon receptor (AHR) and 
aryl hydrocarbon receptor nuclear translocator (ARNT(=HIF-β)), which all contain a 
200-350aa sequence that constitutes the PER-ARNT-AHT-SIM (PAS) domain (Wang et 
al., 1995).  The PAS domain is present in both HIF-α and -β and is required for the 
accurate formation of the HIF protein heterodimer, as well as for DNA binding (Lee et 
al., 2004, Wang et al., 1995).  Active HIF is a heterodimer of HIF-α (of which there are 
three in humans) and HIF-β proteins (of which there are also three in humans) (Lee et 
al., 2004, Lisy and Peet, 2008).  The HIF-α proteins contain both an N- and C-terminal 
transactivtation domain (TAD-N and TAD-C), bridged by an inhibitory domain (ID) at 
residues 576-784 in HIF-1α, which is thought to be the interaction region for FIH (Lee 
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et al., 2004).  The TAD-N (residues 531-575) in this protein overlaps with the oxygen-
dependent degradation domain (ODDD).  The TAD-C (residues 786-826) interacts with 
co-activators 300kd co-activator protein (p300) and CREB binding protein (CBP) an 
action that is required for the function of HIF after the dimer forms in the nucleus (Lee 
et al., 2004, Lisy and Peet, 2008), see Figure 5 
HIF-α although constitutively expressed in cells, has a very short half-life (less than 
5mins) in normoxia and has been shown to be as little as 1 minute in re-oxygenated 
ferret lungs (Huang et al., 1996, Yu et al., 1998, Lisy and Peet, 2008).   The levels of HIF-
α in the cytoplasm are controlled by oxygen dependent regulatory elements within the 
pathway, and its stability is negatively regulated by hydroxylation by PHDs and FIH 
(Bruick and McKnight, 2001, Epstein et al., 2001, Jaakkola et al., 2001, Lisy and Peet, 
2008), see Figures 5 and 6.  It has been shown, using a hydroxylation specific antibody, 
that the proline residues 564 on HIF-1α and 531 on HIF-2α protein are the key residues 
irreversibly hydroxylated in normoxia and that this hydroxylation is diminished in 
hypoxia, regardless of the presence of VHL (Chan et al., 2002).  The hydroxylation 
events by the PHDs leads to the bringing together of a ubiquitin ligase complex 
containing VHL, which interacts with residues within the ODDD of the HIF-α protein, 
initiating ubiquitination and subsequent degradation in the proteasome.   
Other modifications, besides hydroxylation, of HIF have been identified as well 
although their relevance for hypoxic signaling is less clear.  Acetylation of lysine 
residues has also been identified on the HIF-1α protein, Lys532 and Lys674.  The 
acetylation at Lys532 can induce VHL-dependent HIF-α protein degradation, while 
acetylation at Lys674 is required for HIF-1α transcriptional activity (Geng et al., 2011).  
Phosphorylation events have also been described on the HIF-α protein through 
activation of p42/p44 mitogen-activated protein kinases (MAPK), which has been 
shown to promote transcriptional activity of HIF and is proposed to indicate a 
cooperation between hypoxic and growth factor signals (Richard et al., 1999).  
Subsequent studies have shown phosphorylation of Threonine-296 (Thr796) is involved 
in transactivation of the HIF-α protein (Gradin et al., 2002).  The phosphorylation at 
Thr796 has also been shown to interrupt the hydroxylation at Asn803 initiated by FIH, 
ensuring HIF-α activity by allowing the binding of co-activators in the nucleus 
(Lancaster et al., 2004).   
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Figure 5 Key residues on the HIF-α proteins are indicated in their roles and in 
their interaction with other proteins such as PHDs and FIH.   
The hydroxylation of two proline residues (P402 and P564 on HIF-1α, and P405 and P531 on 
HIF-2α) earmarks the protein for degradation.  The hydroxylation (OH) of an 
asparagine residue (N803 on HIF-1α and N847 on HIF-2α) blocks the transcriptional 
functions of the HIFα protein (Keith et al., 2012).  Acetylation (Ac) of Lys532 is involved in 
pVHL-dependent Hif-α regulation, whereas Ac of Lys674 is required for HIF 
transcriptional activity (Geng et al., 2011). The Lys regulation of HIF-2α has not been 
described on a residue level.  In the figure bHLH = basic helix loop helix, two 
transcriptional activation domains (TADs) at the NH(2) terminal and COOH terminals, 
both of which are important for the optimal transcriptional activity.  The TAD-N and 
ODDD or oxygen-dependent-degradation domain overlap.  Thr796 is phosphorylated (P) 
ensuring transactivation of the protein by preventing FIH hydroxylation at Asn803 
(Gradin et al., 2002, Lancaster et al., 2004).  Figure adapted from (Nangaku and 
Eckardt, 2007). 
 
The downstream effects of each of the HIF-α hydroxylation events described in Figure 
5 are described below (See Figure 6) in more detail. 
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Figure 6  There have been different outcomes, demonstrated by Lancaster et al, 
of different hydroxylation events of the HIF-α protein by either PHDs or FIH 
(Lancaster et al., 2004).   
PHD hydroxylation induces VHL mediated ubiquitination and subsequent proteasomal 
degradation, whereas, FIH hydroxylation blocks the binding of p300, a co-activator, 
and simply may blunt the proteins activity.  Abbreviations: hypoxia inducible factor 
(HIF), von hippel lindau (VHL), factor inhibiting HIF (FIH), iron (Fe), prolyl hydroxylation 
domain containing protein (PHD), nuclear co-activator (p300), proline hydroxylation 
(Pro-OH), asparagine hydroxylation (Asn-OH)  
 
The differential nature of HIF-α regulation by VHL and FIH in the homeostasis of the 
pathway means that the loss by inhibition or mutation of the regulators can have 
distinct downstream effects in normoxia.   The loss of VHL leads to the accumulation of 
HIF-α, aberrant signaling and an increase in HIF target gene expression such as VEGF, 
EPO and GLUT-1.  This is tempered by the presence of FIH, which will continue to 
impair HIF-α activity in the nucleus.  The loss of FIH will mean that HIF-α will be able to 
function, should any accumulate, however this will be attenuated by the presence of 
VHL instigating HIF-α breakdown.  The loss of both of these proteins in combination 
can cause a further amplification of the downstream effects of loss of either of the two 
proteins individually.  The various effects of the loss of each of these genes constitute 
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the subject of the current study in the zebrafish and will be described further in the 
remainder of the thesis.   
The different HIF isoforms have been shown to correlate with particular functions 
(Loboda et al., 2010), for example HIF-1α is a key regulator of neutrophil function and 
life span (Elks et al., 2011).  In mice this has also been shown, where HIF-1α has been 
shown to be predominant during mouse embryogenesis and HIF-2α (under 
physiological and stress conditions in adult mice) for Epo regulation in mice (Gruber et 
al., 2007).  In vascular development as well HIF-1α and HIF-2α have also been shown to 
play distinct roles, here HIF-1α regulates endothelial cell proliferation, migration and 
vascular sprouting, while HIF-2α is more responsible for controlling vascular 
morphogenesis, integrity and assembly.  HIF-1α has two zebrafish homologs Hif-1αa 
and Hif-1αb (Elks et al., 2011) and HIF-2α also has multiple zebrafish homologs Epas1a, 
Epas1b and possible ortholog Hif1al2 (Ensembl, 2012). 
HIF- protein stability and activity is regulated by PHD containing proteins and FIH, 
hydroxylating distinct residues on the HIF- protein, which then leads to VHL-
dependent ubiquitination, see Figure 5.  There appears to be quite some complexity in 
the precise regulation.  For instance, HIF-α stabilisation could also be achieved using 
either a constitutively active Akt (Protein Kinase B/PKB) or the introduction of v-Src or 
Ras V12 oncogenes, which resulted in the loss of Pro564 hydroxylation (Chan et al., 
2002).  In acute hypoxia MCF7 cells react by suppressing PHD2, which has been shown 
to have a smaller effect on inducing HIF-2α compared to HIF-1α.  Suppression of PHD1 
and PHD3, independently or in combination with other PHDs had more significant 
effects on HIF-2α than on HIF-1α (Appelhoff et al., 2004). 
The HIF-1β subunit on the other hand, is also known as an aryl hydrocarbon receptor 
nuclear translocators (ARNTs) and is constitutively present in the nucleus (Li et al., 
1996, Lee et al., 2004).  Cells lacking functional HIF-β have been used to assess and 
confirm the necessity of this protein in DNA-binding and transcriptional activation of 
HIF-complex (Wood et al., 1996).  This component of the HIF pathway will not be 
discussed in isolation in this thesis. 
Iyer et al showed that Hif-1α-/- mouse embryonic stem cells (ESCs) showed reduced 
levels of glucose transporters (GLUT) mRNAs, glycolytic enzymes and vascular 
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endothelial growth factor (VEGF), along with reduced cellular proliferation, which are 
known to be induced by hypoxia/HIF signaling, (Iyer et al., 1998).  Complete deficiency 
of Hif-1α in mouse embryos resulted in embryonic lethality by E11, which is the time at 
which Hif-1α is expressed, with the embryos demonstrating neural tube defects, 
cardiovascular malformations and marked cell death within the cephalic mesenchyme.  
Mice lacking Hif-2α have also been investigated and many of those that were born 
alive also developed vascular abnormalities including hemorrhages (Scortegagna et al., 
2003, Peng et al., 2000) and demonstrated congested blood in the liver (Tian et al., 
1998).  The deaths of Hif-2α-/- embryos was suggested to be due to circulatory failure, 
indicating a fundamental role for this protein in the control of cardiac output (Tian et 
al., 1998).   
In the zebrafish, little is known about in vivo HIF function, Elks et al describes the 
generation of a series of dominant active and negative constructs analogous to the 
zebrafish homologs Hif-1αa and Hif-1αb, by mutating the residues where the PHDs and 
FIH have been shown to bind, see Figure 5 (Elks et al., 2011).  Dominant-negative Hif-
1αa blocked the activation of the HIF pathway usually seen by treatment with the pan-
hydroxylase inhibitor DMOG as late as 56hpf (hours post fertilisation), as indicated by 
an increase in phd3 expression (a known Hif target) (Elks et al., 2011).  It was also 
shown that in the zebrafish dominant-negative Hif-1αb alone was sufficient to block 
DMOG regulated delay in resolution of neutrophilic resolution, while dominant-
negative Hif-1αa had no effect on inflammation (Elks et al., 2011).   
 
1.4 Von Hippel Lindau (VHL) 
In 1993, von Hippel Lindau was identified as the gene causing VHL disease; a dominant 
genetic disorder, which was first described in 1936 (Maher et al., 2011) and is 
associated with tumours in a variety of organs, including the kidneys (Maranchie et al., 
2002). The gene encodes a 30kDa protein (Latif et al., 1993) on chromosome 3p25.5 
and was cloned using a genetic linkage-based positional cloning approach (Seizinger et 
al., 1988, Gnarra et al., 1995).  The VHL gene product exists in two forms in humans, a 
larger p30 protein and a smaller p19 protein, the latter generated by internal 
translation initiation at the second methionine (Iliopoulos et al., 1998, Schoenfeld et 
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al., 1998).  Subsequently it was shown that VHL is a critical component in the HIF 
signaling pathway (Ohh et al., 2000, Cockman et al., 2006, Maxwell et al., 1999) and It 
has been shown that this interaction between VHL and HIF is iron dependent (Maxwell 
et al., 1999).   
VHL responds directly to the hydroxylation of HIF-α by PHDs by forming a protein 
complex with HIF, to target it for degradation.  Several studies have been done to 
assess the components of the complex (also known as the VBX complex) with VHL and 
elonginC (Kibel et al., 1995), along with elonginB (Kibel et al., 1995), cullin2 (cul2) 
(Pause et al., 1997) and ring-box 1 (rbx1) (Kamura et al., 1999), have been shown to be 
involved, with VHL acting as the substrate recognition component of the complex, see 
Figure 7 (Iwai et al., 1999, Koth et al., 2000, Kinoshita et al., 2007, van Rooijen et al., 
2011).   
 
 
Figure 7  A computational model of the ElonginB/C-Vhl-Hif complex 
demonstrates the interaction of the various proteins involved. 
Taken from (Domene and Illingworth, 2012) Permissions were granted from Publishers 
the Wiley Company for the republication of this figure 
 
VHL has been shown to move between the cytosol and the nucleus, with most of the 
protein concentrated in the cytosol (Kaelin 2002).  Although VHL’s function in HIF-
signaling is the best studied, a number of additional functions have been described, 
see Figure 8; for example in regulation of microtubules (Thoma et al., 2009, Thoma et 
al., 2010), cilia (Esteban et al., 2006) and extracellular matrix (ECM) deposition (Tang et 
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al., 2006, Lai et al., 2011).   It is likely that some of these functions also contribute to 
the tumour suppressor function of VHL. 
 
 
Figure 8  There are multiple HIF-α-dependent, as well as independent, functions 
of pVHL that could contribute to tumour suppression.    
Arrows (↘) indicate positive or activating effects and the symbol (˫) represents 
inhibitory effects. Abbreviations include ECM-extracellular matrix, EMT-epithelial to 
mesenchymal transition. Figure taken from (Frew and Krek, 2007) and reprinted with 
permission from Elsevier, also Lancet special credit with permission from Elsevier 
 
The function of the VBX complex is to ubiqutinate HIF-α and this process then targets it 
for proteasomal degradation upon cues from HIF-1α hydroxylation in normoxia 
(Figures 2 and 3).   VHL forms the substrate recognition part of this complex, with 
direct binding between VHL and HIF-1α within the complexes (Lai et al., 2011, Ohh et 
al., 2000, Tanimoto et al., 2000), see Figure 9.   In addition Li et al showed that VHL 
mediates an oxygen-dependent interaction between FIH and HIF-1α potentially 
explaining the unexpected inhibitory effects of moderately low oxygen concentrations 
of FIH hydroxylase activity towards HIF.  FIH has a high affinity for oxygen and would 
be expected to be inhibited only in near anoxia (Li et al., 2011b).   
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Figure 9  A schematic of the longest form of the Vhl protein has been 
highlighted in terms of its active domains.  Also highlighted are two points where 
mutations have been found in the zebrafish.   
Q71 and C79 stop indicate equivalent residues that have been mutated in the zebrafish 
lines vhlhu2117 (Q23X) and vhlhu2081 (C31X) that were identified following F1 N-ethyl-N-
nitrosurea (ENU)- induced mutagenesis in a Targeting induced local lesions in Genomes 
(TILLING) screen (van Rooijen et al., 2009). 
 
Heterozygous loss-of-function (LOF) Vhl mutations are relatively common in the 
human population, with about 1 in 36,000 individuals affected (Kaelin 2002) and a 
penetrance of 90% of patients by the age of 65 years (Lonser et al., 2003).  
Homozygous loss of Vhl is linked to a subset of human tumours, suggesting that the 
role of Vhl in tumourigenesis is tissue dependent (Kaelin, 2002) with cause of death in 
many patients being typically metastases from renal cell carcinoma (RCC) or symptoms 
related to central nervous system (CNS) haemangioblastomas (Lonser et al., 2003, 
Maranchie et al., 2002).  Importantly, sporadic kidney cancer is usually also the result 
of biallelic loss of VHL.  Levels of Hif-1α and Hif-2α have been shown to be elevated in 
RCCs and haemangioblastomas lacking functional VHL protein, but HIF-2α is thought to 
be critical for tumour formation (Raval et al., 2005).  Hif expression has been linked to 
the regulation of angiogenesis and erythropoiesis (Krieg et al., 2000), for instance, 
patients with Vhl LOF tumours can show responses to elevated levels of Epo that are 
produced in the serum and can result in polycythemia (Pastore et al., 2003).  Chuvash 
polycythemia patients, which are homozygous for a R200W missense mutation in VHL 
exhibit phenotypes, such as elevated Epo levels and elevated respiration rate that can 
be independent of tumour production, and are phenocopied in vhl-/- zebrafish 
embryos and VhlR/R-/- mice, which are homozygous for the ”Chuvasch allele” (van 
Rooijen et al., 2009, Hickey et al., 2010). 
Heterozygous Vhlh mice appear phenotypically normal; however vhlh knockout mice 
don’t survive, dying at E10.5-12.5.  The development of the null embryos appeared 
normal up to this time, at which point placental dysgenesis developed.  Surprisingly, 
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the placenta was found to demonstrate failed vasculogenesis with hemorrhagic 
lesions, followed by hemorrhage in the embryos causing necrosis and death of the 
embryos (Gnarra et al., 1997).   VEGF protein levels were shown to be high in the 
placental labyrinth trophoblasts of normal E10.5 embryos, while, contrary to 
predictions, it was greatly reduced in the same cells in the VHL-deficient placentas.  
Since VEGF family member null mice demonstrate similar phenotypes in impaired 
vasculogenesis as well as blood island development, along with embryonic lethality at 
around the same stage as was observed in the Vhlh mice, the decreased VEGF levels in 
these mice may play a contributory role in embryonic lethality (Gnarra et al., 1997).   
Several mutant zebrafish lines have been generated, each carrying a null mutation in 
vhl, see Figure 9.  The zebrafish provides an alternative model for studying the 
downstream effects of loss of vhl because, unlike the mouse models, homozygous null 
zebrafish embryos survive through embryogenesis and out to 8-11 days post 
fertilisation (dpf) (van Rooijen et al., 2009).  This survival is due to a combination of 
factors that distinguish the mouse and zebrafish models, namely the zebrafish are 
externally fertilised and are therefore not reliant on placentation/mother’s blood 
supply, they are small enough to survive a lack of circulation and they benefit from a 
certain level of maternal gene expression/rescue in the early stages of development.   
Furthermore, a second homolog of VHL named vhl-like is present, this gene is inactive 
towards HIF but may exert certain HIF independent functions of human VHL (FvE pers. 
Comm.).  The vhl null zebrafish line has been characterised (van Rooijen et al., 2010, 
van Rooijen et al., 2009) and demonstrates several hypoxic phenotypes such as 
polycythemia, increased circulation, hyperventilation and they exhibit a vascular 
phenotype (see Figure 10).  Zebrafish vhl-/- embryos exhibit elevated levels of vegf 
expression and hyper-branched vascular network, visualised using the Tg(fli1;eGFP) 
transgenic zebrafish line, which labels the endothelium throughout development 
(Lawson and Weinstein, 2002b), see Figure 10Error! Reference source not found.. 
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Figure 10 The vascular network of Tg(fli1;eGFP) labeled vhl-/- zebrafish and 
siblings demonstrates the hyperbranching and concurrent increase in VEGF 
expression in the mutant embryos.   
The altered vessel network is highly apparent, with many more, disorganized and 
sprouting vessels in the mutant.  The VEGF in situ photographs in the right hand panel 
show that VEGF expression levels increase in the mutant.  This figure has been taken 
from (van Rooijen et al., 2009). 
 
An ortholog of VHL, Vhl-like protein (VLP) has also been predicted from human 
genome sequence data (Qi et al., 2004), however it is not thought to be related to the 
fish vhl-like gene.  It has so far not been proven to be functional, and therefore its in 
vivo role remains unclear.  In the study by Qi et al it was shown that expression of vlp 
increased in the absence of vhl attenuated ubiquitination of hif-1α resulting in a 
decrease in expression of Hif target genes, which was used to propose that Vlp 
functions as a dominant-negative Vhl as  protector of Hif-α (Qi et al., 2004).  
 
1.5 Prolyl Hydroxylase Domain Containing Proteins (PHDs) 
PHDs were originally identified in both Drosophila, the first known as Drosophila Hif 
Prolyl Hydroxylase (dHPH) (Bruick and McKnight, 2001) and C. Elegans, known as egg 
laying nine (Egln or Egl-9) (Epstein et al., 2001).   Four have been identified in humans 
and they have been shown to hydroxylate the HIF- proteins, resulting in recognition 
by VHL and ultimately causing its breakdown.  The family shares approximately 55% 
sequence homology among their catalytic domains and are able to hydroxylate all 
three HIF- subunits using oxygen as a donor for the oxygen atom in the hydroxyl 
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group (Fong, 2008).  PHDs hydroxylate proline residues 402 and 564 on human HIF-1α 
subunit under normoxic conditions, thus lending oxygen sensitivity to the HIF pathway 
(Appelhoff et al., 2004, Berra et al., 2003) (Figures 2 and 3).  Although they have been 
shown to hydroxylate HIF in order to regulate its function, they are also known to have 
other substrates (Cummins et al., 2006). 
Extended and aberrant signaling through this pathway could lead to uncontrolled 
proliferation of vascular and haematopoietic cell lineages, where the implications are 
vascular diseases and cancers.  To this end HIF- also negatively regulates itself by up-
regulating PHD3 under hypoxia (Fong, 2008) (see Figure 3) to switch off the hypoxic 
response after oxygen concentrations are restored and the tissues are no longer at risk 
is a critical mechanism.  PHD3 has been shown to have a functional HRE, located within 
a conserved region of the first intron, 12kb downstream of the transcription initiation 
site (Pescador et al., 2005).  Using the sequence to drive reporter gene expression was 
successful under hypoxic conditions (Pescador et al., 2005).  Pescador et al also 
showed that HIF was necessary and sufficient to induce gene expression following this 
enhancer sequence.  PHD2 has also been shown to have functional HREs in its 
promoter regions (Pescador et al., 2005, Metzen et al., 2005), and it is induced by 
hypoxia in vitro (Marxsen et al., 2004). Induction of PHD2 by hypoxia was absent in vhl-
/- RCC4 cells, suggesting that hypoxic induction of PHD2 and PHD3 is critically 
dependent on HIF-α and that degradation of HIF-1α after re-oxygenation was 
accelerated (Marxsen et al., 2004) to control the duration and sensitivity to change of 
the hypoxic response (Marxsen et al., 2004, D'Angelo et al., 2003, Rantanen et al., 
2008).   
The chemical reaction, 2-oxoglutarate-FeII+ (2OG-FeII+), connects the key hydroxylases 
that regulate HIF mRNA levels and activity in the hypoxic pathway and forms the basis 
of a number of chemical inhibitors of these hydroxylases.  Cobalt chloride (CoCl2), 
dimethyloxalylglycine (DMOG) and desferrioxamine (DFO) have been used in various 
studies to chemically mimic hypoxia (Groenman et al., 2007), see Figure 11.   DMOG is 
a nonspecific 2-oxoglutarate-dependent dioxygenase inhibitor which has been shown 
to inhibit the PHD family as well as FIH resulting in up-regulation of HIF-α as well as the 
induction of downstream gene expression (Groenman et al., 2007, Shen et al., 2009).  
DFO on the other hand removes intracellular iron in order to stabilise HIF-α, since the 
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enzymatic activity of PHDs and FIH are reliant on both molecular oxygen and iron 
(Groenman et al., 2007, Shen et al., 2009).  CoCl2, a transition metal chloride, has been 
shown to be a strong inhibitor of FIH, while having only a weak effect on the PHDs 
(Groenman et al., 2007, Hirsila et al., 2005).   
 
Figure 11 The effects of a number of inhibitors of the various hydroxylases have 
been highlighted to demonstrate the ways in which they have been shown to 
regulate HIF mRNA levels and activity.   
The figure, adapted from (Lancaster et al., 2004) and again from Figure 6.  
Abbreviations: hypoxia inducible factor (HIF), von hippel lindau (VHL), factor inhibiting 
HIF (FIH), iron (Fe), prolyl hydroxylation domain containing protein (PHD), nuclear co-
activator (p300), proline hydroxylation (Pro-OH), asparagine hydroxylation (Asn-OH), 
cobalt chloride (CoCl2), dimethyloxalylglycine (DMOG) and desferrioxamine (DFO)  
 
Fluorescent fusion proteins were used to assess the subcellular localisation of the 
three PHD proteins and FIH.  Metzen et al showed distinct localisation of the different 
proteins, with PHD1 exclusively being present in the nucleus, PHD2 and FIH mainly 
localised in the cytoplasm and PHD3 spread between both locations.  They also 
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showed that hypoxia was not capable of influencing the localisation of any of the 
enzymes they looked at in vitro (Metzen et al., 2003, Lee et al., 2003, Soilleux et al., 
2005).   PHD1 being present exclusively in the nucleus along with suggestions that it 
has a lower affinity for HIF-1α compared with PHD2 and PHD3 put it as the least 
dominant enzyme for HIF-α degradation (Metzen et al., 2003).   
A fourth PHD protein was identified in 2002 by Oehme et al, which was found to be 
associated with the endoplasmic reticulum, which differentiated it from the other 
PHDs, which are localised to the nucleus or cytoplasm or both (Oehme et al., 2002).  
Over-expression of PHD4 in vitro did suppress HIF activity, dependent on the 
consensus ODDD proline residues, which correlated with a decrease in HIF protein, 
suggesting that it might also be involved in oxygen sensing (Oehme et al., 2002).   
In a review by Fong and Takeda in 2008 the various biological roles of the various PHDs 
were collated, from the initial finding the egg-laying function in c. elegans was lost 
upon the loss of EGL-9 (Epstein et al., 2001, Trent et al., 1983) to the role in cell growth 
in the fat bodies and wing discs of Drosophila (Frei and Edgar, 2004).  The use of short 
interfering RNAs (siRNAs) allowed Berra et al to demonstrate that the PHD proteins 
have distinct functions, with PHD2 as the critical oxygen sensor, which is also up-
regulated by hypoxia, providing a HIF-α dependent auto-regulatory mechanism driven 
by the oxygen tension (Berra et al., 2003).  They showed that silencing Phd2 alone was 
sufficient to stabilise HIF-α in normoxia in vitro, but silencing of Phd1 or Phd3 was not 
(Berra et al., 2003).  Following 5-6 days of Phd2 siRNA treatment with constitutive 
expression of Hif-1α in normoxia they showed a successive decline in Hif-1α despite 
the lack of Phd2, and it was under these conditions that simultaneous Phd1 siRNA 
could re-establish the high levels of Hif-α. This suggested that when one PHD protein 
was suppressed a HIF-dependent mechanism was in place to activate other members 
of the family to compensate (Berra et al., 2003).   
Phd function has been explored in vivo in mouse knock out models.  In mice, knock out 
of Phd2 resulted in embryonic lethality between embryonic days 12.5 and 14.5, 
whereas Phd1-/- and Phd3-/- mice were viable.  The Phd2-/- embryos showed severe 
placental and heart defects, which preceded their deaths, phenotypes that are similar 
to those in Vhlh-/- mice. These embryos showed global increases in Hif-1α protein 
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levels throughout the placenta and the embryo, albeit not in the heart (Takeda et al., 
2006).   Although Phd1 and Phd3 mutants are viable more detailed analysis has shown 
that all Phd deficient mice showed some degree of polycythemia with over-expression 
of Hif-1α in the liver and Epo in the kidneys, with Phd2-/- alone giving the strongest 
phenotype.  For instance, double knock-out of both Phd1 and -3 lead to moderate 
erythropoiesis with elevated levels of Hif-2α in the liver (Takeda et al., 2008). A 
reciprocal experiment, assessing the over-expression of Phd1, revealed that this 
suppressed Hif-1α accumulation and tumour growth (Erez et al., 2003) and immortality 
of human endometrial cancer cell, often associated with Phd2 (Kato et al., 2006).   
Information on the phd genes in the zebrafish has not been published except for 
(Santhakumar et al., 2012) and (van Rooijen et al., 2009).  The Ensembl genome 
browser was used to assess the zebrafish phd gene family and shows that the human 
PHD2 gene has undergone gene duplication in the zebrafish whereas the PHD1 and 
PHD3 genes are each represented by a single homolog.  
 
1.6 Factor Inhibiting HIF (FIH) 
FIH, also known as HIF-1an, is an asparagine hydroxylase enzyme with a length of 349 
amino acids (See Figure 12).  FIH catalyses the splitting of dioxygen, using one oxygen 
atom for hydroxylation of an asparagine residue on target proteins, and the other for 
oxidising the cofactor 2-OG(α-ketoglutarate) to succinate, releasing CO2 (Lisy and Peet, 
2008, Lando et al., 2002a, Mahon et al., 2001).  It has therefore also been described as 
an α-ketoglutarate dependent non-heme iron dioxygenase, with substrate binding as a 
prerequisite for oxygen activation and substrate hydroxylation (Saban et al., 2011b, 
Iwai et al., 1998, Hanson et al., 2003).  Saban et al suggest that this tight control over 
O2-reactivity was a distinguishing feature and was due to strong hydrogen bonding 
(Saban et al., 2011b).   
Leucine-795 (Leu795) (in human HIF-1α) is conserved on HIF-α proteins and can bind FIH 
close to its dimerisation interface (Lando et al., 2002a, Mahon et al., 2001, Lancaster et 
al., 2004) and this HIF- binding pocket is unique to FIH within its enzyme family 
(Lancaster et al., 2004).  FIH hydroxylates a conserved aspargine-803 (Asn803) within 
the C-terminal domain (TAD-C) of HIF-1α proteins under normoxic conditions, 
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attenuating HIF activity by blocking its interaction with p300/CBP co-activators 
(Rantanen et al., 2008, Lando et al., 2002a, McNeill et al., 2002).  The HIF Asn803 
hydroxylation event may be subject to further regulation in addition to oxygen levels 
as phosphorylation of HIF threonine-796 (Thr796) enhances transcriptional responses of 
HIF in hypoxic conditions by preventing hydroxylation of Asn803 (Lee et al., 2004, 
Mahon et al., 2001), see Figure 5.   
 
1.6.1 Regulation of HIF hydroxylation by oxygen 
Lee et al showed that the Km values of FIH and PHDs for molecular oxygen have been 
reported to be roughly 90 and 250µM, respectively in vitro (Lee et al., 2004), where 
the Km is the Michaelis-Menton constant at which a substrate concentration at which 
the reaction rate is half of its Vmax (maximum velocity).  Since physiological oxygen 
concentrations are below this estimated Km value (around 4-40μM) the PHD and FIH 
proteins are not saturated with oxygen and can thus respond to physiologically 
relevant changes in intracellular O2 and decreases in O2 concentrations are likely to 
reduce the catalytic rate of the PHDs before that of FIH (Lee et al., 2004).  Precise 
regulation may be more complex however, for instance VHL has been indicated to 
promote the O2-dependent interaction between FIH and hydroxylated HIF-1α, to 
promote the FIH-mediated Asn803 hydroxylation (Li et al., 2011b).   Li et al went on to 
demonstrate in vitro that FIH repression of HIF-TAD-C was indeed released under 
severe hypoxia.  On its own FIH has a very low rate of ROS production because FIH only 
binds oxygen when it is bound to its substrate HIF (Saban et al., 2011b).  The 
differences in chemical sensitivity kinetics and the different oxygen concentrations 
that are required to activate the PHD proteins as opposed to FIH support the 
hypothesis that their roles in regulating HIF-α were also distinct (Saban et al., 2011a, 
Saban et al., 2011b).  A mutation was identified in the fih gene in a zebrafish line at 
Sheffield University, the mutation resulted in a premature stop codon at Y94, prior to 
any of the functional domains in the resulting protein, and it was designated as allele 
number i217, as shown in Figure 12.   
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Figure 12 A schematic of the FIH protein has been highlighted in terms of its 
active domains.  Also highlighted is the point where a mutation has been found in 
the zebrafish.   
It is made up of 349 amino acids (Mahon et al., 2001) and contains a β-helix core 
domain that contains its 2OG-FeII-Oxy domain (Lando et al., 2002a).  Y94 stop indicates 
the residue that has been mutated in the zebrafish line that was identified at Sheffield 
University, allele number i217.  
 
FIH functions as a homodimer, the C-terminus comprises (right hand of Figure 12) 2 α-
helical dimerisation domains (see Figure 13) (Lando et al., 2002a, Lando et al., 2002b, 
Lancaster et al., 2004).  The protein structure contains a mixture of α and β strands, 
with 14 β-strands arranged into two sheets, one with 9 and the other with 5 strands.  
The central core is a C-terminal 8 β-strand jellyroll (double-stranded β-helix), which is 
homologous to other 2-OG-dependent oxygenases and the cupin protein family.  The 
N-terminus is formed of another 6 strands.  The helical structures are interspersed, 
with several helix-helix interactions in the center, at an apparent FIH dimerisation 
interface (Dann et al., 2002, Elkins et al., 2003).   
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Figure 13 The FIH protein has been shown to function as a dimer and Lancaster 
et al demonstrated the binding domain and included research into key residues that 
were crucial to functional binding of the dimer. 
This figure has been adapted from (Lancaster et al., 2004) and describes: A) the 
positions of FIH protein dimerisation between two α-helical domains and B) the 
positions of point mutations that were made in the protein sequence, mutations that 
interfere with the dimerisation and or catalytic activity of the complex  
 
The two C-terminal helices of each monomer of FIH have been shown to form a tight 
interaction, producing an anti-parallel helix bundle (see Figure 13).  Deletion of the C-
terminal 47aa FIH residues prevents the truncated protein’s ability to hydroxylate the 
HIF-TAD-C, whereas deletion of the N-terminal 33aa of FIH did not affect FIH activity.  
This combined with several other individual deletion studies suggested that the FIH 
homodimer is a functionally relevant structural form, in solution (Dann et al., 2002).  
Valine-802 (Val802) within the TAD-C of the HIF-1α protein, has been shown, through 
targeted mutations, to be essential for the efficient hydroxylation of HIF-α by FIH 
(Linke et al., 2004).  This is proposed to be due to the alteration of the positioning of 
the FIH hydroxylated asparagine residue, resulting in impaired catalysis (Linke et al., 
2004).     
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FIH was first identified to be a HIF-1α interacting protein (Mahon et al., 2001) and this 
interaction has been shown to be enhanced by VHL expression, and diminished by VHL 
knockdown (Li et al., 2011b).  If HIF escapes ubiquitination by VHL complex, it should 
remain inactive due to Asn803 hydroxylation by FIH.  Using tagged peptides Li et al 
demonstrated a direct interaction between the three peptides, FIH, VHL and TAD-C, 
and showed that they assemble correctly in normoxia and less so in hypoxia, with VHL 
interactions with TAD-C and FIH diminished.  HIF was therefore proposed as a 
chaperone of FIH-VHL interaction as FIH was found to associate with VHL regardless of 
presence of HIF but this interaction was markedly reduced in hypoxia (Li et al., 2011b), 
see Figure 14.   
 
 
Figure 14 Several models have been proposed for the orientation and 
interaction of the complex of HIF-VHL-FIH, this figure demonstrates two of these. 
A) Figure from (Li et al., 2011b) provides a schematic representation of interplay 
among HIF-1α TAD-C, FIH, and VHL proposed by in vitro study. They show the HIF-1α 
CT2 (aa782-826) bound to VHL, HIF1a CT1 (aa720-781) bound to FIH; VHL NT (aa1-62) 
bound to CT2, VHL middle portion (aa63-155) bound to FIH; and FIH NT (aa1-164) 
bound to either VHL or CT2.  Abbreviations: full-length (FL), C-terminus-COOH (CT), N-
terminus-NH3 (NT) B) Figure from (Lee et al., 2003) provides a hypothetical model of a 
complex formed between the FIH dimer, VHL and HIF-1α.  Hypothesis indicates FIH 
acting as a bridge in the association between VHL and the HIF-α C-TAD and associated 
HDACs.  Abbreviations: Histone deacetylases (HDAC), C-terminal domain (CAD), 
oxygen-dependent domain (ODD) 
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It has been shown in vitro that FIH hydroxylation of HIF occurs independently of the 
presence of VHL or PHD hydroxylation (Lando et al., 2002a), however, as stated above, 
in cells, PHD dependent hydroxylation of HIF will promote the interaction with VHL, 
which in turn may promote HIF-FIH interaction (Li et al., 2011b).  This can be seen 
when looking at tumour models, VHL loss of function (LOF) in CCRCC has been 
attributed to hyper-vascularity and poor prognosis due to increased levels of HIF even 
in normoxia (Iliopoulos et al., 1996).  If only VHL is lost, however, FIH would still be 
present and it has remained unclear how VHL deficient RCC express functional HIF (Li 
et al., 2011b).  Lee et al suggest that it is the interaction between VHL and FIH that 
ensures that when VHL is induced to bind HIF-α in normoxia, following proline 
hydroxylation by the PHDs its association with FIH brings this alongside the TAD-C 
where it performs Asn-hydroxylation to inhibit binding of co-activators (Lee et al., 
2003).  Li et al proposed therefore, that the HIF TAD-C was activated in the absence of 
VHL due to a decrease in the interaction between FIH and the TAD-C, however have 
also acknowledged that they were unable to identify the O2 dependent FIH 
modifications that regulate their proposed VHL-FIH interaction (Li et al., 2011b).   
The Li et al study proposes a model whereby decreasing O2 levels induces sequential 
process optimising activity of HIF to a level required for cellular adaptation to hypoxia 
and that VHL acts as an adaptor molecule to couple FIH and HIF-1α (Li et al., 2011b).  In 
moderate hypoxia the PHDs lose activity and this stabilises HIF by blocking VHL binding 
and the proposed FIH-VHL complex disassembles leading to partial activation of TAD-C 
by decreasing FIH-TAD-C binding.  However, in severe hypoxia FIH and the PHDs are 
nonfunctional so both HIF TADs are fully activated (Li et al., 2011b).    
Questions remain as to whether, in the absence of VHL, expression of FIH would be 
increased to maintain regulation of HIF.  FIH has been shown to be present in vhl-/- 
mouse embryonic fibroblasts (MEFs) although to a lesser extent than in wild type 
MEFs, see Figure 15. 
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Figure 15 FIH Expression under different oxygen tensions alters depending on 
the presence or absence of VHL, in mouse embryonic fibroblasts (MEFs) 
Figure taken from Zhang et al shows immunoblotting for HIF-1a, FIH, and VHL from 
whole-cell lysates of immortalized WT, FIH null, VHL null, and VHL/FIH double null 
mouse embryonic fibroblasts (MEFs). Cells were treated under normoxia or hypoxia for 
16 hr before harvest. Tubulin was used as the loading control. Figure republished from 
(Zhang et al., 2010) with permission from Elsevier, also Lancet special credit with 
permission from Elsevier 
 
The immunoblot revealed that the loss of VHL did not induce increased expression of 
FIH in the MEFs either in normoxia or hypoxia, although it was present.  These studies 
have largely been performed in vitro, Mahon et al used in vitro peptides in binding 
assays (Mahon et al., 2001) and Li et al used in vitro peptides expressed in various cell 
lines (Li et al., 2011b).  The loss of VHL though, did result in increased expression of 
HIF-1α in these MEFs in normoxia.  In hypoxia, the expression of HIF-1α was elevated 
in all of the mutants as well as, and almost especially, in the wild type MEFs.  These in 
vitro studies indicate binding interactions between the proteins, however Tanimoto et 
al could not demonstrate the interaction between the HIF TAD-C (aa778-826) and VHL 
in immunoprecipitation (IP) assays (Tanimoto et al., 2000).  More investigation is 
therefore necessary to enquire as to the functional interactions between these 
proteins in vivo.   
FIH is a well-conserved gene in vertebrates and the zebrafish genome has a single 
homolog.  In more primitive animals FIH cannot be unambiguously identified, in 
c.elegans it is most closely related to a jmjd-5 gene.  Expanding the “FIH gene tree” in 
ENSEMBL (www.ensembl.org) revealed three distinct clusters of genes, the jmjd 
family, the tyw (jmjc) family and the hif1an (fih) family. The most primitive organism 
containing an hif1an (fih) family gene is the ciona savigni (sea squirt), suggesting it 
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evolved in the chordate lineage.   
JumonjiD (JMJD) homology, and crystal structures of FIH and other members of the 
cupin family have since been used to suggest that FIH may in fact be a member of this 
super-family (Yang et al., 2009, Hewitson et al., 2002).  There is also clear sequence 
and structural similarity of FIH with JumonjiC (JMJC) domain proteins (Trewick et al., 
2005, Mahon et al., 2001, Clissold and Ponting, 2001).  The JmjC domain-containing 
histone demethylases have been shown to be induced by HIF-α dependent mechanism 
in hypoxia (Yang et al., 2009).  However a role as a histone demethylase has not so far 
been shown for FIH.  
 
1.6.2 Transcriptional Regulation of FIH 
Published reports show that FIH protein is ubiquitously expressed, having been 
detected in all tissue culture cell lines examined to date by western blotting 
techniques, and at similar levels (Lee et al., 2004, Lee et al., 2003, Stolze et al., 2004).  
It has also been shown in multiple murine tissues by western blotting, from brain, 
heart and lung, through reproductive organs such as ovary and uterus, as well as in the 
skin and salivary glands (Zhang et al., 2010). 
Melvin et al proposed a mechanism of FIH transcriptional regulation involving a 
member of the chromatin-remodeling complex switch/sucrose nonfermentable 
(SEI/SNF) family, imitation switch (ISWI).  They demonstrated in vitro that reductions in 
the levels of ISWI was correlated with reductions in FIH mRNA levels, and also 
connected ISWI with levels of RNA polymerase II on the FIH promoter, affecting 
protein levels (Melvin et al., 2011).  They propose this as a mechanism of regulation of 
FIH in order to subsequently regulate HIF-α levels and downstream transcriptional 
responses to hypoxia.  They went on to investigate ISWI in negative regulation of two 
HIF target genes, carbonic anhydrase 9 (CA9) and BCL2/adenovirus E1B (BNIP3), and 
showed that mRNA and protein levels of these genes  was reduced in response to 
ISWI, just as FIH responded and that despite these changes levels of HIF were not 
altered (Melvin et al., 2011, Zhang et al., 2010).  This suggests that absolute levels of 
FIH might be important.   
31 | P a g e  
 
Despite an extensive search through renal cell carcinoma (RCC) cell lines, a disease 
where mutations in VHL are known to be causative, and primary tumour samples no 
evidence was found to suggest that germline or somatic mutations in FIH contribute to 
RCC, although the chance that epigenetic regulation of might play a role has not been 
ruled out.  Polymorphic variants were identified that might be useful in further 
investigation of the role of FIH in modifying the hypoxia response (Morris et al., 2004).   
There is some indirect indication that Cut-like homeodomain protein (CDP) may reduce 
FIH mRNA in RCC cells and CDP is associated with metastatic progression of tumours (Li 
et al., 2007a) but proof for a function of FIH is currently lacking.  
 
1.6.3 Other FIH Substrates: a role of Hypoxia/FIH in Inflammation 
FIH was first identified as a negative regulator of HIF by interacting with the TAD-C of 
HIF-α protein by yeast two-hybrid assays (Hewitson et al., 2002, Mahon et al., 2001, 
Wilkins et al., 2012) but has since been shown to have other substrates, including the 
ankyrin repeat domain (ARD) containing proteins such as Notch (Zheng et al., 2008) 
and p105/nuclear factor kappa B (NFκB1), Inhibitor of Kappa B (IκBα) (Wilkins et al., 
2009) and myosin phosphatase target subunit 1 (MYPT1) (Webb et al., 2009).   
Importantly, proteomics experiments suggest it may be generally hydroxylate ARD 
containing proteins (see also Chapter 6.6.4) (Cockman et al., 2009).   
Through a series of in vitro assays and by mass spectrometry analysis of FIH-
transfected cells an interaction was shown between FIH and the ankyrin repeat 
domains (ARD) in the IκB family.  Co-IP studies have shown a direct association 
between endogenous FIH and IκB-ARD proteins (Cockman et al., 2006), and several 
groups have shown that FIH hydroxylates IκBα at Asn210 and Asn244, but that the one at 
Asn244 is preferential, with a mass spectrometry profile that suggests the Asn244 residue 
is 100% hydroxylated while the Asn210 residue is 50% hydroxylated (Devries et al., 
2010).  It has also been illustrated that these interactions occurred more readily than 
those between FIH and HIF-α (Cockman et al., 2006).   The role of IκB hydroxylation by 
FIH has been shown not to be directly relevant to IκB stability, degradation or activity 
of IκB and this observation led to the hypothesis that these regulations and 
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stoichiometric competition could indicate a method of regulating the FIH-HIFα 
interaction (Devries et al., 2010).   
On the other hand degradation of FIH or inhibition by siRNA was sufficient to reduce 
NF-κB activity (Cockman et al., 2006).  A complex has been shown to form between FIH 
and IκB in vitro, which has been shown for FIH and other ARD-containing proteins 
(Devries et al., 2010).  IκBα activated HIF-1α by sequestering FIH away from HIF-1α 
although these effects on HIF activity were only observed in low oxygen environments 
(Shin et al., 2009), possibly due to the continued function of PHD protein hydroxylation 
and VHL ubiquitination of HIF-1α in normoxia.  Knock down of IκBα resulted in 
inhibition of HIF-1α, and this was rescued by subsequent inhibition of FIH, but IκBα is 
thought to be able to activate the HIF-1α TAD-C independently of Asn803 and this might 
be through positive regulation of p300 recruitment to HIF-1α protein (Shin et al., 
2009).  IκBα was also found to positively regulate HIF-1 transcriptional activity by 
antagonising FIH and positively regulating the recruitment of p300 to HIF-1α, in acute 
but not severe hypoxia (Shin et al., 2009).  Shin et al use these findings to suggest that 
IκBα plays a pivotal role in the cross-talk between the HIF-1 and NF-κB signaling 
pathways (Shin et al., 2009).  In this context they propose that IκBα acts a mediator, 
allowing cellular responses to switch between NF-κB-mediated inflammation to HIF-1-
mediated hypoxic adaptations (Shin et al., 2009)(see Figure 16).   However, this is 
difficult to reconcile with the data from Cockman 2009, which suggests that IκBα is just 
one of many FIH binding proteins (Cockman et al., 2009).   
 
 
Figure 16  Two pathways with proposed cross talk are those of hypoxic 
adaptation and the inflammatory response, with IκBα as a key mediator. 
Figure is taken from (Shin et al., 2009) to describe their model of cross-talk between the 
HIF-1 and NF-κB pathways.  Permissions were granted from Publishers the Wiley 
Company for the republication of this figure. 
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In a study assessing the behaviour and function of neutrophils in response to hypoxia 
and HIF regulation, hypoxia is able to increase NF-κB protein expression and activity, 
and this is thought to mediate neutrophil survival (Walmsley et al., 2005).   
Observations that enhanced survival of peripheral blood neutrophils was observed in 
patients with VHL diseases, along with studies of HIF-1α-/- murine neutrophils resulted 
in both reductions in NF-κB message and anoxia-stimulated cell death (Walmsley et al., 
2005).  Hypoxia driven stabilisation of NF-κB is proposed to be a link between oxygen 
deprivation and cell survival, however the mechanism of the interaction remains to be 
elucidated (Walmsley et al., 2005).   
Sakamoto et al have since shown that FIH may be regulated by other proteins in 
addition to ankyrin domain proteins.  They described that FIH was suppressed in 
macrophages by the c-terminal tail of a membrane bound matrix metalloproteinase 
(MT1-MMP/MMP-14).  They proposed that this suggested a role for MT1-MMP 
expression in macrophages as a significant role in regulating HIF-1 activity.  The 
cytoplasmic tail (CPT) of MT1-MMP in the membrane of the macrophage has been 
implicated in glucose metabolism, and It has this process that’s been connected to FIH.  
The CPT is proposed to bind to FIH, inducing the interaction with MINT3 (an FIH 
inhibitor) (Hara et al., 2011, Sakamoto and Seiki, 2009, Sakamoto and Seiki, 2010), 
abrogating the interaction between FIH and HIF.  Inhibition of FIH is then what leads to 
increased HIF activity and the induction of glycolytic metabolism of macrophages even 
in areas of low HIF expression in normoxia (Sakamoto et al., 2011).  In cell line studies 
it has been demonstrated that tumour cells where MT1-MMP was expressed exhibited 
increased glycolytic activity.  These effects mimic the Warburg effect, the observation 
that most cancer cells predominantly produce energy by a high rate of glycolysis 
followed by lactic acid fermentation in the cytosol observed in solid tumours 
(Sakamoto et al., 2011).  Macrophages lacking MT1-MMP exhibit reduced glycolysis 
and a 60% reduction in ATP levels and that these macrophages show defects in 
motility, cytokine production and phagocytosis.   
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1.6.4 Other FIH substrates: a role of FIH Hydroxylation in Notch Signaling 
A complex cross-talk may exist between the Notch and HIF pathways and this has been 
suggested to occur at various levels, either globally with oxygen levels affecting the 
binding of particular components and direct cross-talk between components of the 
two pathways including Notch and FIH. 
The Notch mutation was first identified by John S. Dexter in 1914 who noticed a 
notched pattern in the wings of Drosophila melanogaster, and the alleles of the gene 
were identified a few years later in 1917 by Thomas H. Morgan (Brou et al., 2000).  The 
molecular cloning of Drosophila Notch locus followed in 1982 by Artavanis-Tsakonas et 
al (Artavanis-Tsakonas et al., 1983). 
The pathway has since been shown to affect developmental changes by changing the 
gene transcription repertoire of the receiving cell.  The notch pathway is a cell-cell 
communication mechanism controlled by direct binding of receptors (Notch) and 
ligands (Delta/Delta-like/Jaggged) in the membrane of two cells (Lai, 2004).  Notch is a 
single pass transmembrane protein, 2703 amino acids long (4 homologs have been 
identified in vertebrates) that serves as a receptor for Delta/Delta-like/Jagged proteins 
(3 Delta and 2 Jagged homologs have been identified in vertebrates) (Kidd et al., 1986, 
Ohishi et al., 2000).   Importantly, the notch receptor contains ankyrin repeat domains 
and the crystal structure of the Drosophila Notch receptor ARD has been developed to 
a 2.0Å resolution by Zweifel et al.  The architecture of the domain consists of an 
elongated array of anti-parallel six α-helices and a putative seventh C-terminal 
sequence repeat (Zweifel et al., 2003).   The structure of the mouse and human Notch 
proteins have been shown to be homologous to Drosophila Notch, see Figure 17 
(Lubman et al., 2005, Ehebauer et al., 2005). 
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Figure 17  There are multiple points of homology between Drosophila and 
Human Notch proteins 
Shows the superimposed structures of the Drosophila Notch and the human Notch1 
ANK domains, taken from (Ehebauer et al., 2005). The Asn residues marked are 
indicated are the indicated positions of those where FIH hydroxylation takes place 
(Zheng et al., 2008). 
 
The notch pathway describes a cell-cell communication mechanism controlled by 
direct binding of receptors (Notch and Delta/Delta-like/Jagged respectively) in the 
membrane of two cells (Lai, 2004) (see 
Figure 18). 
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Figure 18 The notch signaling pathway.  
The notch protein is cleaved at the Golgi membrane and transported to the plasma 
membrane. Signaling is initiated when the extracellular domain of Notch is internalized 
by the delta presenting cell.  A second cleavage event then occurs, initiating the 
cleavage at the plasma membrane by -secretase enzymes. This releases the notch 
intracellular domain (NICD) to migrate into the nucleus where it binds a complex of 
other proteins to activate gene transcription (Lai, 2004) by binding a complex of 
proteins including CSL (CBF1, Suppressor of Hairless, Lag-1), a transcription factor 
(Pursglove and Mackay, 2005) 
 
Notch target genes include Hairy and Enhancer of Split (Hes) family members and Hes-
related repressor protein (Hey) family members or the Epidermal growth factor (EGFR) 
receptor family (Sjolund et al., 2008, Lai, 2004).  The Hes and Hey family members are 
transcriptional repressors (Pfaffenroth and Linehan, 2008) that control Notch signaling 
output (Sjolund et al., 2008). 
The NICD interacts directly with HIF-1α, and this has been shown to be recruited to 
Notch-responsive promoters following hypoxia driven Notch activation (Gustafsson et 
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al., 2005, Pear and Simon, 2005) leading to increase in expression of notch target 
genes.  Hypoxia has been shown to stabilise the NICD as well as increase its activity, 
through interactions with HIF-1α rather than pVHL (Gustafsson et al., 2005).  FIH has 
been shown to interact with both full length Notch, within the ankyrin repeat domain 
folds that are cleaved to release the NICD (Coleman et al., 2007) as well as the cleaved 
NICD (Zheng et al., 2008), alongside the proposed interaction between HIF-α and the 
NICD (Gustafsson et al., 2005).  For simplicity, the diagram in Figure 19 indicates the 
interaction between HIF-α and NICD proposed by Gustafsson et al.   
 
 
Figure 19 There is proposed cross-talk between Hypoxia and Notch signaling 
pathways 
This figure has been adapted from one in (Gustafsson et al., 2005) to illustrate the 
cross-talk between hypoxia and Notch signaling.  Abbreviations:- Notch intracellular 
domain (NICD), hypoxia inducible factor (HIF), von hippel lindau protein (VHL), (CSL), 
hairy and enhancer of split (HES), hairy and enhancer of split with YRPW motif (HEY), 
vascular endothelial growth factor (VEGF), erythropoetin (EPO), C-X-C chemokine 
receptor type 4 (CXCR4), phosphoglycerate kinase (PGK), HIF response element (HRE), 
rev response element (RRE).  Reprinted with permission from Elsevier, also Lancet 
special credit with permission from Elsevier 
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In addition, FIH has been shown to interact directly with endogenous Notch receptors 
by hydroxylating highly conserved asparaginyl residues within the ankyrin repeat (AR) 
domains (ARDs) (Coleman et al., 2007, Zheng et al., 2008).  Zheng et al also went on to 
show that FIH hydroxylation of the NICD occurs at two residues N1945 and N2012, before 
the β-hairpin turns separating the ICD ANK 2nd and 3rd repeats and 4th and 5th 
repeats respectively (Zheng et al., 2008), see Figure 20.  These residues are critical for 
the function of the NICD as a transactivator in neurogenesis and myogenesis in vivo, as 
well as for the mediation of Notch complexes.  This is a common feature of the Asn 
residue that is targeted within ARD proteins that are also hydroxylated by FIH (Wilkins 
et al., 2012).  The results of several reports have demonstrated conflict over the effect 
of FIH hydroxylation of different substrates.  Several studies have shown that the 
hydroxylation stabilises localised regions of the ankyrin fold (Yang et al., 2011b, Hardy 
et al., 2009, Kelly et al., 2009), enhancing notch signaling.  Other studies have 
questioned the importance of the actual hydroxylation and suggested the binding of 
FIH itself might be inhibitory when over-expressed (Coleman et al., 2007).  These 
discrepancies could be due to cell type specific or even context specific elements 
within individual studies, making comparison between them difficult and leading to 
the need for further investigation.  
Several features do combine to describe a consensus sequence required for FIH 
hydroxylation, which Wilkins et al have compiled.  The consensus sequence shows that 
there isn’t a single amino acid that is conserved at every residue and that recognition is 
therefore reliant on a few individual positions, (Wilkins et al., 2012).  These findings are 
consistent with Asn hydroxylation by FIH, although also identified are histidinyl 
residues within the ankyrin repeat domain of tankyrase-2 that can also be 
hydroxylated by FIH in vitro (Yang et al., 2011a).  Binding studies performed by 
Coleman et al showed that FIH had a higher binding affinity for these ARDs of the 
notch protein than it did for HIF-α (Coleman et al., 2007), see Figure 20. 
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Figure 20 The binding of FIH to both HIF and notch components have been 
shown to have different binding efficiency 
Figure describes mild ionization electrospray mass spectrometry (MS); Kd or Scatchard 
plot was used plotting the specific binding on the X-axis and the specifc binding divided 
by free ligand concentration on the Y-axis.  The Kd is then described as the negative 
reciprocal of the slope to assess binding efficiencies.  The binding of the Fih dimer (Fih2) 
with N1 (including data for FIH2-(N1)2, FIH2 and N1 (excluding data for FIH2-(N1)2, FIH2 
and N1 ART(OH), and FIH2 and His-HIF-1CAD were assessed. Equimolar Fih plus 
substrate were mixed and analysed in the absence of Fe/2OG. [E]=enzyme 
concentration [S]=substrate concentration.  It demonstrates stronger binding of Fih 
dimer to the notch proteins that were tested than to the c-terminal domain of HIF-. 
Figure from (Coleman et al., 2007). 
 
Fih hydroxylation of the NICD stabilises the ankyrin repeat domain, resulting in an 
increase in Notch signaling, whereas Fih binding of the NICD has an inhibitory role on 
the NICD when Fih is over expressed.  The preferential binding of FIH to Notch and also 
other ankyrin repeat domain containing proteins (of which there are over 200 in the 
genome) may provide an explanation as to how HIF protein, once stabilised in the 
absence of VHL, can escape hydroxylation and be highly active even in the presence of 
FIH (Coleman et al., 2007, Wilkins et al., 2012).  The affinity of FIH for TAD-C could be 
influenced by residues in close proximity to the Asn that FIH has been shown to 
hydroxylate, but appear to be unaffected by increases in length of the unfolded TAD-C 
(Wilkins et al., 2009, Cockman et al., 2009).  Zheng et al suggest that FIH provides a link 
between these two pathways, with differential regulation of the proteins having 
impact on the overall signaling (Zheng et al., 2008).   The affinity of FIH for Notch has 
been shown to decrease upon hydroxylation and this has been proposed to influence 
the ability of Notch to sequester FIH away from HIF-α and regulate transcriptional 
output from TAD-C (Wilkins et al., 2009).   
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The combined effect, in hypoxia, of decreased O2 inhibiting FIH function (stopping FIH 
inhibition of Notch/NICD) and the increased stability of HIF-1α (stabilising the NICD 
after cleavage) can lead to increased stabilisation and function of the Notch signaling 
pathway and downstream targets.  Where Notch protein levels are low, FIH will bind 
HIF-α and hydroxylate it, which inhibits its function.  However, increasing levels of FIH 
or Notch induce sequestering of NICD by FIH in preference to HIF resulting in de-
repression and subsequent signaling (Zheng et al., 2008).   
More research is needed to assess whether or not FIH has a preference for binding 
Notch-ARD (inactive) or the NICD (active), since the literature simply indicates that 
both interactions are possible (Zheng et al., 2008, Coleman et al., 2007).  It is also 
curious that studies have suggested sequestration of FIH away from HIF by specific 
proteins such as Notch/NICD where FIH has been shown to preferentially bind the 
latter over HIF.  If FIH is truly able to interact with multiple pathways where ankyrin 
repeat domain proteins are present, as has been shown by Cockman et al (Cockman et 
al., 2009) then the sequestering of FIH away from HIF-α by Notch/NICD should not be 
specific to this interaction.  The ARD domain is one of the most common amino acid 
motifs in nature, is present in over 300 proteins in the human genome and is 
conserved in all kingdoms of life (Cockman et al., 2009).  This being the case, and with 
FIH having been shown to interact with several of these proteins, including IκB and 
Notch receptors (Cockman et al., 2009), more research is therefore required in order 
to clarify the relationship between these interactions and the specific effect they have 
on different signaling pathways.   
The complexity of the cross-talk between HIF and Notch signaling becomes relevant 
when the downstream effects of each pathway are assessed.   Downstream targets of 
HIF signaling include those involved in angiogenesis, and Notch signaling has been 
reported to be involved in the decision whether to become tip or stalk cells.  Outside 
the vascular system, Notch influences some cell cycle control mechanisms, 
differentiation in neural and haematopoietic cell fates in the developing embryo as 
well as the differentiation of arterial and venous cells by lateral inhibition (Bentley et 
al., 2009).  With respect to sprouting angiogenesis DLL4 expression in a developing tip 
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cell inhibits the expression of DLL4 in neighbouring cells, where Notch is expressed.  
This sets up a lateral inhibition mechanism, which in turn regulates the number of tip 
cells that are identified and therefore the number of developing branch points on a 
particular blood vessel (see Figure 21)(Hellstrom et al., 2007, Caolo et al., 2012, Leslie 
et al., 2007). 
 
 
Figure 21 Some of the links in different pathways involved in the branching 
morphogenesis that allows new blood vessels to form from pre-existing ones  
A) Describes the sources of different signals that dictate the identity of tip cells versus 
stalk cells.   VEGF-A (a hypoxic signaling target) induces the expression of DLL4 (a notch 
ligand) in a newly designated tip cell.  The expression of DLL4 in one cell induces lateral 
inhibition preventing surrounding cells from taking on this fate and inducing the 
expression of Notch and Jagged in these cells, designating these stalk cells.  The tip cell 
reads cues such as Vegf, guiding the migration of the newly forming vessel as the stalk 
cells below it proliferate and drive progress forward. B) Provides a clearer indication of 
the  direct cross talk between adjacent cells through the Dll4 (on the tip cell) and Notch 
(on the stalk cell) providing further downstream signaling through VEGF receptors, 
figure taken from (Tung et al., 2012). 
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The recombining binding protein suppressor of hairless (RBPSUH) encodes the RBP-Jκ 
protein, otherwise known as CSL after mammalian, Drosophila and C. elegans 
homologs (Miele, 2011), which acts as a transcription factor recognising the mouse 
sequence C(T)GTGGGGA (Oka et al., 1995).  It has been shown to interact with all four 
of the mouse Notch receptors, making it important for transcriptional control of 
canonical Notch signaling (Kato et al., 1996, Souilhol et al., 2006, Fortini and Artavanis-
Tsakonas, 1994).  In the mouse, the loss of RBP-Jκ leads to embryonic lethality before 
10.5 days of gestation (Oka et al., 1995).  In the zebrafish its loss leads to an increase in 
the sprouting of ISVs (Siekmann and Lawson, 2007).  By decreasing notch expression, 
or indeed by decreasing expression of just the ligand dll4, there is an increase in the 
tip-cell behaviour and therefore an increase in sprouting (see Figure 22).  
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Figure 22 Dll4 knock-down results in increased endothelial cell number and 
increased vessel branching 
(D-G) Tg(fli1:EGFP) embryos at 2.5 dpf (D,E) or 5 dpf (F,G) either uninjected (D,F) or 
injected with 10 ng MO[Dll4] (E,G). White blobs (arrows in D,E) are endothelial cell 
nuclei. (H) Similar region of a 2.5-dpf dll4-homozygous- mutant embryo (carrying the 
fli1:EGFPtransgene). (I)Endothelial cell counts in the DAs, ISVs and DLAVs of embryos at 
3 dpf. Embryos lacking Dll4 or treated with 100 m DAPT have more cells than 
uninjected or DMSO- treated control siblings. Both effects are significant at the P=0.001 
level (t-test; n6 specimens for each treatment; error bars represent s.e.m.).  Figure 
taken from (Leslie et al., 2007).  Reproduced with persmissions. 
 
In normoxia, increasing expression of DLL4 ligand increases levels of Notch signaling in 
receiving cells, in a non cell-autonomous manner, induces lateral inhibition, ensuring 
individual tip cells are surrounded by stalk cells and an organised development of the 
vasculature (Siekmann et al., 2008).  This means that a decrease in Notch signaling 
leads to an increase in sprouting blood vessels due to the loss of lateral inhibition and 
the increase in cells taking on tip cell identity.  
Hypoxia increases expression of VEGF-A, which binds VEGFR-2 on an endothelial cell, 
inducing tip cells and resulting in increased expression of Notch ligands jagged-1 and 
delta-4 in the nearest cells, thereby desensitising those cells to Notch signaling 
(Jakobsson et al., 2010, Sainson and Harris, 2006, Bedogni et al., 2008)  in a cell-
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autonomous manner through cis-inhibition (Wang et al., 2011) but at the same time 
inhibiting adjacent cells from adopting the same fate through activation of Notch.  The 
down-regulation of dll4 by MO injection (Figure 22), results in increased branching of 
the vessels because it ensures that this lateral inhibition mechanism is not initiated 
and this results in the tip-cell fate being taken on by an increased number of cells.   
At the same time HIF might more directly promote Notch signaling, by a transcriptional 
up-regulation of notch protein via HIF (Sainson and Harris, 2006).  As mentioned 
before, HIF-α can also act more directly on Notch, stabilising the NICD after cleavage 
(directly or indirectly), which can enhance expression of notch target genes (Sjolund et 
al., 2008, Zeng et al., 2005, Zheng et al., 2008).  The interaction between HIF and Notch 
signaling is complex and in vivo models may help to resolve major and minor effects.   
 
1.6.5 Role for Fih in Regulating Metabolism  
Cell culture data, such as that described for the interactions between FIH and its 
substrates, made strong predictions on role of FIH in inflammation, Notch and more 
importantly hypoxia.  The release of a paper describing the generation and initial 
characterisation of an Fih-/- mouse, however, demonstrated some surprising 
phenotypes.  This puts all previous data into perspective and provides a contrast and 
new emphasis that requires clarification.  Zhang et al published the study of the fih-/- 
mouse model, following the start of this project to assess the fih217/217 zebrafish, 
and demonstrated that Fih played a normoxic role in regulating metabolism (Zhang et 
al., 2010)  and phenotypes relating to inflammation/notch signaling were not 
described.  This does not mean that these interactions were not present; it simply 
indicates that they were not obvious phenotypes as the mice were viable.  It was 
shown instead that on Fih-/- mice displaying increased cellular ATP and suppression of 
AMPK, along with a hyper-metabolic state.  This was characterised by looking at the 
elevated oxygen consumption and increase in heat production in the embryos along 
with an increased heart rate.  It corresponded with a decreased body mass and 
adiposity, along with protection from high-fat-diet-induced weight gain. 
Zhang et al also showed that the Fih-/- mice also showed that, consistent with the lack 
of HIF-related changes in vascularisation the basal levels of Epo were not altered, 
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however they demonstrated a decrease in both plasma and renal Epo levels in 
response to hypoxia.  Given that Epo is a HIF-target, the decrease in expression is 
surprising, since in an Fih-/- mouse there would be a loss of Hif-α regulation and if 
anything an up-regulation of target genes could be expected.  They propose that these 
alterations are not due to direct effects on Epo expression, but rather on the 
correlation with altered respiration during hypoxia.   The findings of Zhang et al. 
together led to the conclusion that fih was playing a role that is not directly connected 
to its role in regulating HIF activity, and that this was connected to a metabolic rather 
than hypoxic phenotype.  These data were not released when the current PhD project 
was begun and this provided a change in the course of the investigations that were 
subsequently pursued.   
 
1.7 Use of the Zebrafish as a Model Organism for Hypoxic Signaling 
Zebrafish (Danio rerio) provide many key features that make it a desirable model for 
the study of vertebrate development, and more recently it has also become a popular 
model to model human diseases and processes that are highly relevant to human 
disease.  The zebrafish provide a real time model for studying the development of 
tissues that are inaccessible in other mammalian models.  Taking blood vessels as a 
relevant example there are several different models that have been developed for the 
assessment and visualisation of vascular growth in vivo, with different accessibility and 
opportunities, (Norrby, 2006), see comparison in Figure 23.   
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Figure 23 There are multiple animal models for observing vascular growth, from 
laser Doppler perfusion to window chamber assays.  
A) Hindlimb blood flow monitored serially in vivo by laser Doppler perfusion imaging 
(LDPI), false colours represent normal baseline perfusion (Pre) in red, followed by 
marked reduction in blood flow post excision of one femoral artery (Post) in blue.  
Perfusion then sequentially monitored to return to near normal levels by 28days post 
(Couffinhal et al., 1998). B) Chick chorioallantoic membrane (CAM) assay used to 
visualise effect of VEGF on vascular growth, a) control - with neither vascular growth or 
vascular patterning b) effect of 0.5µg VEGF165, showing weak angiogenic response in 
region of pre-capillary vessels c) effect of 1µg VEGF165 d) effect of 3µg VEGF165 where 
brush-like vessels have formed (Wilting et al., 1993). C) Illustrates the zebrafish as a 
model of tumour angiogenesis at 48hours where injection with tumour cells, where a) 
shows 24hours post injection, embryos were stained with alkaline phosphatase activity 
to visualise newly formed blood vessels b) GFP-tagged blood neovessels (green) 
penetrate the tumour cell graft loaded with Dil fluorescent dye (red) (Tobia et al., 
2011).  D) Window chambers used to visualise vasculature in dorsal skin-flap (Hak et al., 
2010). E) In a window chamber in the rabbit ear, a dotted line indicates the vascular 
front, so observations and measurements can be made of wound healing assays 
(Ichioka et al., 1997). 
 
Each model provides a method for accessing the vasculature, using Doppler imaging to 
visualise flow through vasculature, or cutting windows to access the vessels beneath 
the skin.  The zebrafish model has several strengths, allowing visualisation of the 
vasculature without invasive procedures, with the help of particular GFP transgenics.  
Due to their small size at early stages, diffusion of oxygen occurs through the embryo 
and the developing vasculature and blood cells are not necessary for the delivery of 
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oxygen to internal organs (Pelster and Burggren, 1996, Gray et al., 2007).  This means 
that manipulations of the developing vasculature and circulatory system can be 
studied without seriously compromising development of the embryo as a whole, as it 
does continue to be oxygenated through diffusion.  The zebrafish heart has been 
shown to regenerate following damage, making it a useful model for the mechanisms 
by which this could be achieved (Lien et al., 2012, Poss et al., 2002, Raya et al., 2004).   
Zebrafish are naturally found in still or slow moving streams, river basins or around rice 
agriculture around the Ganges and Brahmaputra in north-eastern India, Bangladesh 
and Nepal (Spence et al., 2008).  In the wild spawning appears to be seasonal, or in 
relation to food availability that might be a consequence of seasonal changes.  In spite 
of this, breeding can be maintained year round in the laboratory and females will 
spawn every 2-3 days in the presence of males (Spence et al., 2008).  Growth rate is 
the most rapid in the first three months and decreases to the time the adults are 
eighteen months old, although this has been observed to be faster in captivity, see 
Figure 24. 
 
 
Figure 24 The natural life cycle of the zebrafish, described with photographs at 
three stages; 1 cell, just prior to hatching and adult 
Including time, along with photographs taken at three stages of the live process.  The 
figure has been taken from various internet sources including: (DanioRerio.com, 2012, 
Fleming, 2007, Nusslein-Volhard, 2008). 
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The generation time is short, often between 3-4 months, and a pair of mating adults 
can produce a clutch of several hundred eggs, enough for large-scale assays.  The 
embryos are small, approximately 0.7mm in diameter after fertilisation, transparent 
and easily manipulated.  External fertilisation and the embryos transparency allows 
visualisation of developmental changes over time; as the organs develop, as the heart 
starts to beat and as blood cells begin to circulate (Spence et al., 2008).   This also 
allows for genetic manipulation of the embryos from the moment of fertilisation by 
the injection of constructs to disrupt or enhance particular genes’ function and study 
the effects (Dodd et al., 2000, FFS, 2011).  TILLING studies use mutagens to generate 
random mutations in large numbers of individual fish, progeny from mutated fish are 
studied to identify the causative gene of any phenotype chosen for study.  The 
biomedical advantages of the fish are found in their systemic similarities to human, 
with circulatory, inflammatory and nervous systems being three examples.   
Kimmel et al., have described the stages of normal development of the zebrafish 
embryo, providing a useful tool for the study both of changes over time but also of 
alterations to the normal pattern (Kimmel et al., 1995).  The rapidity of their 
development, 36 hours to have precursors to all major organs, along with startle 
responses and food seeking within five days, allows for the study of development in 
real time (Spence et al., 2008). These features combined made them candidates for 
the first large scale random mutagenesis screens in vertebrates (Spence et al., 2008, 
Granato and Nusslein-Volhard, 1996). 
Zebrafish are a naturally shoaling fish, and even if raised in isolation take up a shoaling 
behaviour when they are placed together (Buske and Gerlai, 2011).  They are therefore 
being used for many behavioural assays due to their characteristic patterns of 
behaviour and their small size (Norton and Bally-Cuif, 2010). 
 
1.8 The Development of the Vasculature 
The formation of the vasculature is one of the earliest and most important events 
during organogenesis in the developing embryos of many species and is essential for 
the provision of oxygen and nutrients, along with the removal of waste products.  The 
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diffusion distance for oxygen is between 0.1 to 0.2mm, and this necessitates the 
body’s production of an extensive network of blood vessels (Heinke et al., 2012).  In 
1628 William Harvey first described the connection between arteries and veins filled 
with blood to form a circulatory system, despite the fact that he couldn’t visualise it.  
The process of forming the vascular system is divided in two, with vasculogenesis 
forming the initial development and angiogenesis forming the process of expansion 
and remodeling of the network.   
 
1.8.1 Vasculogenesis 
Vasculogenesis, the physiological process of de novo endothelial differentiation from 
mesodermal precursors, by necessity occurs before the onset of circulation and results 
in the formation of the extra-embryonic yolk sac vasculature, the paired aortas, the 
endocardium and the primary vascular plexus (Flamme et al., 1997, De Val and Black, 
2009). 
In the mouse, differentiation of endothelial cells (angioblasts) occurs from mesodermal 
precursor cells in the embryonic yolk sac around E6-E6.5 and then later in the embryo 
itself (Drake and Fleming, 2000).  The angioblasts form into cord-like vascular 
structures before generating vascular lumens and the subsequent organisation of 
vascular networks.  Angioblasts have been defined as being tal-1+/-;flk-1+/-, with the 
expression of tal-1 decreasing as the endothelial cells mature (Drake and Fleming, 
2000, Gering et al., 1998).   
VEGF has been shown to be expressed in the endothelium in regions where it can 
support vessel growth, and over-expression causes anomalous vessel formation in vivo 
(Fouquet et al., 1997).  The VEGF isoforms, of which six have been identified in 
humans, are all secreted as covalently linked homodimers, with monomers associating 
through hydrophobic interactions.  The three most well-described VEGF receptors 
(vegf-r) are receptors 1 (c-fms-like tyrosine kinase - flt-1), 2 (kinase insert domain-
containing receptor - kdr/flk-1) and in the fish a second gene kdrl (Bussmann et al., 
2008) and 3 (fetal liver kinase 4 - flt-4) (Quinn et al., 1993).  The zebrafish kdr-l gene 
has been proposed, at different stages in the literature, to be either a gene duplication 
of the human KDR gene or a fourth class of vertebrate VEGF receptor and therefore a 
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true orthologue.  Bussmann et al propose that kdr/flk1 is the prominent VEGF-A 
receptor in the zebrafish and indicate it should be called kdr-like as a separate ortholog 
of the gene rather than a gene duplication, while the second kdr gene (the one that 
most similar to human KDR should remain kdr in the zebrafish (Bussmann et al., 2008).   
Three acidic residues (Asp63, Glu64 and Glu67) and three basic residues (Arg82, Lys84 
His86) have been identified in VEGF that are essential for binding to Flt-1 and Flk-1 
(Robinson and Stringer, 2001).   Flt-1 and Flk-1 have been shown to have differential 
expression, with Flt-1 implicated in vessel organisation and Flk-1 expression early on in 
the intra-embryonic angioblasts in the mouse as well as different affinities for VEGF 
(Waltenberger et al., 1994, Dumont et al., 1995).  Following vessel formation Flk-1 
expression is reduced while Flt-1 expression, along with other endothelial tyrosine 
kinases remains (Fouquet et al., 1997, Dumont et al., 1995, Waltenberger et al., 1994).  
An inhibitory mechanism exists utilising a soluble truncated form of Flt-1 (sflt-1), which 
has been shown to bind to VEGF as strongly as full length Flt-1 and acts by inhibiting 
VEGF activity by sequestering it from other receptors and forming non-signaling 
heterodimers with Flk-1 (Robinson and Stringer, 2001).  In the zebrafish flt-4, kdr and 
kdr-like are co-expressed in the blood vessels, except in the dorsal aorta.  Here flt-4 is 
down-regulated as development proceeds, indicating that flt-4 is not required for 
arterial differentiation of endothelial cells in the dorsal aorta (Covassin et al., 2006).  It 
is proposed that developmental stage and spatial expression patterns of vegf-a and 
vegf-c are responsible for the ligand accessibility and therefore receptor sensitivity in 
the various vessels in the zebrafish (Covassin et al., 2006).  Differences are observed 
between the phenotypes of loss of function (LOF) of flk-1 in the zebrafish and in the 
LOF of Flk-1 and Flt-1 in the mouse.  In the zebrafish LOF of flk-1 has been shown to 
only disrupt angiogenic sprouting from pre-existing vessels leaving the initial 
vasculogenesis and haematopoiesis unaffected, where in the mouse more initial 
disruptions are observed (Habeck et al., 2002).  These differences are ascribed, by 
Habeck et al, to be down to the fact that in the mouse the primary vascular plexus is 
formed and remodeled whereas the zebrafish vascular system forms initially without 
apparent remodeling (Habeck et al., 2002, Isogai et al., 2001).   
The different vegf ligands have been shown to interact with distinct vegf receptors, 
albeit with some level of overlap.  VEGF-A interacts with FLT-1 as well as FLK-1/KDR, 
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sFLT-1 and Neuropilin (NRP-1), VEGF-B interacts with FLT-1, sFLT-1 and NRP-1, VEGF-C 
and VEGF-D interact with both KDR/FLK-1, FLT4 as well as Integrin αvβ3 and VE-
Cadherin (VEC) (Neufeld et al., 1999, Veikkola et al., 2000).  While signaling through 
FLT-1 and FLK-1/KDR as well as NRP-1 and Integrin αvβ3 has been implicated in 
angiogenesis, signaling through FLT-4 and VEC has been implicated in developmental 
angiogenesis and lymphangiogenesis (Veikkola et al., 2000, Neufeld et al., 1999, 
Shibuya, 2006, Vlahakis et al., 2005).    
In the zebrafish, endothelial cells that line the various vessels in the developing 
zebrafish embryo have arterial and venous identity before circulation starts.  A 
hierarchical signaling cascade was established leading these fate choices (Lawson and 
Weinstein, 2002a, Weinstein and Lawson, 2002), although alternative pathways may 
exist (Wilkinson et al., 2012, Nicoli et al., 2008) (See Figure 25).   
 
 
Figure 25 Signaling in artery-vein differentiation is distinct in order to generate 
distinct tissue 
This flow chart indicates the hierarchy of signaling that induces the difference between 
early arteries and veins (Lawson and Weinstein, 2002a, Lawson et al., 2002). 
 
This signaling cascade is probably also involved in the migration of endothelial 
progenitors (Lawson and Weinstein, 2002a) and lays down the basis for the vascular 
and haematopoietic lineages, as well as in distinguishing between arteries and veins 
(Wang et al., 1998, Adams et al., 1999, Gerety et al., 1999, Herbert et al., 2009).  As the 
endothelial cells migrate under the somites and later, when they reach the midline, 
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dorsally towards the notochord, they are exposed to a variety of signals that is likely to 
determine their final fate choices (See Figure 26). 
 
 
Figure 26 Migration of vascular progenitors in the zebrafish has been described 
and followed in detail, responsive to levels of different cues. 
A) Shh expression in the notochord has been shown to drive the expression of vegf in 
the surrounding somatic tissue, inducing angioblasts from the dorsal lateral mesoderm 
(green), which are then in close proximity to the Vegf.  B) Later in mid-somitogenesis, 
local Vegf activates the Notch pathway, potentially through induction of notch5 in the 
developing dorsal aorta, which goes on to induce expression of ephrinB2a.  Vascular 
progenitors then migrate towards the midline, with arterial progenitors leading the 
way (purple).  C) In late somitogenesis distinguishing the artery from the vein is induced 
by the down-regulation of vein markers (eg. flt4 becomes restricted to the posterior 
cardinal vein (blue circle), and is actively repressed by the Notch pathway) in the 
arteries (red circle = artery). Reprinted by permission from Macmillan Publishers Ltd: 
Arteries and veins: making a difference with zebrafish (Lawson and Weinstein, 2002a) 
copyright (2002) 
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The pruning, maturation and remodeling of this initial plexus is then initiated and 
termed angiogenesis (ten Dijke and Arthur, 2007). 
 
1.8.2 Angiogenesis 
Angiogenesis is the physiological process, which occurs in response to tissue hypoxia, 
disease and developmental alterations (Carmeliet, 2003).  It allows the adaptation of 
the blood vessel network with the branching of new blood vessels from pre-existing 
ones.  This process is implicated in multiple disease processes such as wound healing, 
ischemic myocardial infarction, atherosclerosis, rheumatoid arthritis and tumour 
angiogenesis (Fong, 2008). 
Non-sprouting (intussusceptive) angiogenesis allows for rapid formation of new blood 
vessels under flow, within minutes to hours of the initiation of the process, without 
proliferation of endothelial cells (Risau, 1997).  Sprouting angiogenesis on the other 
hand is a slower process with an invasive component, expanding the blood vessel 
network into un-vascularised tissues (Burri et al., 2004).   
Sprouting angiogenesis is largely dependent on, and regulated by, the downstream 
targets of the hypoxic signaling pathway, such as VEGF (Fong, 2009).  The process is 
initiated when a cell within the vascular wall is induced to become a tip cell.  This is a 
process that depends on the activation of the VEGF receptor (Gerhardt et al., 2003, 
van Rooijen et al., 2010).  A tip cell becomes pro-migratory, extending filopodia into 
the surrounding tissue to aid directional migration.  Behind this tip cell, stalk cells 
proliferate extending the new vessel before it is lumenised and becomes competent to 
carry flow (Figure 27 shows a schematic representation). 
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Figure 27  The process of adaptive angiogenesis in a schematic diagram 
A) The induction of the tip cell, followed by the proliferation of stalk cells and the 
eventual lumenisation of the new vessel, adapted from various sources, including 
(Liman and Endres, 2012, Lammert and Axnick, 2012). B) Figure adapted from Figure in 
(Phng and Gerhardt, 2009) review on the role of Notch in angiogenesis, describes the 
different features of endothelial tip and stalk cells in the vasculature. 
 
These processes are complex and involve the co-operation of multiple signaling 
pathways in addition to VEGF and Notch, which play roles not only in the developing of 
the vessels but in distinguishing their fate from arteries and veins (Nunes et al., 2011).  
The migratory cues to guide the new branching have been linked to the expression of 
cytokines and their receptors, such as stromal-cell-derived factor 1 (Sdf1)/Cxcl12, 
reviewed by Ho et al (Ho et al., 2012).  Motility of neuronal cells can then be shown to 
be enhanced by the presence of Aspartyl-(asparaginyl) β-hydroxylase (AAH), which in 
turn has been shown to hydroxylate Notch in a HIF independent manner (Lawton et 
al., 2010), this could also be possible as a mechanism in the vasculature.  Along with 
the migratory nature of the new tip cells, in order to invade into novel tissues the 
extracellular matrix is remodeled (Foskett et al., 2011).  A list of other genes involved 
in both vasculo- and angiogenesis is tabulated in a review by Heinke et al, along with 
the phenotypes of the various knock-out mice models that have been generated 
(reviewed in (Heinke et al., 2012)).  This collates findings from Vegfa-/- mice, which 
demonstrate abnormal blood island formation and reduced embryonic vasculature, to 
55 | P a g e  
 
Ang2-/- mice, which also have impaired lymphatic vessel formation and patterning as 
well as defects in the development of the vascular bed.  Notably, Hif-1α-/- mice 
demonstrate malformed hearts, yolk sacs and embryonic vasculature and have been 
shown to be embryonic lethal at E11 (Heinke et al., 2012, Patel-Hett and D'Amore, 
2011).   The common feature of the null models that are described in this table is that 
they result in embryonic lethality between E6.5 and E13.5, indicating the necessity of 
these processes of vascular control in the development of the embryos.   
The process of angiogenesis has been modeled in several different in vitro, in silico and 
in vivo systems (Geudens and Gerhardt, 2011, Guidolin et al., 2011).  Most importantly, 
the mouse retina and the zebrafish trunk have both been used to assess sprouting 
angiogenesis, along with studies of vascular patterning in the mouse hindbrain, 
hindlimb and the cornea.  
 
1.8.3 Tumour Angiogenesis and Vasculogenic Mimicry 
A solid tumour can only reach a critical dimension before hypoxia in its center up-
regulates mediators such as HIF and downstream targets like VEGF (Nagy et al., 2009, 
Chung et al., 2010, Evans et al., 2012), which is where tumour angiogenesis resembles 
normal developmental angiogenesis (Persson and Buschmann, 2011, Helfrich and 
Schadendorf, 2011).  In development though, the restoration of oxygen as the tissue is 
sufficiently vascularised leads to the down-regulation of angiogenic initiators such as 
VEGF, allowing the vessels to mature.  In tumour growth the proliferation of vascular 
tissues is unlimited and uncoordinated, see Figure 28 (Chung et al., 2010).   
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Figure 28  Failure to resolve the angiogenesis cascade results in pathological 
angiogenesis.   
A) Shows the process of physiological angiogenesis following a stimulus such as 
hypoxia.  The increase in growth factors (GFs) such as VegfA causes vessel 
destabilization and initiates vascular sprouting.  Matrix metalloproteinases (MMPs) 
facilitate remodeling of the extracellular matrix (ECM).   On vessel stabilisation Vegf 
levels drop and platelet-derived growth factor (PDGF), angiopoietins (Ang) and 
transforming growth factor β1 (TGF-β1) levels increase to begin the resolution phase 
responsible for stabilisation and recruitment of smooth muscle cells to the new vessels.  
B) Shows how under pathological conditions, tumour-secreted VegfA can initiate the 
angiogenesis cascade.  The tumour cells have also been shown to increase expression 
of soluble factors responsible for activating fibroblasts and attracting immune cells, 
and these stromal cell types are capable of sustaining the angiogenic process resulting 
in a failure to resolve and the continued development of immature vessels.  Other 
abbreviations include GcsF (Granulocyte stimulating factor) and IL-1β (interleukin-1β).  
Reprinted by permission from Macmillan Publishers Ltd: (Chung et al., 2010) Targeting 
the Tumour Vasculature: Insights into Physiological Angiogenesis copyright (2010) 
 
Due to high levels of VEGF and other oncogene driven factors, tumour vessels are 
enlarged, disorganized (Persson and Buschmann, 2011, Nagy et al., 2009) and tend to 
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be leaky (Nagy et al., 2012, Weis and Cheresh, 2005, Maeda, 2001) and in this they 
resemble and respond to similar signals and cues as collateral vessels.  Vascular density 
tends to be highest at the interface between the tumour and the host, in both the 
tumour and the host tissue, with uneven distribution, flow directions and shunts 
throughout the network, leading to decreased blood flow in the tumour compared to 
the host (Persson and Buschmann, 2011, Halin et al., 2009).   
 
1.8.4 Vascular Patterning of the Zebrafish 
 Vascular development has been largely studied in vertebrate models, despite 
techniques that often require that the animal be sacrificed for imagining, which often 
affects the number of time points that can be studied.  However the zebrafish provide 
advantages to established techniques in higher vertebrates.  Many have been 
described in the previous section, including their small size and the oxygen availability 
through diffusion in the embryos.  An extensive study of the normal development of 
the zebrafish blood vessel network was undertaken, using confocal imaging and micro-
angiography to map the network over development, by Isogai et al 2001 (Isogai et al., 
2001).   
The predictable patterning of the vasculature of the zebrafish and the extent of the 
information that is available provides an invaluable tool for the study of defects to this 
patterning.   See Figure 29 for a schematic simplification of the key trunk vasculature in 
the zebrafish embryo.   
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Figure 29 A simplified representation of key blood vessels in the zebrafish at late 
embryonic stages demonstrates the regularity of the network 
A greyscale image of a 5dpf wild type zebrafish embryo has been shown here with a 
schematic simplification of some of the key blood vessels and their nomenclature.  
 
The time scale of various assays including the application of vascular inhibitors and the 
appearance of alterations to the vasculature are shown to their comparison when in 
the context of the other animal models.  For example in the study of angiogenesis 
inhibitors (24-48hours) to observe a response in the zebrafish compares with the chick 
(3-4 days) and the murine matrigel plug assay (5-7days), murine (1week) and rabbit (2-
3days), or the mouse xenograft model (several weeks) (Tobia et al., 2011).   
 
1.9 Thesis Aim 
This thesis aims to test the hypothesis that FIH functions in both the HIF/Notch 
pathways focusing on blood vessel development and patterning, and to possibly 
identify further targets, either via transcriptome analysis or detailed phenotypic 
characterisation exploiting a recently created fih null zebrafish line. 
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2  Materials and Methods 
1 Zebrafish 
2.1.1 Fish Maintenance and Feeding 
Zebrafish were fed live artemia brine shrimp, which was hatched in aerated hatchers 
of salted water once a day and a supplement food (flake or pellet) once a day.  They 
are maintained on a 14hour day:10hour night cycle, to simulate sunrise and ensure a 
consistent time for first-light, the time at which the zebrafish will lay eggs.  The water 
temperature is maintained at 28oC and pH 7.   
 
2.1.2 Genetic Crosses 
Individual pairs of adult fish were mated in boxes with mesh for the embryos to fall 
through and collected in a lower box.  Dividers were used overnight and removed the 
following morning where the timing of the lay was important and wanted at some 
point after 8am.    Embryos were collected and the adult fish are returned to their 
tanks.  Fertilised eggs were sorted from un-fertilised ones into Petri dishes and the 
aquarium water was replaced with E3 medium.  The embryos developed in incubators 
kept at 28oC.  
 
2.1.3 Zebrafish Lines 
Wild type strains used included LWT zebrafish strain (where out-crossing mutant lines) 
and Nacre (where embryo imaging would be enhanced by lack of pigmentation).   
Mutant strains included single mutant adults (vhl+/- adult fish, fih+/- and fih217/217 
adult fish), as well as double mutant adults (fih+/-;vhl+/- and fih217/217;vhl+/- adult 
fish).  For assays comparing fih217/217 embryos to wild type, in order to increase the 
number of embryos that could be imaged without the need for post-assay genotyping, 
fih+/- adult fish were crossed to LWT adult fish, resulting in fih+/+ and fih+/- embryos, 
for this study these were interpreted as being wild type.  
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Fih;vhl x Tg(csl-venus)qmc61- (Gering, M. pers. Comm.) provided a GFP read-out of 
cells expressing Notch.  Fih;vhl x Tg(Fli1:eGFP) line allows for the visualisation of the 
vasculature (Motoike et al., 2000, Lawson and Weinstein, 2002b).  Fih;vhl x 
Tg(Flk1:eGFP-NLS) line allows for quantification of endothelial cells as the GFP is 
nuclear localised (Blum et al., 2008).  Fih;vhl x Tg(Phd3:eGFP) line developed by 
Santhakumar et al provides a read-out for phd3 expression and a surrogate read-out of 
hypoxic signaling (Santhakumar et al., 2012). 
 
2.2 Embryo Handling and Genotyping 
2.2.1 De-chorionating Embryos 
Chorions can be removed manually using watchmen forceps to gently release the 
embryos from the chorions.  Alternatively embryos were treated with 1mg/ml Pronase 
in E3 media for 10 minutes at room temperature to degrade the chorions and aid 
removal.   
 
2.2.2 Fixing Embryos 
Embryos were anaesthetised using tricaine in the E3 medium and transferred to 
labeled tubes.  The medium was removed and replaced with 4% para-formaldehyde 
(PFA) in PBS to cover and fix the embryos.  The tubes were stored at 4oC overnight and 
then the PFA was washed off using PBS.  If required embryos were then transferred 
through a series of methanol solutions in PBS; 25%, 50%, 75% and 100% methanol to 
protect the embryos and then stored in the freezer at -20oC. 
 
2.2.3 DNA Preparation from Embryos or Fin Clips 
Embryos/fins were collected in methanol to dehydrate the tissue before the methanol 
was evaporated off at 80oC.  25ul of TE tween was added and heated to 98oC for 15 
minutes in a PCR machine and the block cooled completely before 5ul of 10mg/ml 
proteinase K was added and the samples left at 55oC overnight with the lid at 110oC.  
The proteinase K was deactivated by heating the block to 98oC for 15 minutes and the 
block was cooled again. The samples were made up with 25ul of TE. 
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REDExtract-N-Ampt Tissue PCR Kit (Sigma Aldrich) was also tested for extraction of 
DNA.  Individual embryos could be placed in 0.2ml PCR tubes.  25µl of extraction 
solution was added followed by 6.25µl of tissue preparation solution.  The sample was 
initially incubated at room temperature for 10 minutes and then incubated at 95oC for 
3 minutes.  25µl of neutralising solution was added to the sample before vortexing and 
storing at 4oC. 
 
2.2.4 Genotyping from Embryos or Fin Clips 
Genotyping PCR solutions were set up by making a master mix as per the recipe in 
Table 4, before being placed in a thermal cycler for the PCR reaction.  See Tables 5 and 
6 for PCR program parameters.  The PCR products were then stored at 4oC. 
Reagent FIH/VHL PCRs - 
Volume (µl) 
Gal4/NICD PCRs - 
Volume (µl) 
2x Biomix (Qiagen) 10 10 
Forward Primer 0.1 1 
Reverse Primer 0.1 1 
ddH2O 8.8 6 
DNA 1 2 
Total 20 20 
Table 4 Reagents and volumes of the PCR reaction mixture used to amplify fih 
and vhl (column 1) and gal4 and NICD (column 2) 
 
FIH genotyping primers:  
F – 5’ TGTAGGAGCCTGTTGTACTGA 3’ 
R – 5’ GAGTTTGTGGACAAGATGCA 3’ 
Step Process Temperature (oC) Time (minutes) Cycles 
1 Denaturation 94 4 1 
2 Extension 92 0.5 35 
3 Annealing 56 0.5 
4 Elongation 72 0.5 
5 Final Elongation 72 10 1 
6 Hold 10 Forever  
Table 5 PCR program used for FIHexn genotyping 
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VHL genotyping primers:  
F – 5’ CCGACTCTCACAAGATTACGC 3’  
R –5’ CTC CGAGGAAGTTGATCCAG 3’  
Step Process Temperature (oC) Time (minutes) Cycles 
1 Denaturation 94 4 1 
2 Extension 92 0.5 39 
3 Annealing 56 0.5 
4 Elongation 72 0.6 
5 Final Elongation 72 10 1 
6 Hold  10 Forever  
Table 6 PCR program used for vhl1exn genotyping  
 
The PCR programs were run using 1ul of the DNA extracted from the embryo or fin clip 
to be identified.  Running 5µl out on a 1% agarose gel checked the PCRs had worked 
(226bp for FIH PCR and 412bp for VHL PCR).  To identify mutants from siblings 
diagnostic digests were performed.  For FIH PCRs a digest of 5µl of the PCR using MseI 
enzyme and for VHL PCRs a digest of 5µl of the PCR product using BciVI enzyme, see 
Table 7 for reagents and volumes used for the digestion. 
 
Reagent FIH - MseI Mixture 
 Volume (µl) 
VHL - BciVI Mixture 
Volume (µl) 
Buffer 1.8 (2) 1.8 (4) 
BSA 0.1 0 
Enzyme 0.1 (MseI) 0.2 (BciVI) 
ddH2O 13 13 
PCR product 5 5 
Total 20 20 
Table 7 Reagents and volumes used for digestion of PCR products in diagnostic 
digests in fih and vhl genotyping 
 
The digests were performed at 37oC overnight and the whole digest was run out on a 
1% agarose gel for VHL PCR/digest and 3% agarose gel for FIH PCR/digest. See Figure 
30 for representation of agarose gel post digestion. 
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Figure 30 Indicates expected band sizes following diagnostic digestion  
A) Indicates the expected band sizes of VHL PCR product after digestion with BciVI 
enzyme in a wild type embryo (367bp and 80bp).  In the VHL mutant embryos the BciVI 
enzyme site is lost and the enzyme won’t cut, leaving one band.  In the vhl-/+ embryos 
there will also be the presence of a third band at the uncut size 412bp.  B) Indicates the 
expected band sizes of FIH PCR product after digestion with MseI enzyme for a wild 
type embryo (72bp and 154bp). C) Indicates the expected band sizes of FIH PCR product 
after digestion with MseI enzyme for an fih217/217 embryo (134bp, 72bp, 20bp).   
 
A transgenic line for the gal4-heat shock driven induction of notch signaling 
(hsp70:Gal4;UAS:mycnotch1a-intra) (Scheer et al., 2002) was also used to test the 
Tg(csl-venus)qmc61 transgene, below are primers and PCR programs for the 
identification of the gal4 and NICD components of this line during genotyping.   
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Primers for identification of Gal4: 
F - 5’ CGCTACTCTCCCAAAACCAA 3’ 
R - 5’ CAGTCTCCACTGAAGCCAATC 3’ 
Step Process Temperature (oC) Time (minutes) Cycles 
1 Denaturation 94 3 1 
2 Extension 94 0.5 30 
3 Annealing 55 0.5 
4 Elongation 72 0.5 
5 Final Elongation 72 3 1 
6 Hold  8 Forever  
Table 8 PCR program for identifying Gal4  
 
Primers for identifying NICD: 
F - 5’ CATCGCGTGTCAGCCTCAC 3’ 
R - 5’ CGGAATCGTTTATTGGTGTCG 3’ 
 
Step Process Temperature (oC) Time (minutes) Cycles 
1 Denaturation 9 3 1 
2 Extension 94 0.5 34 
3 Annealing 61 0.5 
4 Elongation 72 0.75 
5 Final Elongation 72 5 1 
6 Hold  8 Forever  
Table 9 PCR program for identifying NICD 
 
Unlike the FIH and VHL PCRs, the Gal4 and NICD PCRs would only amplify in a positive 
sample, so negative controls were run each time, with no DNA, to confirm that positive 
amplification was the result of a positive PCR.   
 
2.2.5 Gel Electrophoresis 
Amplified gDNA product following PCR process was run on a 1% agarose gel for 15 
minutes at 100 volts.  1% agarose was made up using 1g agarose dissolved in 100ml 
1xTAE (242g of Tris Base, 57.1ml acetic acid and 100g 0.5mM EDTA, made up to 1 litre 
of dH2O) and 50µl of Ethidium Bromide.  5µl of PCR product was loaded into each well 
on the agarose gel with 5µl of an appropriate hyperladder in the first lane to assess the 
size of the DNA bands.  The gel was imaged under ultraviolet light using a Uvitec 
lightbox.  For 3% agarose gels, used for fih-mseI digests in order to separate smaller 
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fragments, a 1:1 ratio of standard agarose and low-melt-point agarose was used and 
the agarose added to TAE and left on a roller for 1 hour, in order to aid in the melting 
and prevent boiling over. 
 
2.2.6 Purification of PCR Products 
Prior to sequencing a PCR product the sample must be purified to remove residual 
nucleotides.  Two hydrolytic enzymes are used for this process, Exonuclease 1 (Exo) 
and Shrimp Alkaline Phosphatase (SAP), which are mixed and added to the PCR 
product in a total volume of 10µl using the volumes shown in Table 5.  The mixture is 
vortexed and placed in a thermal cycler and incubated at 37oC for 45 minutes followed 
by inactivation of the enzymes at 95oC for 15 minutes.   
Reagent Volume 
Exo1 (20 U/µl) 0.15 
SAP (1 U/µl) 0.90 
PCR Product 7.00 
Water 1.95 
Total Volume 10 
Table 10 Volumes of reagents in EXO/SAP mixture used to purify PCR products 
prior to sequencing 
 
10µl of purified PCR product are required to send to the Core Genomic Facility at 
Sheffield University, along with 10µl of 1pmol/µl forward primer for DNA sequencing. 
 
2.2.7 Mounting Embryos 
Embryos were mounted in 0.7% low melting point agarose (LMPA) in E3 containing 
400µl of tricaine in 10mls.  For confocal microscopy, embryos were mounted on a 
coverslip on the bottom of a 35mm petri dish.  For standard compound microscopy, 
embryos were mounted on a coverslip.  
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2.3 Vascular Assays 
2.3.1 Vascular Imaging 
Two key endothelial transgenic lines were crossed into the mutant lines.  The 
Tg(Fli1:eGFP) line allows for the visualisation of the vasculature (Motoike et al., 2000, 
Lawson and Weinstein, 2002b) and the transgenic line Tg(Flk1:eGFP-NLS) line allows 
for counts to be made of the cells in the endothelium since the GFP label is nuclear 
localised within the endothelial cells (Blum et al., 2008).  The Perkin Elmer Ultraview 
Vox Spinning Disc confocal microscope and various objective lenses was used to 
observe the blood vessel network of the various mutants at various stages and 
treatments to observe changes in vascular patterning and endothelial cell number.   
Automated method for counting endothelial cells involved imaging the embryos with 
the Tg(Flk:eGFP-NLS) transgene in the background, importing Z-stacks of images at 
maximum intensity.  The images were converted to type 8-bit, and then adjusted to 
maximise the brightness and contrast until only the endothelial cells remain (white) on 
a black background. Using the process tool bar, the image was then converted to 
binary, and analysed to count the particles.   
 
2.3.2 Angiograms 
Using the 16x objective on the Olympus IX81 microscope with a Basler high-speed 
camera images were taken of embryos with the aorta horizontal along the image.  
Images were taken at a rate of 200-500 frames per second and each image saved 
individually.  The images were processed using ImageJ by importing the sequence of 
images and then removing half of the images from the other half of the images, leaving 
a trace of the pixels that had moved between the two sets.  The resulting image was 
processed in order to maximise the contrast between the trace and the background 
and coloured using the Fire lookup table in the ImageJ program.  This was then 
overlaid onto a single image from the original photographs to act as a reference (Chico 
et al., 2008). 
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Figure 31 Image deletion angiograms generated from high-speed imaging.   
A) represents a single frame for the overlay of the angiogram, to give representative 
orientation for the vasculature B) single frame image-deletion angiogram C) an overlay 
of greyscale image with the image-deletion angiogram.   
 
2.3.3 Vascularisation Index 
Three parallel lines were drawn from the pigment line to the notochord over the top of 
vessel bed images, from the first to the eighth somite.  A count was made of the 
number of vessels that intersected with each of the lines, and the sum of these counts 
was plotted to represent the vascularisation index of the embryos (Pelster et al., 2003, 
Yaqoob and Schwerte, 2010), see Figure 32. 
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Figure 32 Method for assessing vascularisation index 
Counts made of the number of vessels that cross over each line. 
 
2.3.4 Haemodynamics 
Using the 16x objective on the Olympus IX81 microscope with a high-speed camera 
and Video Savant software, images were taken of mounted embryos, ensuring the 
aorta horizontal along the image.  Images were taken at a rate of 300 frames per 
second and each image saved individually. The images were imported and processed 
using ImageJ by importing the sequence of images and using the select tool to draw a 
rectangle along the length of the aorta 1 pixel high and the length of 3 somites either 
side of the anus (to maintain consistency).  This was then cropped and saved as a raw 
data file.  The raw data file was then imported, ensuring that the width was adjusted to 
the width of the line that had been drawn, to create a visual kymograph of the aorta 
with the path of individual erythrocytes demonstrated as individual traces.  The height 
of the kymograph is representative of the amount of time that had passed while the 
width of the kymograph represents the distance along the aorta.  The scales were 
adjusted accordingly and the width and height of individual erythrocytes were 
measured using a rectangle drawn in ImageJ, allowing velocity to be calculated using 
the formula:  
Velocity (µm/s) = Distance (µm) 
             Time (s) 
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Figure 33 An example of a kymograph that was derived from imaging a wild type 
embryo  
The box indicates the tracking of an erythrocyte from the start to the end of a heart 
beat, the measurements of which are used to calculate its rate.  
 
The width and height of this rectangle were then put into a spreadsheet and the height 
converted to time and the distance and time used to calculate speed of the pixel that 
curve represented.  3 measurements were taken from each kymograph, so the speed 
recorded was an average for each fish.   
 
2.3.5 Heart Image Analysis and Cardiac Output 
Using an Olympus IX81 microscope connected to a high speed camera, images of the 
heart were taken at 300 frames per second, through a 20x objective lens.  Analysis of 
the images was performed using ImageJ software.  The number of frames to complete 
two heart beats was used along with the frame rate of the recordings to calculate the 
heart rate in beats per minute.  The perimeter of the ventricles was outlined for the 
end-diastolic (EDV) and end-systolic (ESV) volumes.  The software utilises a ‘Fit Ellipse’ 
algorithm, calculating the center of mass and the major and minor axes of the ellipse, 
with the same volume as the perimeter drawn around the ventricle.  These 
measurements were transferred into an Excel spreadsheet and used along with the 
formula of a prolate spheroid; 
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Ventricular volume = 4/3 x π x a x b2, where a and b refer to half of the long and short 
axes of the ventricle.   
The mean stroke volume (µl3) was calculated from the difference between the end 
systolic volume (eSV) and end diastolic volume (eDV) (across two ventricular eDV and 
eSV); 
Stroke volume (µl3) = eSV (µl3) - eDV (µl3) 
Ejection volume (µl3) = stroke volume (µl3) 
            eDV (µl3) 
 
Cardiac output (µl3/min) = stroke volume (µl3) x heart beats (beats per minute) as 
described in (van Rooijen et al., 2010).   
 
2.3.6 Erythrocyte Density 
Using an Olympus IX81 compound microscope connected to a high speed camera, 
images were taken at 300 frames per second, through a 40x objective lens of the sixth 
to tenth somite with the aorta horizontal in the frame.  Analysis of the images was 
performed using ImageJ software.  In a 200µm section of the aorta a count was made 
of the number of erythrocytes.  Three measurements were taken of the diameter of 
the aorta and the diameter of erythrocytes.  Based on the volume of a cylinder being 
πr2xl (where r = radius and l=length), and the volume of an erythrocyte being πr2x0.3 
(Schwerte et al., 2003).  These calculations were used to produce a volume of the aorta 
in µm3 and converted into nl to give a final figure of erythrocytes/nl.   
 
2.3.7 Vascular Competence 
Embryos carrying the Tg(Fli1:eGFP) were collected and mounted, at 4dpf.  Using a 
micro-injector needle 2,000,000MW tetramethylrhodamine dextran (TAMRA) dye 
(Invitrogen Molecular Probe) was injected into the common caudal vein, see Figure 34.   
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Figure 34 Method plan for the injection of dye into the zebrafish embryos to 
study the integrity of the blood vessels 
 
These embryos were imaged overnight using the Perkin Elmer Spinning Disc confocal 
microscope to observe the movement of the dye within the circulation (E. Van Rooijen 
et al. 2010)( http://products.invitrogen.com/ivgn/product/D7139).   
 
2.4 Molecular and Genetic Analysis 
2.4.1 In situ Hybridisation 
The protocol was an adaptation of (Thisse and Thisse, 2008), as described in (van 
Rooijen et al., 2010, van Rooijen et al., 2009). 
 
2.4.2 Microarray 
Agilent Two Colour 4x44k Zebrafish Version 1 Microarrays were selected for the 
comparison of the gene expression patterns.  Four sets of comparisons were designed 
to compare:  
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Slide 1  fih+/-; vhl +/+         vs fih217/217; vhl+/+  
 
Slide 2  fih+/-; vhl+/+         vs fih+/+; vhl-/-  
 
Slide 3  fih+/-; vhl+/+         vs fih217/217; vhl-/-  
 
Slide 4  fih+/+; vhl-/-         vs fih217/217; vhl-/-  
 
For the purposes of the Microarray wild type embryos were those from a fih-/+ x LWT 
cross.  For each comparison samples were stage matched at 3dpf, identified by 
phenotype for mutation and snap frozen in liquid nitrogen, in triplicate, and stored at -
80oC.  Several individual embryos from each cross were preserved in methanol for 
genotyping to confirm the ID of the frozen embryos.   
Sample preparation was performed on batches of whole embryos, with a minimum of 
10 embryos in each sample, attempting to keep the number of embryos in each group 
the same wherever possible to remove bias.  Whole embryos were selected rather 
than specific tissues/regions in order to assess global alterations in gene expression in 
the embryos.  Each group, wild type and mutant alike, was going to be assessed in 
triplicate so sample preparation occurred over several batches, with embryos 
collected, sorted, and prepared at the same time of day in order to maintain 
consistency between the samples.  RNA Extraction of the samples was performed 
using an Invitrogen mirVana RNA isolation kit, and the RNA concentrations were 
quantified using a Thermo Scientific Nanodrop 1000. 
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Figure 35 Nanodrop data following labeling 
Data used for quantifying the amount of labeled RNA in each sample, and in the 
calculations for loading the two samples for comparison onto microarray slides (see 
(Agilent) for calculations). 
 
In order to assess the quality of the RNA the samples were run through an Agilent 2100 
Bioanalyser, to assess for break-down products and integrity and all the samples were 
deemed to have sufficient integrity to proceed with the microarray.  An Agilent RNA 
6000 Nano kit was used to load small aliquots of the RNA samples into a gel for 
quantification and analysis of the samples.   
The RNA was labeled with Cy3 or Cy5 dye using an Agilent Low RNA Input Labeling Kit 
as per the protocols designated by Agilent.  The concentration of RNA to use was 
limited by the sample with the lowest concentration and a total input volume in the kit 
of 1.5ul.  The dye incorporation and final concentration of the RNA sample was 
quantified again on the Thermo Scientific Nanodrop 1000. 
The microarrays were run by continuing the follow the Agilent protocol (Agilent) for 
two-colour microarray-based exon analysis (low input quick amp labeling).  The 
samples were mixed and loaded onto gasket slides before the array slides were 
clamped onto them and the slides hybridized overnight in an Agilent Hybridisation 
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Oven at 65oC.  The slides were then removed from the gasket slides and washed 
before being loaded into the Agilent Microarray Scanner and analysed.  The data from 
the microarrays was fed into GeneSpring software for analysis of genes with altered 
expression compared to WT.  Gene expression changes that indicated a fold change 
above log 1 (2 fold) in the mutants compared to the wild type siblings were considered 
to be a hit.   
 
2.4.3 Quantitative Real Time PCR (qRT-PCR) 
Primers were designed to span neighbouring exons in the cDNA of each gene of 
interest (GOI).  Standard gradient PCRs were performed over a range of annealing 
temperatures in order to test the primers.  The product from the optimised band was 
cleaned up with an EXO/SAP reaction and sent for sequencing in order to confirm the 
correct section of the GOI was being amplified specifically.   
 
Abbreviation Gene Name GenBank 
Accession 
Number 
Primer sequence (5’ – 3’)  
 
Agt Angiotensinogen NM_198063.1 GGGCGTAACTCCAAAGACTG 
CATGAACGTCCTCTTGCTGA 
Ace1 Angiotensin 1 
Converting Enzyme 1 
wu:fb81h03-201 GGAGAAACCCACTGATGGAA 
TTCTGAAGCTCACTGGCTGA 
Ace2 Angiotensin 1 
Converting Enzyme 2 
NM_001007297.1 GCCAAGCTCAACAACTACGA 
GCAAATGTGCTGGAAGACAG 
Cyp11b2 Aldosterone Synthase NM_001080204.1 GAGAGACACGCAGACACAGC 
ACTGGGGTCAAGGGTCAGT 
Renin Renin NM_212860.1 TCTCTCTCAGCGATCAGC  
TCTGAGCTGGTGAACCAATG 
Phd3 (Egln3) Prolyl Hydroxylase 
Domain Containing 
Protein 3 
NM_213310.1 CGCTGCGTCACCTGTATT 
TAGCATACGACGGCTGAACT 
Vhl Von Hippel Lindau NM_001080684.1 ATGTCGGCTGTCTGGAGATT 
GATGCACAGGTGTGCTCAGT 
Vegfab-201 Vascular Endothelial 
Growth Factor A 
NM_001044855.2 CAGTGTGAGCCTTGCTGTTC 
CCATAGGCCTCCTGTCATTT 
Vegfc 
 
Vascular Endothelial 
Growth Factor C 
NM_205734 AAGAAGCTGGATGAGGAGACG 
GAGGTTGACTCCTCGGACAC 
Kdr/Flk1 
 
Kinase Insert Domain 
Receptor (VegfR2) 
NM_131472 CGCGCAACAGGTCACTATT 
GTGAGGAGGATGTCGAGGAG 
Flt4 
 
FMS Rleated Tyrosine 
Kinase 4 (VegfR3) 
NM_130945 TCTCGTTAGTGCCGTATCCA 
GATGATGTGTGCTGGCTGTT 
EphrinB2 
 
EphrinB2a Receptor NM_131023 ACCACGTTGTCACTCAGCAC 
AGATGTTTGCTGGGCTCTGT 
Amy2a Amylase2a NM_213011.1 CAAACGGCAATCTCTGACC 
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ATGGAGCTGGAACTCCTTCA 
Ctrb1 Chymptrypsinogen NM_212618.1 CTGGCCACTCCTGCTAAGAT 
TGCAGTCTTCATTGGTCAGC 
Glut1 Glucose transporter 1 NM_001039808 ACTGCTGTGATTGGCTCCTT 
TGGCCACTGATACAGACCAG 
Hk1 Hexokinase1 NM_213252 TGGATCTGGGTGGCTCTAAT 
AGGTGAAGCCCACAGGAA 
Prepro Preproinsulin NM_131056 AGTGTAAGCACTAACCCAGGC 
TGCAAAGTCAGCCACCTCAGT 
Pepck Phosphoenolpyruvate 
carboxykinase 
NM_214751 GAGAATTCTCACACACACACA 
GTAAAAGCTTTCCGCCATAAC 
Alas2 Aminolevulinate 
synthase 2 
NM_131682.2 GCTCTCAGGTGTCTGTGTGG 
TAGACGGGCCAGTTCATTCT 
Her12 
 
Hairy Related Protein 
12 
NM_205619 GCTGAGGAAGCCGATAGTTG  
GCGAGAGGAAGTGGACAGAC 
Notch3 
 
Notch3(Notch5) NM_131549 CGGCCTGGTTATATTGGTTC 
TCTAAAGCCTCGCTGACACA 
Nrarpa 
 
Notch-regulated 
ankyrin repeat-
containing protein 
NM_181495 AGCTGCTTCGGACTCGTTAC 
CGAGGTAGCTGATGCAGAGA  
Dll4 
 
Delta like ligand 4  NM_001079835 GCTTGGCTCACCTTTCTCAT 
CGGAAGAAAGTCCTGCAGTC 
Cxcr4a C-X-C chemokine 
receptor type 4a 
NM_131882 TTGTGCTCACTCTGCCATTC 
ACCGGTCCAAACTGATGAAG 
Bactin2  actin 2 NM_181601 GCAGAAGGAGATCACATCCCTGGC 
CATTGCCGTCACCTTCACCGTTC 
Table 11 QRT-PCR primer abbreviations, Genbank numbers and Primer sequences 
for all the genes that were validated from the microarray. 
 
QRT-PCR assays were optimised following guidelines described by Nolan et al  (Nolan 
et al., 2006).  A range of cDNA concentrations were selected, a 1/10 dilution series, 
and each line on the graphs in Figure 36 represents a different cDNA concentration.  
The graphs in A and B indicate the amplification curve and melt curve for a pair of 
primers that were re-designed due to the production of primer dimers.  The 
amplification curve (A) indicates a range of threshold values for the range of cDNA 
concentrations, as would be expected, however B) indicates two different peaks in the 
melt curve and this is indicative of the production of primer dimers.  In C and D 
however, the range of threshold values on the amplification curve is more evenly 
spaced and the melt curve (D) indicates only one peak.   These primers would have 
been deemed successful and the assay would have continued.   
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Figure 36 Primer pair optimising  
A) Amplification curve, appear success B) Melt peak, ensure failure, second peak to the 
left indicates potential primer dimer or secondary products C) Amplification curve 
across a cDNA range, peaks provide different ct values and therefore range of ct range 
in correlation with range of cDNA concentration D) Melt peak reveals that despite 
range of cDNA concentrations the single peak indicates consistent product size. 
 
The results of each optimisation were analysed by plotting the threshold ct value 
(where the amplification of product had crossed a computer generated threshold 
number of cycles) against the log of the cDNA concentration in GraphPad software 
program.  The gradient of the line was then calculated using the same software, for 
repeats of each gradient.  The % efficiency was calculated as the average gradient 
divided by -3.3 and multiplied by 100, where -3.3 is the gradient of the line assuming 
100% efficiency, see Figure 37.   
Once this was confirmed a range of cDNA concentrations were run in a qRT-PCR 
reaction.  Starting from 1ug and performing 1/10 dilution series, it was possible to 
observe the linear sensitivity range for each primer pair.   
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Figure 37 Primer Optimisation 
Graphs show the log cDNA concentration plotted against the ct values for each sample 
for7 primer pairs at two different primer concentrations.  Primer Up refers to a 1µl 
volume of 10ng/µl stock of primer added to each reaction, while primer down refers to 
a 0.5µl volume of primer added to each reaction.   
 
This information was used to calculate the primer efficiencies for each pair, and the 
fold changes that will be detectable between wild type and mutant samples for the 
GOI.  The ct analysis method assumes a primer efficiency of 100%, so +/- 10% of this 
was aimed for with each primer pair before continuing in order to avoid building in 
errors.  By plotting the log of the cDNA concentration against the ct values and 
performing linear regression analysis it was possible to get the slope of the lines within 
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the linear range of the primers.  Efficiency was then equal to (the slope of the line/-
3.3)x100, where -3.3 is the slope of a line with 100% efficiency.  Once the primer 
concentrations were optimised and a cDNA concentration was established within the 
center of the linear range of each primer pair, qRT-PCR reactions were set up over 
three biological replicate samples for each of the mutant lines.  Initially the same 
samples were used as for the microarray.   
Within a 96 well plate it was possible to run between 6 and 7 primer concentrations 
over the cDNA gradient with 6 concentrations, therefore between 3 and 4 genes and 
where possible two concentrations of primer were tested simultaneously, in order to 
know whether a decrease or increase in primer concentration would aid optimisation 
when each plate was analysed.  The analysis of the 96 well plate shown in Figure 37 
showed that 0.5µl per reaction of primer at 10ng/µl stock concentration was optimal 
for angiotensinogen (agt) as well as β-actin and that the concentration of primer for 
angiotensin converting enzyme 2 (ace2) and prolyl hydroxylase enzyme (phd3) needed 
to be increased from 1µl per reaction.   
The table below (Table 12) shows a summary of all of the optimisation that was 
performed for each gene that was validated by qRT-PCR for the microarray. 
 
Abbreviation Sequenced Fragment 
Size (bp) 
cDNA 
Concentration 
(ng/reaction) 
Primer Volume 
(µl/reaction – 
10M stock) 
Primer 
Efficiency 
(%) 
Agt X 229 10 0.5 91.18 
Ace1 X 185 10 0.75 101.53 
Ace2 X 228 10 1.75 95.97 
Cyp11b2 X 224 10 1 108.64 
Renin X 173 10 1.5 102.74 
Phd3 (Egln3) X 181 10 0.5 96.58 
Vhl X 189 10 1 96 
Vegfab-201 X 230 10 0.5 102.7 
Vegfc 
 
X  10 0.5 95 
Kdr/Flk1 
 
X  20 1 91 
Flt4 
 
X 164 20 0.5 92 
EphrinB2 
 
X 205 10 1 93.3 
Amy2a X 167 10 0.5 103 
Ctrb1 X 184 10 0.75 91.95 
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Glut1 X 193 10 0.25 91 
Hk1 X 234 10 0.5 93 
Prepro X  20 1.5 94 
Pepck X  20 1.5 97 
Alas2 X 176 10 0.5 97.56 
Her12 
 
X 248 20-25 1.25 111 
Notch3 
 
X 138 20 1.5 116 
Nrarpa 
 
X 229 100 1 95.3 
Dll4 
 
X 155 10 1 92.15 
Cxcr4a X 144 20 0.5 90 
Bactin2 X 322 10 0.5 95.70 
Table 12 Each primer pair used for qRT-PCR was optimised and the parameters 
are indicated in this table.  X indicates that a standard PCR was run and the product 
sequenced in order to confirm amplification of the gene of interest.  The optimised 
cDNA concentration and volume of primer, given a 10ng stock concentration, that was 
ascertained for each primer set for each gene that was validated by qRT-PCR. The 
sequences of each primer pair can be found in Table 11. 
 
Further optimised were the non-template control samples.  Within each qRT-PCR run 
samples were run with no cDNA, these constitute non-template control samples 
(NTCs) and allow a true baseline to be gleaned from the comparison between 
expression in wild type cDNA and expression in the mutant cDNA.  The ideal trace for 
the NTC was to see no amplification of product in the amplification curve, and to see 
no breakdown of product in the melt curve.  Figure 38 demonstrates the traces that 
would be seen if a NTC had contamination that was allowing the primers to generate a 
product (A and B), these results would infer that any difference seen between 
expression of that gene in the wild type samples compared to the mutant samples 
could be contaminated by background DNA and this run would be repeated.  If the 
NTC had no contamination and the primers were unable to generate a product, the 
traces would appear as in C and D.  Here the axes have been amplified and the 
resulting trace shows only the noise within the baseline for both the amplification and 
melt curves.  These samples indicate that true differences can be interpreted between 
the wild type and mutant samples being compared and these samples would not need 
to be repeated.   
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Figure 38 Non-template control Examples 
A and C) are examples of amplification curves for two sets of non template controls 
(NTCs) that passed (A) and failed (B).  B and D) are examples of melt curves for two sets 
of NTCs that passed (B) and failed (D).   
 
Optimisation of these protocols to ensure the quality of the no template control (NTC) 
samples ensured when comparing differences between control and mutant samples 
these were truly the result of these differences and were not obscured by external 
cDNA contamination in any of the reagents used in the master-mix.   
 
2.4.4 In Situ Hybridisation Probe Preparation 
Plasmid would be linearised using an appropriate enzyme, followed by a phenol 
chloroform extraction.  Transcription of the probe was performed by mixing 1µg of 
linear plasmid DNA (where possible) and 10x transcription buffer supplied with 
enzyme, with 2µl 10x DIG labeling mix, 2µl of T7/SP6/T3 RNA polymerase, with “x”µl 
RNase free H2O to make up a final reaction volume of 20µl.   This would be incubated 
for 2 hours at 37oC.  1µl run out on a gel allows the relationship between DNA and RNA 
to be assessed to confirm the transcription success, before adding 2µl (40 units) DNase 
and incubating for 30minutes at 37oC to remove remaining plasmid DNA.  This reaction 
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is then stopped using 2µl EDTA (optional).  RNA is precipitated with 2.5µl 4M LiCl and 
75µ of pre-chilled ethanol for 30minutes on dry ice, at which point a pellet should be 
visible.  Pellets are spun down and dissolved in 100µl RNase free water and stored at -
20oC. 
 
2.4.5 Cloning fih into PCS2+ (Expression construct) 
Bluescript plasmid containing fih gene:  Primers were designed to clone up the fih 
sequence and add BamH1 and Xho1 sites on to the ends of the PCR product.  Phusion 
Taq PCR performed (4 x 20µl reactions) followed by Dpn1 digestion to remove excess 
plasmid DNA.  Following pooling of the 4 reactions, PCR purification was performed 
using the protocols within the Qiagen QiAquick PCR Purification Kit.  Half resulting 
eluted volume was kept on ice/in freezer and the other half was mixed in a 1:1 ratio 
with BioRad PCR Ready Mix in order to T-Tail the DNA for 30minutes at 72oC.  This was 
PCR purified again following the same protocol from the same kit.  A gel was run to 
check this had worked before setting up a ligation of the T-Tailed fih into PGEM-T Easy 
vector, ligation left overnight at 4oC.  Transformation was set up using NEB High 
Efficiency Transformation Protocol for Chemically Competent Cells and plated out onto 
agar plates with Carbenicillin and X-Gal and left at 37oC overnight.  Colonies were 
picked and grown up overnight in 6ml cultures of LB broth (cell media) containing 
Carbenicillin.  Qiagen MiniPrep was performed, holding 1ml of the culture back for 
future inoculation, and a small sample was run on a gel.  An Xho1/BamH1 digest was 
performed for 1 hour and run on a gel to check the band sizes (PGEM-T Easy (3kb), FIH 
(1kb)), and at this stage a sample was sent off for sequencing of the fih to confirm.  
100ml cultures were set up from a single colony and left to grow overnight before 
performing Qiagen MidiPrep according to the manufacturers’ protocol.  Xho1/BamH1 
digest was performed of both the PGEM-TEasy-FIH construct and an empty PCS2+ 
vector, cutting 10µg, for 1 hour.  These were run on a SYBRSafe gel and visualised on a 
DNA safe UV light before cutting out the PCS2+ band and the smaller fih band, these 
were then gel purified using a Qiagen Gel Purification Kit to the manufacturers’ 
protocols.  A ligation was set up between the fih fragment and the PCS2+vector and 
left overnight.  The ligation was transformed and plated out, colonies were selected 
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and grown up, mini preps were performed to check the final size of the product before 
larger cultures were set up to perform midi prep.   
 
2.4.6 Microarray Validation and Target Analysis 
In places microarray targets were analysed due to correlations between pathways that 
they were involved in or direct correlations in the literature between expression and 
function in similar models.  For completeness and clarity of these, the references and a 
brief explanation of the potential relevance of the gene/pathways expression in this 
current project are tabulated below for reference.   
 
Gene/Family/P
rocess 
Relevance to this project and reason for investigating 
expression in microarray dataset.   
Reference(s) 
Fih Role in high-fat-diet-induced weight gain and hepatic 
steatosis 
(Zhang et al., 2010) 
NF-κB 
Iκ-B 
HIF-1 
Mediated cross-talk between inflammation and hypoxic 
adaptations through sequestering FIH away from HIF-1 
(Shin et al., 2009) 
(Cockman et al., 2006) 
PFKFB3 Glycolytic enzyme induced by hypoxia (Calvo et al., 2006) 
(Rider et al., 2004) 
HK1 Glucose sensor, involved in the conversion of glucose to 
pyruvate as well as playing non-enzymatic roles in 
glucose sensing and signaling 
Heme-binding plasma glycoprotein produced in the liver 
after stimulation by pro-inflammatory cytokines and 
maintains heme in soluble monomeric state 
(Cho et al., 2006) 
 
 
 
(Krikken et al., 2010) 
LDH Shown to have a Hif response element, up-regulated in 
hypoxia, catalysing the conversion of pyruvate to lactate 
in anaerobic cells 
(Firth et al., 1995) 
(Zehetner et al., 2008) 
Insulin Binds to insulin receptor kinase, results in 
autophosphorylation of multiple cytoplasmic tyrosine 
residues, also has an HRE 
(Tornqvist et al., 1988) 
(Ellis et al., 1986) 
(Taylor, 1991) 
(Zelzer et al., 1998) 
(Yim et al., 2003) 
(Maltepe et al., 1997) 
(Zhang et al., 2010) 
PEPCK Lyase enzyme in gluconeogenesis pathway (Zhang et al., 2010) 
(Kucejova et al., 2011) 
(Elo et al., 2007) 
Preproinsulin Primary translation product of insulin gene, expression 
up-regulated post exogenous glucose exposure 
(Alarcon et al., 1998) 
(Elo et al., 2007) 
Glut-1 Expression found to be increased in vhl-/- zebrafish 
embryos 
(van Rooijen et al., 2009) 
Fabp1a Involved in intracellular fatty acid trafficking as well as 
metabolism in the zebrafish 
Zebrafish fabp1a correlates with human liver-type fabp, 
implicated in acute coronary syndrome 
(Her et al., 2003) 
 
(Matsumori et al., 2012) 
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UCP Increased O2 consumption caused by changes in 
uncoupled mitochondrial respiration, surrogate 
(Zhang et al., 2010) 
CA Zinc metalloenzyme catalyses reversebile reactions of 
CO2, surrogate for CO2:O2 ratios 
(Gilmour et al., 2009) 
(Perry and Gilmour, 
2006) 
(Rummer and Brauner, 
2011) 
(Gilmour et al., 2004) 
(Lin et al., 2008) 
(van Rooijen et al., 2009) 
EPO and EPO-R Vhl-/- zebrafish embryos have elevated levels as well as 
exhibit polycythemia 
(van Rooijen et al., 2009) 
Alas2 Stimulated by hypoxia, catalyses rate-limiting step in 
heme biosynthesis 
(Hofer et al., 2003) 
VEGFR-2, Dll4, 
PDGF-B, 
VEGFR-3 
Genes shown to be expressed in tip cells in the retina (Strasser et al., 2010) 
(del Toro et al., 2010) 
CXCR-4 Gene shown to be expressed in stalk cells (Strasser et al., 2010) 
Notch1, VEGF-
VEGFR1/R2, 
Dll4 
Notch activation influences responses to vegf, and 
influence in turn the branching nature of blood vessels 
(Williams et al., 2008) 
(Leslie et al., 2007) 
(Phng and Gerhardt, 
2009) 
(Patel et al., 2005a) 
(Hellstrom et al., 2007) 
(Liu et al., 2003) 
(Li et al., 2007b) 
FIH, HIF, Notch-
NICD 
Loss of fih is expected to positively regulate Notch 
activity, and HIF is expected to up-regulate Notch by 
stabilising NICD 
(Zheng et al., 2008) 
(Gustafsson et al., 2005) 
Delta-C Notch ligand shown in early zebrafish embryos in the 
epidermal cells that make up intersomitic vessels, dorsal 
aorta and aortic (branchial) arch arteries 
(Smithers et al., 2000) 
Notch-3 Shown to be involved in vascular tone and blood flow. 
Decreased expression resulted in vascular thickness and 
deficient contractile response to angiotensin II.  
Expression limited to vascular cells, fundamental to 
arterial specification of systemic vascular smooth 
muscle cells 
(Boulos et al., 2011) 
(Merrill et al., 2011) 
(Ghosh et al., 2011) 
NRARP, NICD, 
Xsu(H) 
Over-expression of Nrarp shown to resemble loss of 
Notch signaling models. Zebrafish have two paralogues 
of nrarp gene. Expression shown to be connected to the 
inhibition of the Notch signaling pathway, and 
connected to increases in tip-cell differentiation and 
vascular branching 
(Lamar et al., 2001) 
(Topczewska et al., 2003) 
(Leslie et al., 2007) 
Her and Hey 
family genes 
and Her12, 
Her15, Her2, 
Her 4.1, Her4.2, 
Hes 5 
Notch target family genes with similar expression to 
mouse Hes5, assessed in microarray to ascertain 
downstream Notch signaling effects and levels 
(Katoh, 2007) 
(Fischer et al., 2004a, 
Fischer et al., 2004b) 
(Shankaran et al., 2007) 
Apoptotic 
Genes 
Hypoxia shown to induce expression of pro-apoptotic 
genes 
(Li et al., 2007c) 
(Greijer and van der 
Wall, 2004) 
(Yu et al., 2011) 
FABP Correlation between increased circulating levels of fabp 
and increased levels of cholesterol/triglycerides and LDL 
(Xu et al., 2007) 
Hypoxia and Hypoxia shown to induce increased cardiac output, (Yaqoob and Schwerte, 
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ISVs stroke volume and end diastolic volume along with 
increased ISV vascularisation index. Heart rate in 
hypoxic fish shown to be decreased until 6dpf and then 
elevates, correlated with model of loss of vhl 
2010) 
(van Rooijen et al., 2009) 
RAAS and 
Inhibitors 
Pathway plays critical roles in cardiovascular control and 
disease pathogenesis 
 
Captopril (ACE inhibitor) known not to directly influence 
ace2 activity 
(Basso and Terragno, 
2001) 
(Jacoby and Rader, 2003) 
(Donoghue et al., 2000) 
Agt Produced in the liver and released and cleaved into 
active Agt1 by Renin, produced in the kidneys 
(Bader, 2010) 
 
Ace1 and 2 Enzymes which cleave angiotensin I to release 
angiotensin II and other breakdown products, binding to 
different receptors in different tissues 
(Bader, 2010) 
KKS Kallikrein-Kinin system (KKS) shown to be connected 
with glucose homeostasis and bradykinin stimulation in 
isolated cells, promoting glut4 translocation 
(Barros et al., 2012) 
Table 13 This table comprises a list of genes (or pathways), expression of which 
was investigated in this current project due to the possible correlations with existing 
literature.  
 
2.5 Treatments/Mechanism Assays 
2.5.1 Fih Inhibitor Treatment 
Embryos were treated from 1 cell stage with KKC396, a hypothesized Fih specific 
inhibitor.  The drug was made up in E3 and added to the embryos at 1 cell stage at 
various concentrations in order to test the dose response of the compound.  In order 
to ascertain the function of the compound kymographs were generated in order to 
calculate the velocity of the blood along the aorta.  The compound was considered to 
be toxic above 3µM, but was re-tested at 1 and 3µM, exchanging the solution every 
day (Schofield, C. pers. Comm.). 
 
2.5.2 Viewpoint Activity Assay 
Embryos were selected and placed into multi well plates in a small amount of E3 media 
(1ml for 24 well plates, 2ml for 12 well plates) and allowed to habituate both to the 
well plate and the view point scanner for an hour.  The settings in the software were 
optimized to select the number of wells in the plate and then the experimental 
parameters were added.  Initial experiments had the lights on a 15 minute cycle of 
100-0%, to test the startle response to the lights being switched off.  The software is 
capable of picking up different classes of movement based on selected settings.  A 
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range of movement was considered by the software to assess the movement of each 
fish to define freezing movement (0 pixels), mid-range movement (0-10 pixels) and 
burst movement (>10 pixels).   
These experiments were repeated over 24 hours with the lights on the same cycle as 
the adults are exposed to in the aquaria, lights on between 8am-10pm and lights off 
between 10pm-8am to test the embryos natural circadian dictated swimming patterns 
(Blanco-Vives and Sanchez-Vazquez, 2009).   
In conjunction with data and suggestions from Bally-Cuif laboratory a secondary assay 
was performed, assessing total distance swum over 5 minute period following 1 hour 
rest period following placing the embryos in the well plates and in the Viewpoint 
platform.  These assays were performed at 6dpf.  Methylphenidate (MPH/Ritalin) was 
tested in the assessment of hyperactivity in the fih217/217 embryos, also in 
conjunction with data from Bally-Cuif laboratory.  The embryos were first placed in 12 
well plates and allowed to acclimatise for 1 hour and imaged for 5 minutes to assess 
total distance swum.  The embryo media was removed and replaced with either Ritalin 
(various concentrations made up in DMSO) in E3 or E3 only or DMSO only and left for 1 
hour before imaging again for 5 minutes.   
Activity was assessed as a % activity    =  Post-treatment distance    x 100 
       Pre-treatment distance 
 
2.5.3 ATP Assay 
An ATP quantification assay (ATPLite) from Perkin Elmer, was used in conjunction with 
an Invitrogen CyQuant - NF cell proliferation assay kit to provide ATP quantification 
normalised to DNA concentration (as a surrogate for cell number).  This allows for 
variations in cell number created by homogenising whole embryos to be accounted 
for. 
ATPLite protocol: Sort and pool embryos into batches of 10 in eppendorfs and add 
tricaine for 20 minutes, aiming for triplicate samples where possible.  Embryos were 
washed twice in PBS before adding 250µl of lysis buffer and homogenizing with a 
needle (4 dpf embryos require 30 passes through the needle).  Add 1.25µl lysis buffer 
to get to working concentration.  50µl of PBS was added to wells of 96 well plate, 25µl 
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sample solution was added, along with 25µl of ATP substrate (achieving technical 
triplicates as well as biological triplicates).  The plate was shaken for 5 minutes 
followed by 10 minutes in the dark before reading the fluorescence.   
CyQuant protocol: 1.1ml buffer was added to 4.4ml miliQ (MQ) water and 22µl 
CyQuant dye.  50µl was placed in each well alone with 50µl of sample (technical 
triplicates as well as biological triplicates).  Plates are incubated in the dark for 40 
minutes to an hour before reading the fluorescence.   
 
2.5.4 Cholesterol Assay 
Roche produce a Cobas enzymatic, colourimetric assay that is used to assess 
cholesterol levels in blood samples in the screening process for atherosclerotic risk 
factors as well as the diagnosis and treatment of disorders involving elevated 
cholesterol.  The system is in place at the Medical School at Sheffield University and 
the samples were sent to them for analysis.  50-100 embryos (wt and fih217/217 
embryos) were isolated in sterile eppendorf tubes at 6dpf following tricaine treatment.  
The E3 media was removed and replaced with 100µl of PBS before the embryos were 
macerated using a plastic pestle (Sigma Aldrich) designed to fit in the end of the 
eppendorf tube.  The tubes were centrifuged for 1 minute at maximum speed to spin 
down the tissue debris, and the supernatant was removed and placed in a clean tube 
and transferred to the Medical School team for performing the Cholesterol assay.   
 
2.6 Statistics 
Experiments were repeated a minimum of three times, and the data was pooled to 
provide an average of the results.  Where embryos were obtained through marbled 
zebrafish tanks, this would constitute a single batch of embryos; therefore multiple 
set-ups were required to acquire repeat data sets.   In order to obtain sufficient 
numbers of embryos with the double mutant phenotype (fih-/-;vhl-/-) it was necessary 
on occasion to pool embryos from multiple parent pairs, meaning that repeated data 
sets were obtained through multiple pair mated set ups.   
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Statistical analysis of each data set was performed using the Prism Graph Pad software 
program to obtain the graphs, as well as the statistical features such as averages and 
significance factors.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
88 | P a g e  
 
3 Morphological and Structural 
Analysis of the fih Mutant Zebrafish 
3.1 Introduction 
The transcriptional output of the hypoxic signaling pathway is controlled at several 
levels and is subject to a number of feedbacks.  The effect of the loss of vhl, in the 
zebrafish, has been characterised in the past, both as a model of vascular response to 
hypoxia and as a model of Chuvash disease (van Rooijen et al., 2010, van Rooijen et al., 
2009).  This chapter aims to characterise the phenotypes, in the zebrafish, caused by 
the loss of fih gene function.  Analysis began with the observation of embryos with a 
range of genotypes; from fih+/+;vhl+/+ to fih217/217;vhl-/-.   
 
3.2 Observations of the effect of loss of fih  
3.2.1 fih is expressed in a variety of tissues and activated by the loss of vhl 
In mouse tissues and cell lines that have been tested, FIH protein has been shown to 
be expressed at similar levels (Zhang et al., 2010).  A zebrafish fih null mutant line was 
generated by TILLING, prior to the publication of data on the Fih knockout mouse, to 
characterise the role of fih in vivo.  The mutation results in a C to A conversion 
resulting in a premature stop codon and a functional null mutant.   
Initial morphological observations of the fih homozygous mutant phenotype did not 
detect obvious morphological abnormalities.  Homozygotes could be raised to 
adulthood, were present in normal mendelian ratios, showed normal fertility, and no 
maternal effects were detectable in embryos derived from matings of homozygous 
mutant parents.  To address the effect of the hypoxic signaling pathway and also the 
fih mutation itself on its own transcript fih mRNA expression patterns and levels were 
assessed in the zebrafish embryos; by in situ hybridisation (Figure 39) and 
microarray/qRT-PCR (Chapter 9). 
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Figure 39 Expression of Fih assessed by in situ hybridisation at 4.5dpf 
Fih mRNA expression in wild type, fih217/217, vhl-/- and fih217/217;vhl-/- embryos at 
4.5dpf.  Left shows whole body images to show global expression patterns. Right shows 
isolated images of the heads at higher magnification to show details.   
 
Fih mRNA message appears in wild type embryos to be localised to the brain in 
general, heart and trunk/internal organs.  Its expression in vhl-/- embryos is up-
regulated throughout the whole body, suggesting that it acts as a negative feedback 
regulator acting on hif-α in the face of accumulation that occurs due to the loss of vhl 
(Santhakumar et al., 2012), although this is so far an assumption.  There is some 
expression of Fih message in both the fih217/217 embryos and the fih217/217;vhl-/- 
embryos, higher in these latter.  The reduction of expression was unexpected, as loss 
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of fih would be expected to increase the activity of HIF-α to some degree, thus an 
increase in expression would be expected; either weaker or similar to that seen in vhl 
mutants.  A possible explanation for this might be nonsense mediated decay of the 
message due to the early stop codon in fihi217 fish.  Further investigation of fih 
expression at various developmental stages is necessary in order to answer questions 
such as the time at which these differences/increases can be observed.  Further 
investigation of fih expression has been performed by qRT-PCR, which will be discussed 
later in this thesis.  
 
3.2.2 The fih mutation can enhance the vhl-/- phenotype 
Since fih is induced in vhl mutants and can act in vitro to hydroxylate and inactivate HIF 
independently of the presence/absence of VHL, we expected that loss of vhl might not 
represent a full activation of the HIF pathway.    
To test whether fih is capable of enhancing or otherwise altering the vhl mutant 
phenotype the fih and vhl mutant zebrafish lines were crossed together it was possible 
to observe a range of phenotypes that were changed from the known characteristics of 
the vhl-/- embryos.  In a blind observation of known vhl-/- embryos with mixed fih 
backgrounds, phenotypes were sorted from the strongest to the weakest and 
subsequently genotyped it was revealed that the strongest phenotypes were exhibited 
by fih217/217;vhl-/- embryos (see Figure 40 for examples of the phenotypes).   
These results showed that although loss of fih on its own does not have easily 
detectable morphological consequences, the loss of fih in the context of the loss of vhl 
may lead to further up-regulation of HIF signaling, see Figure 6 and 11 in Introduction.  
The combined loss of both of these genes results in accumulation of functional HIF-1α 
protein in normoxia, a hypothesis that has been proposed by Li et al (Li et al., 2011b) 
since it will be neither ubiquitinated (by VHL) and broken down, or hydroxylated (by 
FIH) and inhibited.  The observed phenotypes ranged from what has been 
characterised for vhl-/- embryos, including enlarged heart and decreased yolk usage 
through to fih217/217;vhl-/- embryos which exhibited further enlargement of the 
heart region and associated oedema along with dorsal curvature of the body axis.  The 
loss of one copy of fih did not detectably alter the phenotype of vhl-/- embryos and for 
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this reason and for the remainder of this thesis where wild type embryos are being 
referred to these could include a small mixture of genotypes, see Table 14.  
 
WT FIH Null VHL Null 
fih+/+;vhl+/+ 
fih-/+;vhl+/+ 
fih-/+;vhl-/+ 
fih217/217;vhl+/+ 
fih217/217;vhl-/+ 
fih+/+;vhl-/- 
fih+/-;vhl-/- 
Table 14 Table describes various different genotypes collectively referred to as wild 
type, FIH Null or VHL Null, from this point forward in the thesis 
 
For closer inspection, higher magnification images of the embryos were taken to assess 
the influence of the loss of fih in vhl-/- embryos.  The fih217/217;vhl-/- phenotypes, at 
first sight, included features such as smaller eyes, an increased curvature of the body 
axis, as well as a larger amount of remaining yolk compared to wild type siblings, see 
Figure 40.  The reduction in yolk usage has been hypothesised to be due to 
developmental delay rather than a direct result of an altered rate of metabolism, and 
as such will require additional experimentation.   
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Figure 40 Key elements of the various phenotypes in the zebrafish embryos at 
4.5dpf  
The red arrow head indicates the enlarged heard and heart cavity, the red diamond 
indicates the smaller eye observed in the fih217/217;vhl-/- embryos.  The blue arrows 
illustrate the development of vascular loops in the tail.  The green arrow indicates an 
area of sluggish circulation in the double mutant embryos.  A high quality image of 
fih217/217 embryos was not obtained and these embryos were indistinguishable from 
wt embryos and are not shown.  The composite images were taken on multiple focal 
planes. 
 
The human eye was used to sort the different morphological features described above, 
at least as far as distinguishing between vhl null and fih;vhl double null embryos, as 
compared with each other or compared with wild type phenotype. In order to more 
accurately test how good the human eye is at this sorting, fish could be sorted by 
multiple operators into classes and individual embryos from the classes could be 
independently genotyped to find out the exact error rate, false positives and negatives 
within each class.  For the purposes of this thesis that error rate is not known, however 
genotyping of embryos was constant to ensure results were attributed to the correct 
class of embryo. 
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ImageJ was used to quantify morphological parameters such as fish length and the 
number of functional ISVs (see Figure 41).  At 4dpf the differences were small, 
however at 5dpf the vhl-/- and fih217/217;vhl-/- embryos did appear to have 
decreased total fish length compared to wild type and fih217/217 embryos.  The total 
number of functional ISVs was also decreased at 5dpf in the fih217/217;vhl-/- 
embryos.  
 
 
Figure 41 Quantification of total vessel length and ISV number was performed in 
order to assess possible differences in these characteristics between the different 
mutant classes.  
Measurements taken from image deletion angiograms using ImageJ to assess whole 
length and the total number functional of ISVs at different stages of development in the 
various mutants, showed little change although a slight increase in total fish length in 
the vhl-/- embryos was observed at 5dpf.   
 
To further characterise the observed phenotypes in the heads of the vhl-/- and 
fih217/217;vhl-/- embryos in comparison with wild type, image deletion angiograms 
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were used to illustrate blood flow and in so doing highlight the blood vessels and heart 
regions, see Figure 42. 
 
Figure 42 Features such as the diameter of the eye, the horizontal diameter of 
the heart and the development of a space between the heart and the heart sack 
were measured to quantify changes in these features in the different classes of 
embryo 
Left) Illustrates the heads of embryos imaged using image deletion angiography at 
4.5dpf.  Right) Illustrates quantification of the eye diameter, heart diameter and 
distance between the heart and heart sack at both 4 and 5dpf 
 
The eye diameter of the fih217/217;vhl-/- embryos is decreased compared to the non 
double mutant siblings.  The heart diameter in the vhl-/- and fih217/217;vhl-/- 
embryos is increased, and these latter also have a measurable increase in central 
oedema surrounding the hearts.  In terminal cardiac failure, as well as some cancers, 
where low levels of oxygen are reaching the tissues, peripheral oedema can be caused 
both by decreased venous return and an increase in Vegf (Bates, 2010, Chin et al., 
2003), so these were factors that were investigated in this model to assess their roles 
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in this phenotype.  These early observations and quantification showed that 
differences between wild type and fih217/217 siblings were minimal or absent 
suggesting that Fih has only a weak effect on Hif as compared to Vhl, and that it does 
not significantly impact on embryonic morphology.  For this reason the focus of the 
investigation remained on the ways in which the vhl-/- phenotypes were altered by the 
loss of fih as well.    
3.2.3 Loss of fih increases expression of HIF target genes compared to vhl-/- embryos 
Expression patterns of several HIF signaling targets were examined by in situ 
hybridisation.  The levels of phd3 were shown to be elevated in the vhl-/- embryos (van 
Rooijen et al., 2010, van Rooijen et al., 2009).  These finding were confirmed through 
repetition of the in situ hybridisation, including fih mutant embryos and post-assay 
genotyping allowed for the effect of the loss of fih to be assessed simultaneously.  A 
further increase in phd3 expression was seen in fih217/217;vhl-/- embryos whereas 
expression was unchanged in the fih217/217 embryos, see Figure 43 and Figure 44.  
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Figure 43 in situ hybridisation of phd3 
Phd3 mRNA is found in the brain, heart, internal organs, kidney pronephros and blood 
island in the tail, to differing degrees in the vhl-/- embryos and more in the 
fih217/217;vhl-/- embryos.  A high quality image of fih217/217 embryos was not 
obtained and these embryos were indistinguishable from wt embryos and are not 
shown.  The composite images were taken on multiple focal planes. 
 
 
A Tg(Phd3:eGFP) transgenic line, expressing GFP under the Phd3 promoter 
(Santhakumar et al., 2012), has been  used to provide a live read-out of areas of 
hypoxic signaling, given that phd3 is a strongly responding target of HIF-driven 
transcription with very low expression in normoxic embryos.  The transgenic line was 
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crossed in to the fih;vhl mutant backgrounds in order to assess levels of hypoxic 
signaling in the live embryos, see Figure 44.   
 
 
Figure 44  Tg(Phd3:eGFP) zebrafish line crossed into the fih and vhl mutant 
zebrafish lines provides an in vivo method for visualising the levels of phd3 
expression 
Tg(Phd3:eGFP) expression demonstrates varying degrees of regulation in the different 
mutant backgrounds, from low/no expression in wild type and fih217/217 embryos to 
increased levels in vhl-/- embryos and then a further increase in fih217/217;vhl-/- 
embryos.  A high quality image of fih217/217 embryos was not obtained and these 
embryos were indistinguishable from wt embryos and are not shown.  Images were 
taken at 4dpf and consist of composite images taken on multiple focal planes. 
 
As described in the introduction phd3 has a HRE in the promoter, the transcription of 
the gene can therefore be seen as a surrogate read-out of HIF signaling.  phd3 is 
necessary to keep HIF-α hydroxylated and the pathway switched off, however it is also 
a target and is therefore being amplified when the pathway is on.  The low levels of 
expression in the absence of HIF signaling are therefore more difficult to explain and 
may be down to the difference in role of the different Phd proteins, for example phd2 
could be the regulator that keeps the baseline HIF activity low.  It is currently unclear 
what the low level of phd3 expression in wild type is caused by, it might be HIF 
independent, and these investigations are ongoing (Santhakumar unpublished data).  
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The increase in HIF signaling in normoxia in these fih217/217 and vhl-/- embryos allows 
for the study of the downstream effects of this pathway without the need to maintain 
depleted oxygen levels.   These data show that fih can modulate the phenotype of vhl 
mutants and is consistent with the expectation that loss of fih further enhances HIF 
signaling in a vhl mutant background.  It also argues against a purely vhl dependent 
role of fih on HIF as might be predicted from Li et al (Li et al., 2011b).   
 
3.3 Vascular Branching Phenotype 
Hypoxia is known to initiate vascular gene expression along with vascular proliferation 
and remodeling in order to ensure adequate supply of lowered oxygen availability to 
the tissues.  For this reason, along with knowledge of known vascular defects in the 
vhl-/- embryos, the vascular network in the fih217/217 and fih217/217;vhl-/- embryos 
was assessed.  The phenotypes that were observed in the fih217/217 and vhl-/- 
zebrafish embryos distinguish each mutant from the other, apart from the fih217/217 
embryos from their wt siblings.  These phenotypes include hyper-branching of the 
network, alterations in remodeling along with changes in gene expression. 
 
3.3.1 Loss of fih causes further branching of the blood vessels in vhl-/- background 
Confocal imaging of the blood vessels using transgenic zebrafish line of a fusion of the 
friend-leukemia integration 1 transcription factor to GFP Tg(fli1;eGFP) was performed 
(Cha and Weinstein, 2007, Lawson and Weinstein, 2002b), see Figure 45. 
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Figure 45 Vascular patterning in the different embryos using Tg(Fli1;eGFP) 
transgenic to highlight the vasculature 
Images were taken at 4.5dpf using a Spinning Disk Confocal microscope.  The wild type 
and fih217/217 embryos show the expected patterning of the posterior caudal vein, the 
dorsal aorta and the intersegmental vessels (ISVs) connecting at the top at the dorsal 
longitudinal vessel. The patterning of both the vhl-/- and fih217/217;vhl-/- embryos 
showed distinct levels of branching of the vasculature. 
 
A hyper-branched blood vessel network in the vhl-/- embryos was shown by Dr Van 
Rooijen (van Rooijen et al., 2010) with associated increase in expression of vascular 
endothelial growth factor (vegf-a) a gene associated with the stimulation of 
angiogenesis and vasculogenesis and a target of HIF signaling.  The hypothesis was that 
the further up-regulation of vegf-a due to the dual loss of fih and vhl in these embryos 
resulting in the further loss of negative control of Hif in the fih217/217;vhl-/- compared 
to the vhl-/- only embryos would lead to further complications in the blood vessel 
networks.  The fih217/217 embryos showed no observable change in the blood vessel 
patterning compared with fih+/+ siblings.  However the patterning in the 
fih217/217;vhl-/- embryos was altered compared with vhl-/- embryos, with many 
additional branches in the vascular structure.   
The extra complexity of the vasculature led to the assessment of how many of the new 
connections were functional.  Using image deletion angiography as a tool for assessing 
the competence of the vessels it was shown that many of these additional branches in 
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the blood vessels were lumenised and competent to carry flow (Chico et al., 2008).  
These differences were quantified using a vascularisation index technique (Yaqoob and 
Schwerte, 2010, Schwerte et al., 2003) and showed that there was statistical 
significance to the differences, Figure 46. 
 
 
Figure 46  Quantification of vascular index 
The image deletion angiograms illustrate the level to which branches in the blood 
vessel network are competent to carry flow. Vascularisation index taken across the first 
eight somites back from the head illustrate that this is most striking in the 
fih217/217;vhl-/-.   
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This increase in vascular density observed using the Tg(fli1;eGFP) transgenic line 
revealed the hyper-branching of the vascular network in both the vhl-/- and the 
fih217/217;vhl-/-, the image deletion angiograms revealed that several of these neo-
vessels and extra branches were also competent to carry flow.  These were particularly 
evident in the region behind the head, in the first 8 somites, in the fih217/217;vhl-/- 
embryos.  Vascular index provides one tool for assessing complexity of branching.  
However it may be seen to provide confounding results, in relation to extra branching 
versus the result of branches being missing.  Alternative assays will need to be 
investigated to confirm these findings.  
 
3.3.2 Loss of fih causes a small increase in endothelial cell number in vhl-/- 
background 
To assess the way in which these new vessels form, and assess the contribution that 
endothelial cell proliferation, rather than vascular remodeling, had on the complexity, 
the transgenic zebrafish line Tg(flk1:eGFP-NLS) was used (Blum et al., 2008).  The 
transgenic line leads to GFP contained in the nuclei with a translational link to a 
nuclear localisation sequence (NLS) in the endothelial cells within the embryo, allowing 
for a physical count of the cells.  A count of the endothelial cells in particular regions of 
interest; firstly behind the head where the additional bundle of blood vessels showed 
in the image deletion angiograms (Figure 31), and secondly in the tail above the anus, 
see Figure 47. 
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Figure 47 Endothelial cells were imaged in order to assess proliferation  
Images taken using spinning disc confocal microscopy of fih;vhl;Tg(Flk1:eGFP-NLS) 
embryos at 5dpf and displayed as z-projections of the z-stacks taken through the 
embryo.  
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The images displayed in this way make the assessment of endothelial proliferation too 
ambiguous to judge, however using counts through the z-stacks and representing 
these numbers graphically it was possible to see trends that were more difficult to see 
from the images alone, see Figure 48.  These were taken from the same batch of 
embryos, maintaining consistency.  
 
 
Figure 48  Quantification of endothelial cell number 
Quantification of the number of endothelial nuclei observed in the z-stacks 
demonstrated an increase between the wild type embryos and the fih217/217;vhl-/- 
embryos in both regions that were counted.  Comparisons besides those marked were 
not significantly different.  
 
The trend increase in cell number in these regions at 5dpf was not extensive, it did 
however suggest that a combination of proliferation of the endothelium along with 
remodeling of the existing vasculature could be used to explain the branching of the 
blood vessels in the fih217/217;vhl-/- embryos.  The loss of fih did not materially affect 
the number of endothelial cells, compared with wild type. The limitations of this data 
set are human error in the counting of the endothelial cells and could be combated by 
the inclusion of multiple operators counting the same samples and comparing the 
results, this is ongoing.  The investigation of alternative methods, of generating 
algorithms for making the counts, was also ongoing at the time of writing this thesis.   
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3.3.3 Loss of fih causes an increase in Vegf family expression in the vhl-/- embryos 
Vegf, like phd3 has been shown to be a target of hypoxic signaling, which has been 
shown to respond to hypoxia via HIF (Forsythe et al., 1996) and contain both a Hif 
binding site (HBS) and a Hif ancillary sequence (HAS) within the HRE.  The core 
sequences for the HBS and HAS were determined as TACGTG and CAGGT, respectively, 
with these elements offering an imperfect inverted repeat that is crucial for the 
function of the promoter (Kimura et al., 2001).   
An in situ hybridisation revealed the same pattern of up-regulation of vegf in these 
zebrafish embryos as had been shown for phd3, with no detectable change in 
expression in the fih217/217 embryos, see Figure 49.   
 
 
Figure 49  in situ hybridisation of Vegfaa at 4.5dpf 
Vegfaa mRNA expression in wild type, fih217/217, vhl-/- and fih217/217;vhl-/- embryos 
at 4.5dpf.  Left) whole body images to show global expression patterns Right) isolated 
images of the heads at higher magnification to show details.   
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The systematic up-regulation of vegf in conjunction with both the individual loss of fih 
and then vhl and then both correlates with the roles each of these genes plays in 
regulating Hif-α.   
 
3.3.4 Role of Vegf in vascular permeability in the zebrafish embryo 
The increase in vegf-a has been illustrated in Table 15 and Table 16, in the vhl-/- 
embryos as well as in the fih217/217;vhl-/- embryos.  In the zebrafish it is possible to 
inject high molecular weight dye or quantum dots (Q-dots) and observe the 
vasculature microscopically in real time provides an opportunity to assess the 
immaturity and permeability of the vessels.  
With the increased levels of vegf it could be hypothesised that the vessels in the 
fih217/217;vhl-/- embryos would be benefiting from pericyte recruitment, however 
they may also be experiencing increased vascular leakage.  To test this in the 
fih217/217;vhl-/- embryos the same functional angiograms were attempted and 
imaged over time in order to observe the competence of the blood vessels, see Figure 
50.   
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Figure 50  An attempt to assess vascular competence by injection of high 
molecular weight dye into the circulation 
A) demonstrates the TAMRA dye within the vessels on day of injection B) demonstrates 
the TAMRA dye diffused out of the vessels by 5dpf.  This pattern was observed in all 
embryos regardless of their genotype. 
 
The experiment was impossible to repeat exactly in the fih217/217;vhl-/- embryos due 
to their shorter survival times.  These embryos experience cardiac contraction but 
blood ceases to circulate following 4.5dpf.  This necessitated attempting to repeat the 
injections at much earlier stages, when the vessels in all the embryos including the wt 
siblings were several days more immature.    
 
3.4 The loss of fih does not enhance all phenotypes observed in vhl-/- 
embryos 
One of the phenotypes observed in the vhl-/- embryos, from around 3dpf, is 
observable looping of the ISVs over and above the pigment line and dorsal longitudinal 
vessel.   
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For the most part, to this point, the loss of fih in the vhl-/- embryos has lead either to 
further branching of blood vessels or stronger up-regulation of gene expression.  One 
vascular phenotype of the vhl-/- embryos that did not conform to this trend was this 
looping of the ISVs in the tail of the embryos up above the dorsal longitudinal vessel 
(DLV) and the pigment line, see Figure 51. 
 
 
Figure 51  Resolution of vascular looping (vhl-/-) in the tail vasculature in the 
fih217/217;vhl-/- 
The loops in the top of the ISVs occur in all the embryos, but in the vhl-/- embryos the 
loops extend higher above the dorsal longitudinal vessel.  This was quantified using 
ImageJ to measure the distance between the pigment line and the inner curve of the 
loop in the ISV. Each mark is equal to one fish, n numbers for this assay are 3 to 8 per 
genotype and requires repetition. 
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The looping of the ISVs wasn’t observed in any of the other mutants by this technique, 
despite the lack of vhl in both the vhl-/- and the fih217/217;vhl-/- embryos.  The 
observation that this is one phenotype that isn’t exacerbated by the loss of both fih 
and vhl, despite the fact that these embryos do demonstrate excessive branching of 
the blood vessel network and increased vascular factors, suggests that other factors 
play a role in controlling this phenotype specifically.  Shear stress presented itself as a 
possible mechanism for this control as it was recently found that flow is an important 
prerequisite for the development of the angiogenic phenotype by vhl mutants 
however this hypothesis has not been tested in these double mutants at this time, the 
preferred method would be to restore flow in these mutants to check whether the 
phenotype could be enhanced.  In the absence of a reliable method for this the 
injection of the tnnt2-MO (silent heart) or the use of measured doses of tricaine to 
either remove the heart beat in order to ensure the embryos never experienced flow 
or only at a reduced rate might show a reduction in phenotype (despite the presence 
of high levels of VEGF and KDR(L)). 
  
3.5 Discussion and Future Work 
3.5.1 The Hypotheses 
The first hypothesis to test, the first observation to make, was to assess the effect of 
the loss of fih on both wild type embryos and on vhl null embryos.  Previous analysis of 
the vhl-/- zebrafish revealed that the embryos exhibit several phenotypes most likely 
as a result of activation of HIF signaling; including enlargement of the heart, increased 
buccal movement, hyperventilation, polycythemia, and an increase in vascular 
complexity (van Rooijen et al., 2010, van Rooijen et al., 2009).  The loss of vhl in this 
case appears to suggest that a level of HIF regulation was removed and these observed 
phenotypes correlate with those that would be seen under hypoxia in order to 
respond to decreases in atmospheric oxygen.  Given the roles of fih and vhl are 
independent of each other in regulating HIF function (FIH regulating HIF function, 
while VHL regulates HIF turnover), the hypothesis in this case would be that the loss of 
fih alone may not show dramatic phenotypes, however in the context of the loss of vhl 
it may alter or exacerbate phenotypes observed in the organisms where vhl was lost.  
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There have also been studies predicting the necessity for VHL acting as a bridge 
between FIH and HIF for efficient binding (Lee et al., 2003) suggesting a loss of vhl 
would disrupt the hydroxylation of HIF-α by fih as well.  The hypothesis in this case 
would therefore be that the loss of fih as well, in an individual that had lost vhl 
function, would result in no alteration in the phenotypes observed.   
 
3.5.2 HIF Regulation 
These hypotheses could be tested when the fih217/217 and fih;vhl double 
heterozygous carriers were generated.  For instance, fih217/217;vhl-/- embryos were 
found to show further increases in the size of the heart/heart cavity compared to vhl-/- 
embryos along with increased complexity of the vascular patterning.  Prolyl 
hydroxylase domain protein hydroxylation of HIF-α initiates the formation of a 
ubiquitination complex involving VHL protein and the degradation of HIF-α.  The 
absence of VHL therefore leads to ectopic accumulation of HIF-α and downstream 
gene expression changes, of which phd3 is one.   The increase in vascular complexity, 
correlated with increased expression changes of the hypoxic target phd3.  In contrast 
the expression of phd3 in the fih217/217 embryos did not differ from wild type 
embryos.  These preliminary findings supported the first hypothesis.  
 
The second hypothesis, that the FIH, VHL and HIF-α form a complex, with individual 
components being necessary to bridge between and act as chaperones for the others 
(Lee et al., 2003, Li et al., 2011b), see Figure 14 in Introduction.  The findings from this 
study, that the loss of either fih or vhl have distinct effects on the down-stream 
signaling of HIF in the zebrafish suggest that more investigation is needed into the 
possible interactions between these proteins in vivo.  Due to the different phenotypes 
observed in each of the single mutants compared with the double mutant, if either fih 
or vhl were needed to form the FIH-VHL-HIF-α complex, these phenotypes might be 
hypothesised to be more similar, which they are not.  
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Since fih has been shown to bind to and hydroxylate multiple ankyrin repeat domain 
proteins (ARDs) and affect the function of many of these (Cockman et al., 2006, 
Cockman et al., 2009, Coleman et al., 2007), it is conceivable that its loss is affecting 
other pathways besides HIF.  However, our data suggest that these functions are not 
essential for early patterning of the embryo and are instead more involved in fine 
tuning the role of signaling, which conforms with findings in mice where Fih knockouts 
are viable and fertile (Zhang et al., 2010).   
 
3.5.3 VEGF and angiogenesis 
Overall, vascular patterning of the fih217/217 embryos appeared, from these assays, 
to match that seen in wild type siblings, with no observable excess branching.  The loss 
of fih in the vhl-/- embryos however did result in a further increase of vascular 
branching, with a concurrent increase in endothelial cell number, which might be more 
profound in time (not yet assessed).  This correlated with the increase in vegfaa shown 
by in situ hybridisation in these double mutants.  These findings were in support of the 
first hypothesis.   
 
3.5.4 VEGF and vasculature permeability 
Vascular endothelial growth factor (vegf) is also known as vascular permeability factor 
(vpf), and was originally identified as a tumour-secreted protein (Dvorak et al., 1995).  
Here it plays a role in increasing permeability and promoting extravasation of plasma 
proteins from the vessels (Dvorak et al., 1995).  The increase in vegf expression along 
with the characterised vascular abnormalities (increased branching) in the vhl-/- 
embryos, led to further investigation of the vasculature in the fih217/217;vhl-/- 
embryos, based on the role of vegf in vascular permeability (Nagy et al., 2002).  The 
zebrafish provides a model for observing alterations in vascular permeability, the 
embryos size and transparency makes imaging of fluid dynamics both within and 
without the vessels possible in real time (Arbiser, 2012).  This has been shown in the 
vhl-/- embryos at 6-7dpf where dye was observed outside of the enclosing retinal 
vessel in the vhl-/- embryos and not in the wild type siblings several days post injection 
(van Rooijen et al., 2010). 
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Several distinct factors have been shown to regulate endothelial differentiation, 
growth and function.  Multiple roles of VEGF have been described, in physiological 
angiogenesis, postnatal vessel remodeling and in tumour angiogenesis (Dvorak et al., 
1995).  It has been shown to increase microvascular permeability through enhancing 
functional activity of so called vesicular-vacuolar organelles (VVOs) involved in 
extravasation of circulating macromolecules from microvasculature (Dvorak et al., 
1995).   Increased vegf-a expression is reported to lead to an increase in vascular 
permeability (Nagy et al., 2012, Weis and Cheresh, 2005, Keck et al., 1989) and a 
development of a weakened vascular network with immature vessels that remain that 
way (Lu et al., 2011, Koukourakis et al., 2004).  If these factors lead to the maintenance 
of a weaker/more immature vascular network in the fih217/217;vhl-/- embryos it is 
conceivable to that this could be a reason for this not being a viable assay in these 
mutants, however the levels of vegf expression in these fih217/217;vhl-/- embryos at 
early stages does suggest that the vascular integrity is compromised and would 
illustrate vascular permeability if the embryos matured past 4.5dpf.  In order to clarify 
these details, the investigation of larger dyes and smaller time frames between 
injection and imaging could be utilised.  Also the investigation of other factors known 
to affect vascular permeability in the zebrafish, such as VE-Cadherin (cdh5), which 
when knocked-down weakens cell-cell junctions, affecting vasculogenesis and 
sprouting of the vasculature could be attempted (Mitchell et al., 2010, Larson et al., 
2004, Montero-Balaguer et al., 2009). 
 
3.5.5 Conclusions 
The observations using the Tg(fli1;eGFP) transgene to visualise the vasculature, in 
conjunction with the angiogram technique to reveal functional vessels, revealed that 
the loss of fih in a vhl-/- background did not in fact exacerbate all the observed 
phenotypes.  Looping of the dorsal longitudinal vessel above the pigment line in the 
vhl-/- embryos showed instead a resolution to a more wild type phenotype in the 
fih217/217;vhl-/- embryos.  In these embryos at the stages where this was observed 
(4-5dpf), a slowing of the blood flow was observed in the fih217/217;vhl-/- embryos 
and this reduction in shear stress could be hypothesised to be responsible for the 
resolution of this phenotype, following investigation by Dr. Watson.  Further 
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investigation into the effects of flow on vascular patterning and remodeling are 
ongoing in the vhl-/- embryos.   
Overall, these data support the hypothesis that the loss of fih does not result in a 
significant increase in hypoxic signaling, vhl being present to maintain HIF-α levels at 
normoxic levels.  However, its loss in vhl mutants does have quantifiable effects on 
characterised phenotypes of these embryos, which indicate that these vhl-/- embryos 
don’t exhibit full activation of hypoxic signaling in normoxia and that fih control is 
necessary for maintaining this homeostasis in vivo.   
At this stage only structural characteristics had been tested, rather than the levels of 
hypoxic signaling in its entirety.  One finding however was that while not generating 
phenotypes as distinct to wild type as seen when vhl is lost, the loss of fih was having 
an effect.  The hypothesis and basis for further investigation was that the loss of fih 
was not significant enough to cause a phenotype, however it did sensitise embryos to 
the loss of vhl and therefore it does make a difference.   
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4 Transcriptome Analysis of Fih 
Function 
4.1 Introduction 
FIH is a hydroxylase with a wide variety of targets in addition to HIF, including Notch 
and NFκB (Cockman et al., 2009), with effects also in regulating metabolism as seen in 
the Fih knockout mouse study (Zhang et al., 2010).  Although no morphological 
phenotype was noted, more subtle changes to the transcriptome may occur.  In 
addition, not all defects need to have a morphological consequence and there may be 
sensory or genetic alterations that are not visible, their hearing or reflexes for 
example.  As the in vivo function of the fih gene is not well characterised, it is well 
possible that the main function of fih lies outside the hypoxic signaling pathway.  This 
is also consistent with the surprising phenotype of the mouse knockout.  In order to 
characterise the effect of fih mutation further, a microarray experiment might provide 
novel candidate genes or pathways that are controlled by FIH.  Furthermore by 
comparing changes to the transcriptome in fih mutants with changes in vhl mutants it 
might be possible to distinguish between those phenotypes caused by uncontrolled 
HIF signaling and those mechanisms that fih might control independently of HIF, e.g. 
Notch signaling.   
Previous studies have been performed to assess the genes that could be designated as 
vhl targets, the majority of these were shown to be regulated by oxygen, but a number 
were not, indicating that at least some of the influences on gene expression were 
independent of HIF (Wykoff et al., 2000).  To assess these possibilities in vivo along 
with assessing the possible influences of FIH in these mechanisms, a comparison of vhl-
/- to fih217/217;vhl-/- embryos would allow us to confirm that fih acts by further 
enhancing the expression of HIF target genes.   
For our purposes an Agilent two-colour microarray was performed, with each of the 
different mutants compared back to wild type and also fih217/217;vhl-/- compared to 
vhl-/- embryos.  The microarray was performed at 3dpf, which is the time when the 
phenotypes of the vhl-/- and fih217/217;vhl-/- mutants begin to be strong enough to 
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sort the embryos from their siblings, but avoiding secondary changes due to, for 
example, reduced circulation in the fih217/217;vhl-/- embryos as much as possible.   
 
4.2 Performing the microarray 
The process of sample collection, preparation and labeling are described in the 
materials and methods section of this thesis along with the protocols used for the 
performance of the microarray, all performed in sequence.  Embryos were collected in 
batches, multiple pairs were mated with embryos collected from each pair and grown 
until 3dpf, the time at which the distinguishing phenotypes of the vhl mutant and 
fih;vhl double mutant embryos could be identified by eye.  This stage was also selected 
as it was believed to be prior to adaptations of the mutations or potential 
developmental delay causing significant alterations to the transcriptome.  Since the 
collection of double mutants was rate limiting, multiple pairings, over multiple weeks 
had to be set up in order to collect sufficient embryos for each microarray sample.  The 
embryos were sorted and then their identity confirmed by a second observer, 
individual embryos also being genotyped from each batch.  The embryos were 
processed and labeled in batches in order to maintain consistency.  The lengthy 
process of collection and optimisation produced a large amount of resulting 
microarray data, which was analysed using Genespring software.   
 
4.3 Expression profiles revealed that Fih functions mainly through Hif 
The Genespring software allows the data to be assessed in a number of different 
formats, which can be used to assess the fit of the data across the triplicates for each 
comparison to look for outliers (scatter plots), to look for clusters of genes where 
expression is being altered in one mutant group and not others (scatter plots and venn 
diagrams) or to compare the expression of individual genes across the different groups 
(heat maps).   
Venn diagrams revealed the clusters of genes where expression was altered, to greater 
than log 2 fold compared to wild type, by the loss of fih, vhl or both genes (not shown).  
The venn diagrams suggested that the majority of those genes with altered expression 
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in the fih217/217 embryos showed altered expression in the other two mutant groups 
and supported the indication that FIH function is largely through HIF activity.  To assess 
this, along with other trends in the gene expression profiles, the microarray data sets 
were analysed in comparison with each other it was possible to look for correlations 
between the genes that were regulated in each mutant group (Figure 52).   
 
 
Figure 52 Scatter plots were used to assess independent regulation of gene 
expression by fih 
Illustrates the correlations between both up and down regulated genes altered up or 
down by more than log 2 fold.  The bold lines on each graph highlight the 0 fold change 
line.  In each case the green highlighted genes indicate those that are log 2 fold up (or 
down) regulated in the both genotypes on each graph, the orange highlighted genes 
indicate those that were less than log 2 fold up regulated in either the vhl-/- or 
fih217/217;vhl-/- embryos, while the grey/blue highlighted genes are those less than 2 
fold down regulated in either the vhl-/- or fih217/217;vhl-/- embryos.  In each case, the 
majority of the genes highlighted are in green.  A) Illustrates that almost all genes up-
regulated significantly in fih mutants (>2 fold) are on or above the “no change” level in 
vhl mutants (above) and fih;vhl mutants (below) B) shows the equivalent effect for 
genes down-regulated in fih mutants.   
 
The scatter diagrams indicated that greater proportion of genes that were up (or 
down) regulated by log 2 fold in the fih217/217 embryos were also up (or down) 
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regulated by the same degree, in either the vhl-/- or fih217/217;vhl-/- embryos, this 
indicated that FIH functions largely through HIF-α.   
Individual entity lists could be generated from the scatter plots or venn diagrams, 
essentially highlighting individual clusters of genes and asking the software to isolate 
only the fold changes of those genes across the mutant groups.   
 
4.4 Validation 
4.4.1 Cluster/GO terms 
Cluster analysis and the assessment of Gene Ontology (GO) terms within entity lists 
(formed using Genespring software during analysis of particular criteria from the 
datasets) would normally provide information connecting genes within a particular set 
in terms of their function or connected pathways.  The Agilent Zebrafish version II 
microarray probe set, which was used for all of these microarrays, was not annotated 
with sufficient detail, making this type of analysis difficult (data not shown).  Other 
tools are being developed for analysing GO terms in zebrafish microarray data sets, 
including GeneTools (eGOn v2.0) a web based ontology software, and Database for 
Annotation, Visualisation and Integrated Discovery (DAVID).  A tool was also developed 
by Stockhammer et al to connect the better GO annotation of the human genome with 
data from zebrafish UniGene lists (Stockhammer et al., 2009).  Tools such as these 
might be used to increase the GO analysis of this data-set. 
 
4.4.2 Identifying Hits 
Certain entity lists, such as those indicated to be selectively up or down-regulated in 
individual mutants or in particular segments of scatter diagrams (Figure 52), were used 
to identify particular hits for follow up.  For example, two hits were identified as being 
selectively regulated in the fih217/217 embryos by assessing the 63 genes identified by 
the venn diagram in Figure 52 and the heat maps as being down-regulated specifically 
in these embryos, for further details of the follow up of these targets.   
The need to annotate the microarray data sets for individual entity lists in order to 
make connections and identify potential hits required a level of selective identification 
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of hits.  Websites such as www.iHOP-net.org (Information Hyperlinked Over Proteins) 
proved to be useful tools in searching for the genes coded by specific zgc numbers and 
this was used to annotate whole entity lists in the search for potential hits.  However, 
this was laborious and while this work continued in the background certain pathways 
were targeted for wider investigation in the dataset based on hypotheses concerning 
the function of fih and the observed phenotypes in the embryos, such as vascular 
patterning, blood markers, and the notch pathway.  For the identification of these 
targets the whole dataset was analysed in its entirety and individual components 
known to be involved in either the phenotype or pathway were searched for by hand.  
The fold changes observed for these individual components were then compiled into 
an excel spreadsheet for assessing the trends within the group of genes in each 
individual mutant group, see Figure 53.   
 
 
Figure 53 One method of data collation was to cherry pick through the data and 
collect individual fold change numbers into a new Excel spreadsheet  
Screen shot of excel sheet used to collate individual components of individual pathways 
and genes thought to contribute to individual phenotypes.   
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The expression levels of these families of genes were then displayed in graphs in order 
to observe patterns and changes within the family of genes or between the different 
mutant groups, see data through the rest of this chapter. 
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Group Gene Microarray Derived Fold Change qRT-PCR in situ hybridisation 
WT vs 
Fih217/217 
WT vs Vhl-/- WT vs 
Fih217/217;Vhl-/- 
RAAS  Angiotensinogen (Agt) 0.22 1.50 0.98   
Angiotensin converting enzyme 1 (Ace1) 0.88 0.94 0.87   
Angiotensin converting enzyme 2 (Ace2) 0.24 0.72 0.93   
Renin 1.38 1.02 1.27   
Cyp11b2 (Aldosterone) 0.39 0.40 0.67   
Angiotensin II receptor Type 1 (Agt1ar) 0.69 1.04 1.26   
Apelin (Apln) 0.63 0.86 0.91   
Apelin receptor a (Agtrl1a/Aplnra/Msr)      
Apelin receptor b (Agtrl1b/Aplnrb) 1.42 1.49 1.86   
Hypoxia Pathway Hypoxia-inducible factor1 a like (Hif1 al) 0.92 0.86 1.04   
Hypoxia-inducible factor1 a like 2 (Hif1 al2) 2.86 2.90 3.73   
Hypoxia-inducible factor1 ab (Hif1 ab) 0.95 0.83 0.77   
Aryl hydrocarbon receptor nuclear translocator (Hif1 b) 1.11 1.06 1.41   
Aryl hydrocarbon receptor nuclear translocators 2 (Hif1b2) 1.29 1.46 1.47   
Hif1an (Factor inhibiting hif (Fih)) 0.39 2.91 4.31   
Von Hippel lindau (Vhl) 1.27 2.36 3.20   
Prolyl hydroxylase domain containing protein 1 (Phd1) 1.39 3.32 6.05   
Prolyl hydroxylase domain containing protein 3 (Phd3) 2.62 46.73 163.50   
Vegf Ligands Vascular endothelial growth factor aa (Vegfaa) 1.03 2.31 4.45   
Vascular endothelial growth factor ab (Vegfab) 1.10 2.63 9.83   
Vascular endothelial growth factor c (Vegfc) 0.95 1.01 1.16   
c-fos induced growth factor (Vegfd) 0.99 1.00 1.13   
Vegf Receptors Vascular endothelial growth factor Receptor 1 (Flt1) 0.84 2.12 2.21   
Vascular endothelial growth factor Receptor 2 (Kdr/Flk1) 1.40 1.90 2.78   
Vascular endothelial growth factor Receptor 3 (Flt4) 1.11 1.31 1.32   
Vascular Markers EphrinB2a 1.15 1.15 1.41   
Friend Leukemia Integration 1 Transcription Factor 1a (Fli1a) 0.97 1.00 1.09   
Friend Leukemia Integration 1 Transcription Factor 1b (Fli1b) 1.06 1.24 1.47   
Pancreatic 
Metabolism 
Amylase 2a (Amy2a) 0.17 0.53 0.82   
Chymotrypsinogen 0.26 0.65 0.94   
Glycolysis Enzymes Hexokinase 1 (Hex) 1.20 1.99 2.90   
Phosphoglucose isomerase (Gpib) 1.04 1.37 1.27   
Phosphofructokinase, muscle b (Pfkm-b) 1.08 2.39 4.01   
Triosephosphate isomerase 1a (Tpi1a) 1.25 1.21 0.99   
119 | P a g e  
 
Triosephosphate isomerase 1b (Tpi1b) 0.97 1.72 1.90   
Phosphoglycerate kinase 1 (Pgk1) 0.93 1.72 2.06   
Phosphoglycerate mutase 1a (Pgam1a) 
Phosphoglycerate mutase 1b (Pgam1b) 
1.00 3.81 5.54   
0.64 0.67 0.49   
Enolase1 (Eno1) 0.92 2.00 3.98   
Pyruvate kinase, muscle a (Pkm2a) 
Pyruvate kinase, muscle b (Pkm2b) 
0.83 1.60 2.25   
1.08 1.13 1.08   
Lactate Dehydrogenase (Ldha/LdhA4) 0.98 2.25 3.49   
Gluconeogenesis Preproinsulin  0.78 1.08 1.63   
Insulin growth factor binding protein 1a 0.96 2.96 11.53   
Phosphoenolpyruvate carboxykinase (Pepck) 1.22 3.00 11.17   
Glucose and fatty 
acid Regulation 
Glucose transporter 1 (Glut1) 0.88 1.15 1.03   
Peroxisome proliferators-activated receptor  (PPAR) 1.01 1.30 1.51   
PPAR-coactivator 1 (PGC1) 0.84 0.77 0.76   
Uncoupling protein 1 0.94 0.76 0.72   
Uncoupling protein 4 0.85 1.68 1.94   
Uncoupling protein 5 1.21 1.05 0.78   
Adiponectin-like (Adipoql) 
Adiponectin like 2 (adipol2) 
0.75 0.71 0.55   
0.83 0.75 0.53   
Adiponectin receptor 1a (adipor1a) 
Adiponectin receptor 1b (adipor1b) 
Adiponectin receptor 2 (adipor2) 
0.92 0.92 0.81   
0.87 0.86 0.77   
0.69 0.67 0.75   
Fatty acid binding protein 1a (Fabp1a) 7.48 4.78 7.38   
Blood Markers Erythropoietin (Epo) 1.38 3.37 14.24   
Erythropoietin Receptor (EpoR) 0.89 1.12 1.51   
GATA transcription factor 1 (GATA1) 1.58 2.06 2.68   
Delta-aminolevulinate synthase 2 (Alas2) 3.32 7.52 11.59   
Hemopexin (Hpx) 3.36 4.39 12.99   
Coagulation 
Cascade 
Factor I - Fibrinogen alpha chain (Fga) 
Factor I - (Fibrinogen beta (Fgb) 
Factor I - Fibrinogen gamma (Fgg) 
1.02 1.11 1.29   
1.10 1.16 1.28   
1.31 1.35 1.41   
Factor II -  Thrombin (FII) 1.15 1.33 1.30   
Factor X (F10) 2.26 2.24 2.29   
von Willebrand factor 5B1 
von Willebrand factor 5B2 
1.28 2.05 2.39   
1.29 1.20 0.79   
Kininogen (Kng1) 1.17 1.59 1.71   
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Fibronectin 1a (Fn1) 
Fibronectin 1b (Fn1b) 
0.98 1.00 1.06   
0.74 1.03 1.24   
Heparin cofactor 1 (serpind1) 1.01 1.22 1.30   
Plasminogen (plg) 1.35 1.47 1.74   
Plasminogen activator inhibitor 1 (PAI1/serpine1) 
Plasminogen activator inhibitor 2 (serpine2) 
1.33 1.11 1.20   
1.15 2.12 2.94   
Notch Pathway Notch1a 1.40 1.29 1.76   
Notch1b 0.49 0.45 0.58   
Notch2 0.90 0.92 0.89   
Notch3 (Notch5) 0.77 0.90 1.26   
Jagged1b (Jag1) 1.06 0.93 0.97   
Jagged2 (Jag2) 1.75 1.51 1.85   
Delta A 1.33 1.27 1.45   
Delta B 0.98 0.83 0.96   
Delta C 0.95 1.07 1.35   
Delta D 1.12 1.26 1.61   
Delta-like ligand 4 (Dll4) 0.95 1.19 2.90   
Notch Targets Hairy related protein-Epidermal growth factor receptor (Her1) 1.40 1.18 1.44   
Hairy related protein (Her8a) 1.31 1.68 2.41   
Hairy related protein (Her12) 0.08 0.06 0.07   
Hairy/enhancer-of-split related with YRPW motif (Hey2) 1.45 1.61 1.55   
Notch Inhibition Notch-regulated ankyrin repeat-containing protein (Nrarpa) 
Notch-regulated ankyrin repeat-containing protein (Nrarpb) 
1.22 1.34 1.84   
1.10 1.18 1.23   
Vessel Chemokine C-X-C chemokine receptor type 4a (Cxcr4a) 1.01 1.47 5.26   
Apoptosis Induced myeloid leukemia cell differentiation protein (Mcl1b) 1.56 3.04 5.70   
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like 
(Bnip3l) 
1.06 2.30 3.76   
Caspase C 0.73 1.43 2.35   
Hypoxic Target Troponin T1 (Tnnt1) 2.38 2.07 5.87   
Nitric oxide synthase 2a (Nos2a) 1.27 1.34 2.15   
Parathyroid hormone 1a (Pth1a) 2.99 4.70 5.10   
 
Table 15 Key genes of interest selected as hits from the larger microarray data set.  Those indicated in green are the genes that were used for 
qRT-PCR validation of the microarray data set. Patterns of altered gene expression from each mutant in the microarray data set were confirmed by 
qRT-PCR and also in situ hybridisation.  Data for PEPCK only from qRT-PCR as this was not annotated in the array 
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4.4.3 qRT-PCR Validation 
Once selected genes had been identified for validation qRT-PCR primers were designed 
to each one in turn, according to criteria dictated in the materials and methods 
chapter of this thesis.  Once each primer pair was optimised biological triplicate 
samples for each mutant (initially from cDNA generated from the RNA used for the 
microarray), with technical triplicates of each sample were then run, in order to 
calculate the ΔΔct for each gene of interest compared to β-actin, which was used as a 
reference gene throughout.  For information on the method development and 
validation of qRT-PCR, see Materials and Methods chapter. 
As independent correlation of the microarray and qRT-PCR data the fold changes 
derived from 10 genes were plotted on one graph, see Figure 54. 
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Figure 54 Correlation between microarray and qRT-PCR data was used to 
interpret the validity of the microarray data. 
Using 10 genes as examples the fold change derived from the microarray was plotted 
against the fold change derived from qRT-PCR and a linear regression analysis was 
performed in order to assess the correlation between the two assays, specific to each of 
the three mutants.   
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The correlation between the fold change derived from the microarray and that derived 
from the qRT-PCR shows that the microarray data-set is independently validated.  This 
confidence has been used to further interpret the microarray derived fold changes of 
certain genes that have not been independently validated by qRT-PCR throughout the 
rest of this study.   
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Group Gene qRT-PCR Derived Fold Change 
WT vs Fih217/217 WT vs Vhl-/- WT vs Fih217/217;Vhl-/- 
RAAS  Angiotensinogen (Agt) 0.31 3.15 0.68 
Angiotensin converting enzyme 1 (Ace1) 0.81 0.90 0.78 
Angiotensin converting enzyme 2 (Ace2) 0.33 1.07 0.50 
Renin 1.92 3.09 3.20 
Cyp11b2 (Aldosterone) 0.39 0.40 0.67 
 Prolyl hydroxylase domain containing protein 3 (Phd3) 2.24 232.7 251.7 
Vegf Ligands Vascular endothelial growth factor aa (Vegfaa) 1.56 7.08 6.61 
Vascular endothelial growth factor c (Vegfc) 1.50 1.79 2.43 
Vascular endothelial growth factor Receptor 2 (Kdr/Flk1) 1.69 2.86 3.11 
Vascular endothelial growth factor Receptor 3 (Flt4) 1.85 0.98 0.88 
Vascular Markers EphrinB2a 1.25 1.54 1.17 
Pancreatic Metabolism Amylase 2a (Amy2a) 1.32 10.32 4.70 
Chymotrypsinogen 0.35 1.82 1.04 
Glycolysis Enzymes Hexokinase 1 (Hex) 1.43 2.04 1.97 
Gluconeogenesis Preproinsulin  0.73 1.18 1.27 
Phosphoenolpyruvate carboxykinase (Pepck) 1.22 3.00 11.17 
Glucose and fatty acid Regulation Glucose transporter 1 (Glut1) 0.94 1.02 0.64 
Blood Marker Delta-aminolevulinate synthase 2 (Alas2) 2.86 8.15 9.48 
Notch Pathway Notch3 (Notch5) 0.98 1.32 1.00 
Delta-like ligand 4 (Dll4) 1.47 2.31 2.73 
Notch Target Hairy related protein (Her12) 0.29 0.35 0.33 
Notch Inhibition Notch-regulated ankyrin repeat-containing protein (Nrarpa) 1.35 1.48 1.36 
Vessel Chemokine C-X-C chemokine receptor type 4a (Cxcr4a) 1.25 2.42 3.47 
Table 16 Compiled list of qRT-PCR data 
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4.5 Hypoxic Signaling 
4.5.1 Loss of fih does not affect hifα or hifβ expression levels  
To assess alterations in the HIF pathway caused by the loss of fih and/or vhl, 
microarray data was scanned for expression levels of various components of the 
pathway, see Table 15.   
 
 
Figure 55 Fold change in hypoxic pathway genes 
The top left graph indicates the expression of the hypoxic pathway component genes in 
the fih217/217 embryos, the top right graph indicates the same for the vhl-/- embryos 
and the bottom left graph indicates the same for the fih217/217;vhl-/- embryos. 
Abbreviations:- Using ensembl genome browser to match the zebrafish genes 
annotated in the microarray with the human homologues, (in brackets): - hif-1αb (HIF-
1α), hif-1aL2 (HIF-2αa/HIF-2αb), epas-1 (HIF-2αa/HIF-2αb), hif-1aL (HIF-3α), arnt (HIF-
β), egln1 (PHD1), egln3 (PHD3), hif1an (FIH), vhl (VHL).  The probe sequence for epas-1 
was missing from current list and checking exact homologue is ongoing. 
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The lack of significant alterations in gene expression of the HIF genes in response to 
the loss of fih and/or vhl is not necessarily probative given that HIF protein is mainly 
regulated by protein degradation.  The fold changes observed indicated that hif-α-like 
and hif-αb genes, along with the two hif-1β/arnt genes, are not being differentially 
regulated in any of the three mutants, whereas hif-1α-like2, is up-regulated in all three 
mutants.  This suggested that this isoform is individually affected by the loss of fih and 
vhl and then expression was increased further by the combined loss of both fih and 
vhl.  This isoform has been described as a possible ortholog to both human HIF-1α and 
HIF-3α on Ensembl.  Expression trends in fih (hif1an) show down-regulation in the 
fih217/217 embryos, then up-regulation in the vhl-/- embryos.  The up-regulation of fih 
in fih217/217;vhl-/- embryos indicates nonsense mediated decay.   
 
4.5.2 Loss of fih increases expression of HIF target genes compared to vhl-/- embryos 
The trends in gene expression for vhl and phd3 genes demonstrate a pattern that was 
seen in several of the targets that were assessed:- a slight alteration in expression in 
the fih217/217 embryos, an increased level of altered expression in the vhl-/- embryos 
and a further increase in altered expression in the fih217/217;vhl-/- embryos, and 
these could be alterations either up or down compared with wild-type.  Over-
expression of HIF targets has been shown in response to increasing expression of HIF, 
along with functional inactivation of VHL gene (Wiesener et al., 2001).  This further 
trend in increased expression in fih217/217;vhl-/- embryos follows the hypothesis, 
already described that both FIH and VHL regulate HIF-α function. 
In Figure 55, using expression of phd3 as an example, as it has been shown to be a 
sensitive readout of HIF function, it was possible to see that expression is up-regulated 
by a factor of 2 in fih217/217 embryos versus up-regulated by a factor of 200 in vhl-/- 
embryos indicating that FIH is responsible for 1% HIF function, although this remains 
an assumption pending further testing.   
qRT-PCR validation of the microarray was performed using cDNA from the three 
biological replicate samples that were used in the microarray.  These findings were 
then confirmed with an independent sample of each of the mutant embryos at the 
same stage, in order to be sure that the qRT-PCR faithfully validated the microarray 
127 | P a g e  
 
findings; and that the findings were not specific to those three samples but were 
consistent with the mutants, see Figure 56. 
 
 
Figure 56 Fold change in phd3 used for microarray validation 
Left) The fold change derived from the microarray.  Centre) The fold change derived 
from qRT-PCR using cDNA from samples that were used in the microarray.  Right) The 
fold change in phd3 derived from independent biological samples of each of the 
mutants.   
 
The trend changes in expression correlate throughout the three graphs in Figure 56, 
which indicated that the findings were indeed consistent for the mutants and not 
simply the three samples that had been used to perform the microarray.   
 
4.6 Blood 
4.6.1 Loss of fih enhances expression of genes involved in blood-cell development 
Where fih is lost in conjunction with vhl, as in the fih217/217;vhl-/- embryos, pooling 
of blood in the ventral tail region and a cessation of circulation at between 4.5 and 
5dpf can be seen, the latter can be as observed in image deletion angiograms, see 
Figure 57.   
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Figure 57 Image deletion angiograms of embryos at 5dpf 
Illustrate the continued circulation in WT, and vhl-/- embryos throughout the embryo 
(the top embryo is representative of the phenotype observed in wild type, as well as fih 
-/+ and -/- embryos).  The lack of visible circulation in the posterior trunk and tail of the 
fih217/217;vhl-/- embryos at this stage was present in all embryos observed at this 
stage.  N=3. 
 
These observations could be the result of enhanced polycythemia in these embryos (a 
phenotype that is known to be present in the vhl-/- embryos), enhanced coagulation, 
or the result of altered vascular function.  The loss of fih as well as vhl in these embryos 
has the effect of releasing Hif from all normoxic inhibitory regulation.  In order to 
further investigate this, the expression levels of various genes involved in blood-cell 
development were assessed in these embryos using the microarray data-set. 
The expression of epo mRNA was assessed by in situ hybridisation in order to validate 
the microarray findings, see Table 13 and Figure 58. 
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Figure 58 Illustrates in situ hybridisation of epo at 4dpf 
mRNA expression of epo was assessed by in situ hybridisation in 4dpf zebrafish 
embryos. These images are composite images taken on multiple focal planes. 
 
The expression of epo appeared elevated in the fih217/217 embryos compared to the 
wild type sibling, further elevated in the vhl-/- embryos and further elevated again in 
the fih217/217;vhl-/- embryos.  This was quantified using the microarray data-set, 
along with several other key regulators of erythropoiesis and heme scavenging; see 
Table 15 and Table 16.  These genes are involved in various processes from 
erythropoiesis (epo) and erythroid development/differentiation (gata1), to heme 
biosynthesis (alas2) and the binding of free heme (hpx).    
Literature surrounding expression of erythrocyte density and genes involved in this, 
Alas2, hexokinase and others, see Table 13, lead the investigation to an attempt to 
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assess the erythrocyte density and other parameters of the blood cells, through high 
speed imaging techniques, see Figure 59. 
 
 
Figure 59 Quantification of erythrocyte density, erythrocyte count and 
erythrocyte volume  
Using high speed imaging and ImageJ software (protocol in Materials and Methods).  
Hemoatocrit is the volume percentage of red blood cells in a given volume of blood.   
 
The data revealed that while a slightly elevated erythroid count, aortic diameter, and 
hemoatocrit, could be observed in the fih217/217 embryos compared with wild type, 
the same could not be said of either the vhl-/- embryos or the fih217/217;vhl-/- 
embryos.  The erythropoetic markers that were assessed do however demonstrate 
that the loss of fih in vhl-/- embryos leads to an increase in erythrocyte markers and an 
inferred increase in erythrocyte numbers in these double mutants compared with vhl-
/- embryos.     
131 | P a g e  
 
4.7 Vascular Branching 
Several features of the vasculature of the fih217/217, vhl-/- and fih217/217;vhl-/- 
embryos were characterised in Chapter 3, and searches through the microarray data 
for indications of mechanisms for some of these were possible, including the 
assessment of genes known to be involved in tip-cell migration and differentiation. 
 
4.7.1 Tip cell guidance by cxcr4a 
The extra branching of the blood vessels in the vhl-/- embryos and the fih217/217;vhl-
/- embryos led to the assessment of chemokines cxcr4 and sdf-1 in the microarray data 
set, see Table 13 and Figure 60. 
 
 
Figure 60 Microarray derived fold change in chemokine expression 
The top left graph indicates the expression of chemokines in the fih217/217 embryos, 
the top right graph indicates the same for the vhl-/- embryos and the bottom left graph 
indicates the same for the fih217/217;vhl-/- embryos. Abbreviations:- chemokine (C-X-
C) motif ligand (cxcl12 or sdf-1), chemokine (C-X-C) motif receptor (cxcr4) 
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The microarray data indicated that the expression levels of both isoforms of sdf-
1/cxcl12 was not altered in any of the three mutant groups, and that the second 
isoform of cxcr4 was also not significantly altered by the loss of either Fih or Vhl, 
although it was elevated significantly in double mutants, this was further quantified by 
qRT-PCR techniques (Figure 60) and in situ hybridisation (Figure 61).  
 
 
Figure 61 Microarray and qPCR-validation of cxcr4a expression 
Quantification of cxcr4a expression by microarray and qRT-PCR techniques at 3dpf.  
The expression pattern showed an increase in expression in the fih217/217 embryos 
and no change in expression in the vhl-/- embryos or the fih217/217;vhl-/- embryos, all 
compared to wild type.   
 
The expression of cxcr4a demonstrated the expression pattern that had been seen for 
other hypoxic targets, such as phd3 and vegf, an in situ hybridisation was performed 
for cxcr4a in order to assess the locations as well as levels of expression within the 
embryos, see Figure 62. 
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Figure 62 in situ hybridisation pattern of cxcr4 expression 
Cxcr4a expression patterns in the fih and vhl mutant embryos at 4dpf revealing 
increasing levels of expression in the fih only mutant embryos through to the 
fih217/217;vhl-/- double mutant embryos.  
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The strikingly increased expression of cxcr4a in the fih217/217;vhl-/- embryos is in 
agreement with the increased level of branching in the vasculature observed in these 
embryos and a pattern of tip-cell enrichment.  
 
4.7.2 Expression of Notch signaling components and downstream targets 
As previously described, the Notch signaling pathway, in combination with vegf 
signaling, has been shown to be involved in both the distinction between tip and stalk 
cell fates, and also in vascular remodeling, see Table 13.  Observations in the vhl-/- and 
fih217/217;vhl-/- embryos using both angiogram and Tg(fli1;eGFP) imaging revealed 
increased vascular branching over time in these embryos (Chapter 3).   Before 
assessing the expression of Notch target genes we assessed whether the loss of fih or 
vhl had significant effects on the genes of the pathway itself (data not shown), see 
Table 13 for background.  The majority of the genes that were annotated in the 
microarray were not differentially expressed in the fih217/217 embryos, there were 
slight overall elevations in expression in the vhl-/- embryos and this was then further 
elevated in the fih217/217;vhl-/- embryos.   
Expression of deltaC (dllc) has been shown throughout early development of the 
zebrafish embryo, see Table 13.  On the basis that this might be a vascular specific 
ligand, the levels of deltaC were assessed by in situ hybridisation and in the microarray 
data set in the fih217/217 and vhl-/- embryos, see Figure 63. 
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Figure 63 Expression level of deltaC by in situ hybridisation and microarray 
A) Expression of DeltaC, pattern by in situ (4dpf) and B) quantified by microarray 
(3dpf). These images are composite images taken on multiple focal planes. 
 
DeltaC expression in the different mutants showed that it was up-regulated in the 
fih217/217;vhl-/- embryos by in situ hybridisation, and quantified as such by 
microarray analysis.  The in situ revealed its expression at 5dpf is concentrated around 
the head vasculature and the region of the pronephric ducts; in the wild type, 
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fih217/217 only and vhl-/- only embryos.  However in the fih217/217;vhl-/- embryos 
the expression is expanded throughout the embryos in a pattern consistent with ISVs 
and slightly stronger expression in the region of the pronephric ducts.  Increased 
expression of deltaC was observed in the in situ hybridisation, however the changes, as 
quantified by the microarray data, were not large.  These findings indicated the need 
for further investigation of other Notch ligands and receptors, which were assessed by 
microarray and qRT-PCR.    
Alterations in notch3 expression have also been shown to be involved in vascular tone 
and blood flow, see Table 13 and Figure 64. 
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Figure 64 Expression of notch3 by in situ hybridisation, microarray and qRT-PCR 
A) Expression pattern of notch3 in the mutants by in situ hybridisation at 4dpf.  These 
images are composite images taken over multiple focal planes.  Expression of notch3 at 
3dpf was also quantified by both microarray (B) and qRT-PCR techniques (C).   
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The expression profile of notch3 in the different mutants indicates that its expression 
is not altered in the fih217/217 only embryos, that It has slightly up-regulated in the 
vhl-/- only embryos, and then not altered in the fih217/217;vhl-/- embryos, compared 
back to wild type, as shown by the qRT-PCR and the in situ hybridisation.  The lack of 
dramatic changes to notch3 or deltaC expression suggests that while their role in aortic 
specification is present in each of the groups of embryos It has not responsible for 
differential phenotypes.   
 
4.7.3 Notch Inhibition (Chemical and Intrinsic) 
Initial observations and the known effect the need for lateral inhibition, set up by 
differential Notch receptor and ligand on neighbouring cells in the vasculature 
indicated an opportunity to assess the effect of the inhibition of Notch signaling on the 
vasculature of these embryos.  This would aid the investigation as to whether this was 
the causative signaling pathway being affected to generate the increased branching in 
the double mutants.  Treatment with N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-
phenylglycine-t-butyl ester (DAPT), a γ-secretase inhibitor, was used to assess the 
effect of global inhibition of Notch-signaling on the branching pattern of the 
vasculature, see Figure 65. 
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Figure 65 The effect of DAPT treatment (Notch signaling inhibition) on vascular 
branching, revealing the increased branching and sprouting of the blood vessels 
The left panel indicates DMSO control treated embryos while the right panel indicates 
DAPT treated embryos.  The top panel indicates the common phenotype observed in 
both wild type (fih+/+) embryos and in fih217/217 embryos.  The bottom panel 
indicates the phenotype observed in the fih217/217;vhl-/- embryos.  The vhl-/- embryos 
weren’t represented. N=1 cross with multiple embryos.  
 
The data from the DAPT treatment can only be used as an indicator of the effect of 
inhibiting the notch signaling pathway on the vascular branching due to the low 
number of embryos imaged.  What can be indicated is that upon treatment of both 
wild-type and fih217/217 embryos with DAPT there was an observable increase in 
branching of the ISVs.   
Overall expression of Notch expression were also assessed using the fih;vhl;Tg(csl-
venus)qmc61 zebrafish line (Gerring, M. pers. Comm.), see Figure 66. 
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Figure 66 The overall expression of Notch signaling 
Levels of Notch signaling using the fih;vhl;Tg(csl-venus)qmc61 zebrafish line (Gerring, 
M. pers. Comm.),  
 
The vascular expression of the Tg(csl-venus)qmc61 expression correlated with the 
Notch pathway’s known roles in vascular development, as well as with the increased 
expression observed in the microarray and qRT-PCR.   
The expression patterns of other components of the pathway with roles in negative 
regulation, notch regulated ankyrin repeat domain protein (NRARP) and the notch 
intracellular domain (NICD), were assessed using microarray and qRT-PCR techniques, 
see Table 15 and Table 16.  
The discrepancy in the expression of nrarpa in the fih217/217;vhl-/- embryos between 
the microarray data and the qRT-PCR is slight but makes drawing conclusions on the 
role of nrarpa in the increased branching and tip cell formation observed in these 
embryos difficult and further tests would need to be conducted.  However, NRARP is 
also a target of Notch signaling so the slight elevation of expression could also indicate 
slight activation of the pathway so care must be taken using it as an indication of the 
pathway’s activation.   
More importantly, we checked the microarray for indications of increased levels of 
Notch signaling by analysing target/effector genes such as the her and hey genes, 
where there were differences in expression levels, most notably in her12 expression, 
were annotated in the microarray data and collated, see Table 15 and Table 16. 
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Her12 showed the strongest down-regulation (12-18 fold) and was confirmed by qRT-
PCR, albeit at a somewhat less impressive level, it is expressed in several places where 
Notch signaling is known to be active and was also found to be expressed in the 
endothelial cells.  The finding that her12 is down-regulated is not consistent with the 
idea that Notch signaling can be enhanced by HIF or by the loss of FIH.  Nevertheless 
some her and hey genes showed a weak up-regulation, thus a small effect in particular 
tissues cannot be excluded.   
 
4.8 Discussion and Future Work 
4.8.1 Performing the Microarray  
The microarray was performed in order to assess candidate genes or pathways that are 
being controlled by Fih and to compare changes to the transcriptome in fih mutants 
with changes in vhl it might be possible to distinguish between those phenotypes 
caused by uncontrolled HIF signaling and those mechanisms that fih might control 
independently of HIF; e.g. Notch signaling.  Samples were carefully collected, prepared 
and analysed to ensure as much consistency between triplicate samples and the 
highest quality possible.  Venn diagrams, scatter plots and heat maps provided entity 
lists of potential hits, which was only made laborious by the need to systematically and 
individually annotate genes from codes.  Looking at the trends rather than the specifics 
however it was possible to see that high proportions of genes that could be seen to be 
up- or down-regulated in the fih217/217 embryos were also up- or down-regulated in 
the vhl-/- embryos, this indicated that FIH was acting predominantly through HIF.   
The microarray revealed few genes with expression patterns that were drastically 
different in the fih217/217 embryos compared with the wild type embryos.  When 
looking at the genes that were most strongly up-regulated there were few that were 
immediately annotated, and even once probe sequences had been used to annotate 
the list there were few genes with increased expression that were easily connected to 
the phenotypes observed and several mapped to regions that were not transcribed 
according to Ensembl it is tempting to speculate that many of these could be false 
positives from the microarray.  Nevertheless the tight correlation between up-
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regulated genes between fih and vhl mutants suggests that there is a true effect of fih 
on the transcriptome detectable. 
 
4.8.2  Microarray Validation  
The physiological follow up to all of the potential hits has not been completed, 
although the microarray was validated for 20 genes by qRT-PCR and so a certain level 
of interpretation has been made.  However conclusions drawn from the data rely, for 
these interpretations, on the connection between phenotypes and gene expression 
and remain speculation until such time as they can be assessed.   
Processing the data took on multiple approaches in order to both search for trends 
based on the relationship between expression in the different groups, and also 
selectively sorting through the data-set to identify hits.  The need to move to a more 
targeted search process didn’t prevent the identification of several genes selectively 
regulated by the loss of fih, to be described.   
Once the hits were identified and qRT-PCR primers were optimised it was also possible 
to begin assessing the microarray as a validated data-set and begin pooling together 
the expression levels of families of genes either surrounding the validated hits or based 
around previously observed phenotypes.   
One experiment used to assess the validity of the microarray data was to obtain a new 
sample from each of the different genotypes of embryos, and compare the qRT-PCR 
results from these with those obtained by performing qRT-PCR on the same samples as 
the microarray.  The data showed the same trend in gene expression of phd3, although 
at different magnitude.  While acknowledging that both these techniques (microarray 
and qRT-PCR) exhibit their own levels of bias and specificity, the correlation between 
the profiles in these three graphs suggests that the microarray data can be used to 
draw preliminary conclusions on gene expression changes in these embryos.   
 
4.8.3  HIF Family Genes 
The first family of genes to select was the hif family members that were annotated in 
the array, along with the phds, fih and vhl themselves.  It was clear that expression in 
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fih217/217 embryos was almost entirely unchanged, with two exceptions hif-1al2 (a 
HIF-1/HIF-3 homologue) and phd3, whereas in vhl-/- and fih217/217;vhl-/- embryos 
expression of phd3 rose to 46 fold and 163 fold respectively compared to wild type.  
Expression of phd3 was validated by qRT-PCR and demonstrated that Fih was 
contributing to 1% of Hif function in altering the expression of phd3.  The increased 
expression of hif-1al2 may not be significant in itself since Hif activity and function is 
known to be regulated at the protein level.  The increased expression of fih in 
fih217/217;vhl-/- embryos could be due to fih being a HIF target gene, which is unlike 
what has been published on fih and would need to be investigated further.   
The microarray revealed expression patterns that correlated with the hypothesis 
proposed in Figure 6 of the Introduction, that the roles of Fih and Vhl in regulating Hif 
levels and activity are distinct.  The loss of fih alone leaves Vhl to function, responding 
to Phd3 hydroxylation of Hif to induce its breakdown, ensuring continued regulation of 
Hif function, suggesting that down-stream expression of target genes could be kept to 
close to wild type levels.  In the vhl-/- embryos, this breakdown of Hif fails to occur and 
regulation of Hif function is left to Fih hydroxylation at the active site of Hif co-
activators, allowing an increase in down-stream target gene expression.  The double 
mutants have neither of these mechanisms in place and expression of down-stream 
targets therefore resembles that during hypoxia, when Fih, Phds and therefore Vhl are 
naturally inhibited.   
 
4.8.4 HIF Targets 
The expression of the haematopoiesis inducing hormone epo, the first gene in which 
an HRE was identified, along with vegf demonstrated the same expression profile as 
phd3 across the three mutant groups.  Since two known phenotypes of the vhl-/- 
embryos are polycythemia and hyper-branching of the vascular network, the elevated 
expression of these genes correlated and further validated the microarray findings, 
especially in combination with observations in the fih-/-;vhl-/- embryos of these 
phenotypes being enhanced compared to vhl-/- only embryos and observing the 
further up-regulation of these genes.   Also a point of note and worthy of further 
investigation, given that polycythemia that has been characterised in the vhl-/- 
embryos, is the observation of elevated vegf-ab in these embryos and its role in 
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haematopoiesis (Bahary et al., 2007).  The further up-regulation of vegf-ab in the 
fih217/217;vhl-/- could therefore be indicative of an increase in blood cells in these 
embryos too, which is yet to be definitively characterised.   
Given the interactions between the different Vegf ligands and receptors and the 
alterations in expression of vegf-aa in the embryos, the other members of the Vegf 
family along with other vascular markers that could contribute to the visible 
differences in the vasculature were investigated, see Table 15 and Table 16.  The 
increase in VEGF receptor expression is less pronounced than the increase in ligand 
expression.  The ligand binding with particular receptors indicates that the increase in 
expression of vegf-aa and -ab, along with the increased expression of flt-1 and kdr/flk-
1 are the receptors that these ligands have been shown to bind to.  These ligands and 
receptors are known to bind to each other, the correlation in their changes in 
expression patterns are therefore connected.   
The slight increase in expression of vegf-c is not correlated with an increase in flt-4 (the 
ligand), which would have been indicative of simultaneous increases in both blood 
vessel proliferation as well as lymphangiogenesis.  The up-regulation of flt-1 and kdr is 
to the same degree in the vhl-/- embryos and the fih217/217;vhl-/- embryos, which 
suggests that the loss of fih is not a major factor in the regulation of these receptor 
genes.  The microarray results indicate that the loss of fih only has an impact on vegf-
aa and vegf-ab in the context of the vhl-/- embryos.  Taken together, the fih217/217 
embryos exhibit slight elevation in kdr expression, the vhl-/- and fih217/217;vhl-/- 
embryos have increased expression in both vegf-aa and vegf-ab along with increased 
expression of both flt-1 and kdr-l/flk-1.  The further increase seen in these double 
mutants indicates that VEGF signaling is further increased.  The striking effect of vegf-
ab expression is interesting and merits further investigation and suggests a more 
important role of vegf-ab than was currently assumed.  The vegf-a locus is duplicated 
in the zebrafish, isoforms vegf-aa and vegf-ab, and these have been shown to have 
distinct expression patterns by in situ hybridisation (Bahary et al., 2007).  vegf-ab 
morphants have been shown to develop normal vasculature and haematopoiesis until 
2dpf, whereas vegf-aa morphants lack the major intersegmental vessels and show 
reduced haematopoiesis, indicating distinct roles for the two genes (Bahary et al., 
2007).  Although both vegf-aa and vegf-ab are increased, from the current 
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experiments, it is not clear what the relative expression of vegf-aa is to vegf-ab, if vegf-
aa is normally 100 fold higher expressed than vegf-ab, the 9 fold increase of vegf-ab is 
still a minor contribution to the total VEGF signal.  It would be interesting to block the 
function of vegf-ab by morpholinos or mutation and see whether it could modulate 
the double mutant phenotype.  Similarly morpholinos against vegf-aa or even chemical 
could be used to (partially) block VEGF function to determine whether the phenotypic 
alterations in fih;vhl double mutants are the result of increased VEGF signaling (Bahary 
et al., 2007, Liang et al., 2001, Nasevicius et al., 2000). 
Overall the expression of these genes was not significantly altered in the fih217/217 
embryos, with the exception of a slight elevation in kdr/flk1.  In the vhl-/- embryos the 
expression of vegf-a, vegf-ab, flt1 and kdr/flk1 can be seen to be elevated, and these 
same genes are elevated, albeit further elevated, in the fih217/217;vhl-/- embryos.  
The expression levels demonstrated in the microarray were assessed by qRT-PCR for 
validation, see Table 16.  This supports the hypothesis made whereby the differing 
effects of Fih and Vhl regulation of Hif.   
The expression patterns of many of these genes has been described on the Zfin.org 
website, Vegf-aa has been shown in the blood vessels, the caudal vein plexus, the 
dorsal aorta, the ISVs and the new sprouting vessels, whereas Vegf-ab shown in ISVs, 
nucleate erythrocytes and the sub-intestinal vein, indicating more restriction of the 
expression of this gene in the zebrafish.   The microarray data showed that vegf-ab was 
the highest regulated gene in the fih217/217;vhl-/- embryos but all these ligands 
demonstrated the trend in expression of slight increased expression in the fih217/217 
embryos, an increase in the vhl-/- embryos and a further increase in expression in the 
fih217/217;vhl-/-embryos.  VEGF-AB was not validated at this time, by qRT-PCR, however 
primers were ordered.   
The microarray data suggested little to no alteration in expression of either vegf-c or 
vegf-d, both of which have been connected mainly with lymph-angiogenesis rather 
than vascular-angiogenesis (Vlahakis et al., 2005), new data is blurring this slightly, 
suggesting that the lymphatic system is not being differentially organised in these 
embryos.   
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The previously described trend in expression was present except for all three of the 
Vegf receptors that were annotated.  There was a discrepancy between the microarray 
data and the qRT-PCR profiles for flt4, where the microarray suggested that there were 
no changes observed in expression between the different mutants and the qRT-PCR 
showed an increase in expression in the fih217/217 embryos and no change in 
expression in the vhl-/- embryos or the fih217/217;vhl-/- embryos, all compared to 
wild type, see Table 15 and Table 16.   This discrepancy could be due to the increased 
sensitivity of the qRT-PCR assay in comparison with the microarray (Dallas et al., 2005), 
ensuring continued caution in interpreting the data.   
In the zebrafish, the two kdr genes have been shown to have strikingly different effects 
with kdr-l having been shown to be functionally necessary for artery development 
(Covassin et al., 2009), the qRT-PCR for this gene is ongoing to confirm the microarray 
findings, since they indicate kdr is differentially expressed rather than kdr-l. 
The alterations in both vegf ligands and receptors could well be responsible for, or a 
contributing factor, to the altered vascular phenotypes that were observed in the 
Tg(Fli1:eGFP) background.  In early zebrafish embryos, arterial fates are induced by 
VEGF signaling from the somites, as well as via Notch signaling (Adams et al., 1999, 
Herbert et al., 2009, Iso et al., 2006), and ephrinB2/ephB4 expression.  EphrinB2 
(arterial) and ephB4 (venous) have been shown to be differentially expressed in the 
primary vascular plexus in the early chick embryo prior to the onset of circulation 
(Moyon et al., 2001, Othman-Hassan et al., 2001, Kume, 2010).  Since shear stress has 
also been shown to increase the expression of ephrinB2 via VEGF-Notch signaling 
pathways in vitro (Masumura et al., 2009, Obi et al., 2009) and in vivo (Suzuki et al., 
2012) the expression of this marker was also analysed.  
In this case of ephrin B2 (see Table 15 and Table 16) the expression of ephrinB2a didn’t 
alter across the three different mutants at 3dpf, at this stage its expression is restricted 
to the dorsal aorta as shown by Zfin.org.  Murine embryonic stem (ES) cells expressing 
kdr/flk1 that are then exposed to shear stress exhibit ephrinB2 expression whereas 
ephB4 mRNA (associated with venous cells) decreased (Masumura et al., 2009).  This 
has been shown, in mouse ES cells, to be regulated by Notch signaling, where abolition 
of notch intracellular domain (NICD) translocation blocked stress-induced up-
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regulation of ephrinB2 expression, and forced NICD expression induces mRNA 
expression of ephrinB2 (Masumura et al., 2009, Iso et al., 2006).  More specifically, 
Dll4-Notch stimulation and not Jagged1-Notch markedly induced ephrinB2 expression 
(Iso et al., 2006).  Observations in ephrinB2-/- and ephB4-/- mice have revealed 
deficiencies in primary capillary remodeling into the mature vascular network, with no 
clear boundaries between the arterial and venous vessels (Wang et al., 1998).  The 
expression of this gene is therefore important for the establishing of arterial-venous 
interactions, not necessarily in the initial endothelial specification (Wang et al., 1998, 
Kume, 2010).  The absence of an effect of vhl and/or fih loss on ephrinB2 expression 
suggests that it does not play a distinct role in the different vascular phenotypes that 
were observed in the fih217/217 and vhl-/- embryos at 3-4dpf.  In the absence of 
further data on earlier embryos however, effects during the initial arteriovenous 
specification cannot be excluded.  
Observations of alterations in heart function in the vhl-/- and fih217/217;vhl-/- 
embryos compared to wild type siblings (described in more detail in Chapter 5 as well 
as (van Rooijen et al., 2010) lead to the assessment of troponin T2 heart marker in the 
microarray data set, see Table 15.   The expression of tnnt2c is up-regulated to roughly 
the same degree in both the fih217/217 embryos and the vhl-/- embryos, and then 
that expression is doubled in the fih217/217;vhl-/- embryos, indicating that tnnt2c was 
influenced equally by the loss of either fih or vhl and then further by the loss of both 
genes, indicating perhaps an independent effect.  Phenotypes observed in the heart 
size and function of these embryos can therefore be thought to be caused by alternate 
factors, which need to be investigated. 
 
4.8.5 Inflammation 
Having described the positive effect of FIH hydroxylation on NFκ-B1 and Iκ-Bα activity 
in Section 6.6.3, the expression levels of these and other inflammatory markers were 
assessed in the microarray data set.   Since the effect of FIH has been shown to be 
post-translation, with hydroxylation events at designated Asn residues affecting the 
stability of the proteins, it was not surprising that the levels gene expression were not 
significantly altered in any of the three mutants being studied compared with wild 
type.  However, since FIH has been shown to bind to many proteins besides these and 
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in order to assess the role of fih in vivo a preliminary search for the expression of NF-κB 
target genes was made in the microarray dataset.   No alterations were observed in 
the expression of TNFa or TNFb (known to also be involved in activation of NF-κB), or 
in target genes such as interleukin 6 (IL-6), signal transducer and activator of 
transcription 3 (STAT3), or bcl-xl (data in supplementary excel file) in the fih217/217 
embryos at 3dpf, see Table 13 for references.  Further investigation of the microarray 
dataset could be performed, however the data suggests that fih is not directly 
influencing nfκb expression or activity in vivo.  The observation of little or no changes 
in expression of NFκB or IκB family members remains just that, since the role of FIH 
interaction with these has been shown to be post-translational.  Of course it cannot be 
excluded that fih has an effect on NFκB in a particular cell type.  For instance, hypoxia 
has been shown to affect the behaviour and function of neutrophils with hypoxia able 
to increase NF-κB protein expression and activity and mediate neutrophil survival 
(Walmsley et al., 2005).  The direct effect of fih on neutrophil and/or macrophage 
behaviour would also be possible with the crossing of the fih217/217 fish with GFP-
transgenics available at the university which label these cell types.   
 
4.8.6  HIF and Circulatory System 
One observation in the vhl-/- embryos which elicited a specific search through the 
microarray data was that of the enlarged heart and increased cardiac output compared 
to wild type siblings.  This along with observations described in Chapter 3, of the 
further enlargement of the heart and associated oedema in the fih217/217;vhl-/- 
embryos lead to the assessment of the troponin family of genes known to be integral 
to skeletal and cardiac muscle contraction along with association of the sarcomeres.  In 
the zebrafish the assembly of sarcomeres and the role of thin filaments has been 
linked to Tnnt2, the silent heart locus (Ferrante et al., 2011, Sehnert et al., 2002).  Since 
the loss of the Tnnt family has been linked to the failure of sarcomeres to form, the 
increased expression of one of these genes correlates with the enlarged hearts that 
are observed in the vhl-/- embryos and particularly the fih217/217;vhl-/- embryos 
compared to both the wild type and fih217/217 siblings and with the increased 
amount of work that is required in these mutants, although this requires further 
investigation.  Tnnt2c expression showed a similar level of up-regulation in either fih or 
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vhl single mutant, with a further up-regulation in fih217/217;vhl-/- embryos, indicating 
that it may contribute to extra work needed in these embryos.  Here tnnt2 over-
expression may indicate a sign of cardiac stress (indicated in humans (Gomes et al., 
2002, Linnemann et al., 2012)) and may in turn correspond with an observation in the 
fih/- embryos that the hearts may be pumping harder against normal vessels, whereas 
vhl-/- has less problems at 3dpf and fih217/217;vhl-/- embryos a more  
 
4.8.7 Blood and Circulation 
Data from the initial analysis attempted to count RBCs along the aorta was difficult to 
interpret since the vhl-/- embryos have been previously shown to exhibit polycythemia 
(van Rooijen et al., 2009).  This data was generated from counts and measurements 
made from images taken during high-speed imaging, and to ensure the aorta was at 
precisely the same angle for each fish in order to measure the inner wall of the vessel 
made the accurate mounting of the embryos essential and difficult to compare.  There 
was consistency between the different parameters that were assessed when they 
were compared with the other data from the same group, however the lack of 
corroboration of previously reported findings in the vhl-/- embryos does raise concerns 
about drawing conclusions based on these data in isolation. 
Utilising the microarray data to test hypotheses became another avenue of 
investigation.  Following observations in the fih217/217;vhl-/- embryos that circulation 
in the tail and trunk ceased to flow from 4.5dpf.  The attempted assay that was used to 
assess erythrocyte volume, number and haematocrit (erythrocyte number per unit 
volume) was difficult to assess through inherent difficulty in consistency of mounting 
embryos for imaging and in built human error in measuring.  Data did suggest 
differences but did not confirm results known for vhl-/- embryos, albeit at a different 
developmental stage.  Assays such as taking blood smears and using o-dinanisidine and 
May-Grunwald Giemsa stains have been used to quantify and characterise blood cells, 
along with confocal imaging at high magnification and would aid in characterising 
blood phenotype in these double mutants (van Rooijen et al., 2009).  One possible 
hypothesis to explain the sluggish circulation in double mutants was the possibility of 
increased clotting.  To this end all the clotting factors in the intrinsic as well as extrinsic 
coagulation cascades that were annotated in the array were isolated to reveal that 
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several were up-regulated in the fih217/217;vhl-/- embryos, although not dramatically 
and it is not clear from their RNA level whether these influence the actual clotting 
process in vivo.   The increased expression of vegf that has also been reported in the 
fih217/217;vhl-/- embryos could also be a contributing factor in the sluggish 
circulation, releasing fluid from the vessels leaving the RBCs to clump. 
Epo is an essential hormone involved in red blood cell production and also plays roles 
in breathing rates and tidal volumes (Semenza and Wang, 1992, Yalcin et al., 2007).  
Since it plays other roles besides those in haematopoiesis, other genes were also 
assessed including runt-related transcription factor (runx) and t-cell acute lymphocytic 
leukemia (scl/tal1) although these were not differentially regulated. 
Up-regulation of several genes involved in erythrocyte proliferation and heme 
scavenging in response to HIF signaling is consistent with published data.  However 
angpt1 and epo-r, which have previously been demonstrated to be elevated in the vhl-
/- embryos at 7.5dpf (van Rooijen et al., 2009) are not significantly different from wild 
type at 3dpf, suggesting that further investigation of later time-points might be 
necessary to infer conclusions from this data.  Gata1 mRNA and protein levels have 
been shown to be increased under hypoxic conditions (Zhang et al., 2011) and the up-
regulation of gata1, along with epo, in the fih217/217;vhl-/- embryos is a strong 
indication that haematopoietic proliferation and erythroid differentiation is being 
initiated in these embryos despite their normoxic environment.   
Assays such as taking blood smears and using o-dinanisidine and May-Grunwald 
Giemsa stains to quantify and characterise blood cells, along with confocal imaging at 
high magnification would aid in characterising the potential polycythemia in these 
double mutants (van Rooijen et al., 2009).   
 
4.8.8 Blood flow and blood clotting 
Blood flow analysis by high speed video-microscopy of the fih217/217;vhl-/- embryos 
was assessed in Chapter 3 and revealed that blood flow in the fih217/217;vhl-/- 
embryos became sluggish and then ceased around 4.5dpf.  This reduced flow infers a 
reduction in LSS and therefore supports the connection between LSS and cxcr4 
expression proposed by Melchionna and Packham (Melchionna et al., 2005, Packham 
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et al., 2009).  The in situ hybridisation images shown by Packham et al for cxcr4 
expression in tnnt2 morphants (where flow is never initiated), compared to control 
morphants, do reveal an up-regulation of cxcr4 (Packham et al., 2009), however not to 
the same extent as observed in the fih217/217;vhl-/- embryos.  Further investigations 
into the stage at which the cxcr4 expression becomes elevated, would aid the 
investigation of how this expression correlates with observations of the slowing of 
circulation in the fih217/217;vhl-/- embryos.  Also, if blood flow were to be slowed, 
potentially using titrated doses of tricaine, it would be possible to assess to what 
extent flow was able to influence cxcr4 expression, in conjunction with fih and/or vhl 
function.   
Since only fih217/217;vhl-/- embryos show circulation defects, clotting factors was 
thought to play a role in this, increased expression of Factor 10 (F10 or FX) was 
observed in each of the mutant groups.  This suggested the possibility that if 
proliferation of the erythrocytes was not entirely responsible for the sluggish 
circulation then another candidate could be coagulation.  However only minor changes 
(<2 fold) were observed, with no clear correlation with fih;vhl double mutant 
phenotype (since changes were also observed in the single mutants).   
Analysis of clotting has been tested in adult zebrafish by analysing the bleeding times 
(Jagadeeswaran and Sheehan, 1999), although the small volumes of plasma make 
assessing total coagulation activity (TCA) difficult (Jagadeeswaran et al., 2000).  This 
being the case in the adult fish along with the fact that the fih217/217;vhl-/- embryos 
do not survive to adulthood makes the direct assessment of clotting in these fish more 
difficult.  An assay has been developed using a nitrogen laser to create a vascular 
lesion in order to observe dynamic wound healing response and assessing the role of 
thrombocytes in clot formation (Gregory et al., 2002, Thattaliyath et al., 2005, Lang et 
al., 2010), this technique could be used to assess wound healing and clotting in the 
embryos.  These assays could be tested in order to assess the contribution of clotting 
factors in the circulation defect in the fih217/217;vhl-/- embryos. 
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4.8.9 Vascular Development 
Cxcr4a over-expression causes a directed migration of somitic cells to the aortic region 
in a manner similar to that seen in Notch induced migration in the chick embryo 
(Ohata et al., 2009).  Hypoxia can induce expression of cxcr4 through Hif-1 activation in 
human monocytes, macrophages, endothelial cells and cancer cells (Zagzag et al., 
2005).  The regulation of cxcr4 levels in endothelial cells may occur transcriptionally or 
post-transcriptionally (Melchionna et al., 2005).  Increasing laminar shear stress (LSS) 
has been shown to result in down-regulation of cxcr4a in endothelial cells (Melchionna 
et al., 2005) and mediates collateral vessel formation in zebrafish embryos (Packham 
et al., 2009).  Blood flow rates and perturbations, such as arterial occlusions, are 
detected by the endothelial lining of the vasculature, and this results in alterations in 
gene expression and further regulation of blood flow and EC function (Melchionna et 
al., 2005, Packham et al., 2009).  The hypothesis was that LSS maintained cxcr4 
expression on the endothelium at lower levels than in ECs either subjected to low LSS 
or kept in static conditions.  High levels of cxcr4 expression have been found in ECs 
from human carotid artery atherosclerotic lesions, while found at low levels in 
minimally diseased carotid artery endothelium (Melchionna et al., 2005).   Since this 
was not an avenue of investigation, assessing the vascular phenotypes, as well as 
observations of the migration of endothelial cells (using the Tg(fli1;eGFP) line) in 
response to chemical inhibitors such as AMD3100, a specific cxcr4 inhibitor, could 
answer some of these questions as to post-translational role of cxcr4 in the vascular 
patterning of the fih;vhl embryos.   
Investigation of other tip-cell enriched genes such as nidogen-1 (nid1), uPAR, apelin 
(apln), and angiopoetin 2 (angpt2), each identified as being tip-cell enriched by 
assessment of endothelial cells from dll4+/- compared to wild type retina in the mouse 
(del Toro et al., 2010) would be needed to further investigate these phenotypes.   
 
4.8.10 Notch signaling and its role in vascular development 
Connections between notch signaling and blood vessel development and arrangement 
has been studied widely in different models, see Table 13, and connections between 
these data sets have been seen in the fih217/217;vhl-/- embryos, see Figure 67.   
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Figure 67  Correlation between phenotypes of Dll4 MO knockdown and vascular 
branching of fih217/217;vhl-/- embryos 
Literature derived correlation between the phenotype of a Dll4 MO knockdown and the 
subsequent increase in branching of the vessels with the increase in vascular branching 
observed in the fih217/217vhl-/- embryos. 
 
In order for the hypothesis to be tested, the levels of dll4 expression in the 
fih217/217;vhl-/- embryos were assessed and the indication from the morpholino 
experiments would need for dll4 to be down-regulated for the hypothesis to be 
supported, see Table 15 and Table 16.   
Since dll4 is a Notch activator expressed in the tip-cells and involved in the lateral 
inhibition to prevent neighbouring stalk-cells taking on tip-cell identity the loss of dll4 
has been shown to result in the increased branching of the vasculature through an 
increase in tip-cell identity.  This led to the hypothesis that increased branching of the 
vessels in the vhl-/- and fih217/217;vhl-/- embryos could be induced by a decrease in 
dll4 expression.  When this was tested, an increase in dll4 was found to be highest in 
double mutants.  On the other hand, since vegf has been shown to induce the 
expression of dll4, in itself potentially increasing the number of tip-cells and inducing 
the branching phenotype, it is possible that the increased level of dll4 expression 
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observed by microarray and qRT-PCR could simply be a read-out of the increased 
number of tip-cells.   
High levels of dll4 have also been shown to result in decreased expression of 
identifiable markers immature pericytes, suggesting that there is an interaction 
between Dll4 and pericytes.  This was proposed to be important for pericyte coverage, 
but that this coverage wasn’t essential for vessel maturation in tumour vasculature (Li 
et al., 2007b).  These connections to hypoxia driven dll4 expression in tumour 
vasculature and pericyte coverage suggest that these roles might be more critical in 
these embryos than its direct effect on tip-cell differentiation in the fih217/217;vhl-/- 
embryos.   
Activation of dll4 and hey2 has been shown to be induced by vegf in conjunction with 
foxc1 and foxc2 (Hayashi and Kume, 2008).  Foxc transcription factors have been 
shown to activate the Hey2 promoter in ECs, potentially through direct interaction 
with Su(H) (Hayashi and Kume, 2008), implicating these transcription factors in the 
arterial program.  Foxc1a expression is lowest and foxc1b is only slightly elevated in 
the fih217/217;vhl-/- embryos, while dll4 expression is slightly elevated in the 
fih217/217 embryos and more strongly elevated in the fih217/217;vhl-/- embryos.  
Expression of hey2 is slightly elevated, to around the same level in each of the 
zebrafish embryo groups indicating that if dll4 is involved in its regulation there are 
other factors contributing to the differential regulation of dll4, which is where vegf 
becomes a possible candidate.  Down-regulation of dll4 is not the cause of the 
increased branching, but there is increased expression of deltaC as well as notch1b, 
which could be contributing factors.   
The expression of dll4 in the zebrafish is indicated to be specific to the vasculature and 
the primitive pronephric duct, when assessed on Zfin.org, however alternative 
expression domains could be possible.  The possibility that dll4 is expressed elsewhere 
makes drawing definitive conclusions on the role of dll4 in the vascular branching 
phenotype in these embryos difficult.  However, overall levels of Notch signaling have 
been observed, using the Tg(csl-venus)qmc61 line (Gering, M. pers. Comm..) indicating 
a strong increase in overall Notch signaling in the fih217/217;vhl-/- embryos, which 
could indicate that the dll4 expression was more likely to reflect, simply, an increase in 
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tip-cell number.  The Tg(csl-venus)qmc61 line provides a tool, as yet, not completely 
utilised for assessing the fih217/217 zebrafish response to alterations in Notch 
expression and the role of Notch in the vascular patterning defects in the 
fih217/217;vhl-/- embryos. 
The connection between FIH and Notch has been shown to be in post-translational 
modification, and in the sequestering of FIH away from HIF modification due to 
enhanced binding capacity to Notch (Zheng et al., 2008).  As such the lack of 
immediate and significant alterations in the expression of the ligands and receptors 
themselves are not sufficient to rule out the interaction in this model.   
The mechanism of Notch signaling in the lateral inhibition of tip-cells having been 
shown, the inhibition of Notch could still be involved in the increased branching of the 
vessels, so the next thing to investigate was to assess other methods of Notch 
inhibition.  The fih217/217;vhl-/- embryos when treated with DAPT didn’t exhibit the 
same drastic increase in branching, potentially due to the increased number of 
branches that already exist in these embryos.  Altogether this is consistent with the 
previously published data that inhibition of Notch signaling is capable of increasing 
vascular branching in the zebrafish embryos.  The increase of branching in the wild 
type and fih217/217 embryos in response to DAPT treatment does indicate that a 
decreased activation of Notch could be responsible for the vascular patterning in the 
vhl-/- and fih217/217;vhl-/- embryos.   
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5 Evaluation of Mouse versus 
Zebrafish Data on the effects of the 
loss of FIH 
A report in 2010 demonstrated that finding that loss of Fih, in a mouse knockout 
model, surprisingly resulted in a “wide-ranging derangement of physiological response 
and causes a hypermetabolic phenotype, but result[ed] in few of the classical effects of 
HIF activation in vivo” such as increased vascularisation or high levels of erythropoiesis 
(Zhang et al., 2010).  The mice exhibited lower body weight despite increased food and 
water intake and were protected from high-fat-diet weight gain.  The mice had 
increased O2 consumption and increased evolution of CO2.  They also had an increased 
heart rate with no alteration in breathing frequency but with an increased tidal 
volume.  The mice had decreased EPO expression following hypoxia.  Mice were 
administered with insulin in hypoxia, and this resulted in a decrease in AMPK, leading 
to an alteration to fasting glucose and fed insulin levels as well as reduced lipogenesis.  
They also had an increase in ATP generation and increased heat production (Zhang et 
al. 2010).   The findings from the study by Zhang et al were able to put the data from 
this study in context.   
 
5.1 Comparing Two Data-sets 
A study has been published describing findings in a mouse model of Fih knockout 
(Zhang et al., 2010), and this study also included a microarray study, using mouse 
embryonic fibroblasts (MEFs) as sample cells.  Scatter diagrams were generated 
following an average being made across the two replicates for each sample (WT, fih-/-, 
vhl-/-  and fih-/-;vhl-/-) by comparing the fih-/- data set against the vhl-/- data set it 
was possible to isolate genes that were down-regulated in one data set and not the 
other, see Figure 52.  Venn diagrams also provided information on genes that were up 
or down regulated in individual mutant MEFs and not the others.  Looking at the 478 
genes that were isolated by this method as being down-regulated in the Fih-/- MEFs 
and not in either the Vhl-/- MEFs or the Fih-/-;Vhl-/- MEFs, it was possible to see that 
genes including angiopoeitin like 1 (angptl1), ephrin receptor A3 and A5 
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(epha3/epha5), C-X-C receptor 1 (CXCR1), friend leukemia factor 1 (Fli1), uncoupling 
protein 2 (ucp2), and carbonic anhydrase 3 (car3) were all represented.  Several of 
these genes provide commonalities between the mouse MEF expression profiles and 
those found in the whole zebrafish embryo data set.  Another commonality between 
the two data sets was that when looking at the up-regulated genes in the Fih-/- MEFs 
that weren’t up-regulated in the other groups there were only 8 genes isolated, 
indicating that the loss of Fih, either in MEFs or in the zebrafish embryo, does not lead 
to significant induction of gene expression, and is more likely to lead to down-
regulation of expression.   
Some of the genes listed in Table 17 were not annotated in the zebrafish microarray, 
such as adm, fabp4 or kdm3a although other family member genes were annotated, or 
in the case of Li202b do not have fish homologues.  Key differences in the source 
material (MEFs versus whole organism) as well as different microarray platforms 
(Affymetrix versus Agilent) between the two studies make it difficult to draw direct 
correlations between the data-sets.  However, with this in mind it is possible to see 
that in general, where there are homologues to be found in both studies the trend in 
expression (increased or decreased) in response to the loss of fih or vhl or both was 
consistent between the two studies.  Table 17 also shows that the fold changes 
observed in the MEFs are documented as being stronger than those seen in the 
zebrafish embryos, for the most part, with the exception of the change in expression of 
egln3 in response to the loss of either vhl or both fih and vhl.  Where deviations are 
present it could be due to tissue/organism specific alterations in the expression or 
other factors introduced by the different studies.  The list did provide several 
directions to search within the present study, including hypoxic targets (egln3), 
metabolic indicators (ca9, fabp4), and endothelial markers (end2, adm/adm2) and 
several of these will be discussed in more detail through this chapter. 
A list of genes that were deemed hits from this previous study into the effect of the 
loss of Fih, was provided in the supplementary data and has been reproduced here, 
see Table 17.   
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Symbol WT vs  
Fih217/217 
WT vs  
Vhl-/- 
WT vs  
Fih217/217;Vhl-/- 
Fih217/217;Vhl-/- vs  
Vhl-/- 
Car9 
Cahz 
1.01 
1.51 
4.45 
2.24 
236.25 
3.75 
52.91 
1.39 
Edn2 
Edn2 
2.34 
1.37 
3.72 
2.26 
103.62 
4.31 
27.84 
1.77 
Ankrd37 
Angkrd37 
1.45 
1.31 
6.93 
5.08 
75.75 
16.41 
10.92 
1.73 
Cox7a1 
No homolog 
0.93 
 
3.43 19.51 5.86 
 
Pygl 
Pygl 
1.54 
0.72 
14.04 
1.35 
74.49 
1.02 
5.31 
0.64 
Egln3 
Egln3 
1.81 
2.61 
8.75 
46.73 
36.34 
163.5 
4.15 
1.29 
Adm 
Multiple 
homologes 
1.04 4.55 18.83 4.14 
 
Cdkn1a 
No sig change 
0.93 1.33 4.61 3.46 
 
Adm2 
Adm2 
1.33 
1.20 
10.96 
2.75 
37.18 
4.16 
3.38 
1.29 
Fabp4 
No homolog 
1.15 1.70 5.19 3.05 
 
Li202b 
No homolog 
0.90 2.64 7.25 2.75 
 
Ddit4 
Ddit4 
1.43 
1.03 
1.96 
3.56 
4.87 
3.90 
2.49 
0.13 
Adam8 
Adam8 
1.29 
0.84 
2.69 
1.12 
6.32 
0.95 
2.35 
0.90 
Papass2 
Papass2 
1.26 
1.15 
1.70 
1.04 
3.50 
0.93 
2.06 
1.00 
Galr2 
Galr2 
0.88 
1.19 
4.74 
1.13 
9.56 
1.45 
2.02 
1.20 
Kdm3a 
No homolog 
1.26 2.00 3.99 2.00 
 
------------------ ------------------ ------------------ -------------------------- ----------------------------- 
GCK 1.17 1.16 1.42 1.22 
G6Pase 1.70 1.26 0.85 0.73 
Table 17 Describes expression fold change of genes in Fih-/- mouse (top line of 
each row) vs fih217/217 zebrafish (bottom line of each row) 
Taken from Supplementary Data Table S1 (Zhang et al., 2010) and adapted for this study. 
Describes the expression fold change of genes that were selected from Zhang microarray with 
expression validated by qRT-PCR (black text) and the comparable expression in the zebrafish 
microarray (red text).   
Abbreviations: Carbonic anhydrase 9 (CA9), Endothelin 2 (edn2), ankyrin repeat domain 
protein 37 (ankrd37), cytochrome c oxidase subunit VIIa 1 (cox7a1), liver glycogen 
phosphorylase (pygl), EGL nine homolog 3 (egln3), adrenomedullin (adm), cyclin-dependant 
kinase inhibitor 1A (cdkn1a), adrenomedullin 2 (adm2), fatty acid binding protein 4, adipocyte 
(fabp4), interferon activated gene 202B (li202b), DNA-damage-inducible transcript 4 (Ddit4), a 
disintegrin and metallopeptidase domain 8 (Adam8), 3’-phosphoadenosine 5’-phosphosulfate 
synthase 2 (Papass2), galactin receptor 2 (Galr2), lysine (K)-specific demethylase 3A (Kdm3a), 
(GCK), (G6Pase) 
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The first element of note from this table of genes (Table 17) is that it does not indicate 
a single gene where the loss of Fih in the MEFs caused a significant alteration in gene 
expression compared to wild type, which exceeded the gene expression change caused 
by the loss of either Vhl or both Fih;Vhl.  The relevance of this could be that this was 
not a factor that was being assessed in this study or that no such genes were identified 
in this study.  The data set is available through the GEO database and was imported 
into Genespring software in order to assess this and allow for further comparison 
between the two data sets.  There are multiple ways of importing the data, allowing 
for the use of all the data or control samples to be used in both normalisation and 
baseline transformation, and the information on how this was done in the original 
analysis wasn’t available and therefore replicating the analysis was difficult.  However, 
trends that matched with data described in Table 17 allowed for some interpretation 
to be made of the data.    
 
5.2 The loss of fih causes hyperactivity in zebrafish larvae  
Observations in the Fih-/- mice revealed that these nocturnal animals exhibited a 
surprising hypo-activity during dark cycles, breaking fewer photo-beams than their 
wild type littermates, despite an increase in food and water consumption and 
increased metabolic rate (Zhang et al., 2010).  To examine whether analogous effects 
could be observed in zebrafish fih mutants, a Viewpoint imaging system was used to 
track embryo movements at different stages of development, a system that has been 
used in multiple studies (Delcourt et al., 2009, Steenbergen et al., 2011, Ellis et al., 
2012).  After optimising the parameters of the imaging protocols for background optics 
and tracking abilities various assays were performed.  Embryos at 4 and 5dpf were 
observed both in the light and in the dark, to quantify the levels of movement they 
exhibit under each condition.   Initial experiments observing the activity levels of the 
zebrafish embryos aimed to assess the embryos response to light and dark cycles, 
every 15 minutes, see Figure 68. 
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Figure 68 Plate layout used for viewpoint tracking experiments 
Using the Viewpoint software for tracking individual embryos the traces are collected 
over the course of the protocol and can be displayed over the well plate to look at 
patterns, which the software then uses to provide quantitative data.  Plate layout for 
this example included wild type embryos in wells A1-B2 and fih217/217 embryos in 
wells B3-C4.  
 
The parameters of the tests can be grouped to classify particular rates of movement, 
from low speed, standard and burst movement.  The quantified data can then be 
plotted on a graph to identify the trends in movement over the course of the protocol, 
in terms of a % of time spent in burst movement, see Figure 69.   
 
 
Figure 69  Graph illustrates startle response to dark 
% time spent in burst movement increases immediately after the light is switched off 
and returns to baseline when the lights are switched on.  The strongest extent of this 
pattern was exhibited by fih217/217 embryos.   
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The observed activity levels were highest in the dark, with a peak of activity just as the 
lights were switched off.  This was reminiscent of a startle response to a predator 
being overhead, suggesting that the fih217/217 embryos had a stronger startle 
response compared to WT embryos.  Studies such as these have been used to assess 
zebrafish responses to light and their ability to adapt to changing light levels as well as 
responses to a dark stripe in a circular tank (Li and Dowling, 1997, Fleisch and 
Neuhauss, 2006).  If the pattern of light-dark cycles were repeated and maintained at 
the same intervals it was observed that in all the groups, the startle response to the 
lights going off reduced steadily as the fish became habituated to the cycle, a response 
that has also been previously characterised in the zebrafish (Wong et al., 2010).  
Overall, the fih217/217 embryos spent a greater proportion of time in burst movement 
in the dark cycles compared with the light and also moved more overall than the other 
genotypes being imaged.  The fih217/217 embryos had a greater startle response to 
the light being switched off compared with the other embryos.   
In order to assess the embryos responses to more physiological  light cycles the 
experiments were repeated recording movement over 24hours between 4 and 5dpf 
with the lights on the same light cycle as is used in the aquaria, light-dark for 14hours 
and 10hours respectively, see Figure 70.   
 
 
Figure 70  Graph illustrates average time in burst movement over 24 hours 
The % time spent in burst movement in light (Day) and dark (Night) cycles over 24 
hours.  The fih217/217 embryos spend more time in burst movement overall and that is 
stronger in the light.   
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The fih217/217 embryos spent more time in burst movement compared to WT siblings 
in the light.  Embryos at this age spend the majority of their time in quiescence, and so 
the proportion of the time the embryos are spending in burst movement only amounts 
to an average around 1% of the time measured (de Esch et al., 2012, MacPhail et al., 
2009).  The trend increase in movement supports the data that was observed in the 
pilot test of 15minute cycles, that the fih217/217 embryos exhibit a hyperactive 
phenotype compared with wild type siblings.   
As the levels of activity are quite low in young larvae, the next test was to observe the 
embryos at 10dpf, when movement has become more consistent, and this test 
confirmed that the fih217/217 embryos spent more time in motion compared to WT 
siblings, see Figure 71 (Lange et al., 2012, Norton and Bally-Cuif, 2010).  The protocol 
involved tracking the embryos more directly, and was able to provide data on total 
distance swum instead of % time in movement.   
 
 
Figure 71 Graph Illustrates total distance swum over 5 minutes 
The total distance swum over a five minute period, demonstrates that the fih217/217 
embryos swim further than wt siblings.  Units of distance are in µM. 
 
Overall, the fih217/217 zebrafish exhibited an increased activity level compared to wild 
type embryos and this did not correlate with the findings in the Fih-/- mouse, leading 
to the need for further interpretation.  
Studies by the Bally-Cuif lab into the attention-deficit hyperactivity disorder (ADHD)-
susceptibility gene lphn3.1 used knockdown studies to demonstrate hyperactivity in 
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the zebrafish, connecting this gene with phenotypes that are connected with ADHD.  
They have also demonstrated that treatment of these morphants with 
methylphenidate and atomoxetine (drugs used in the treatment of ADHD) rescues the 
hyperactivity phenotype.  Given that fetal hypoxia has been connected with the 
incidence of ADHD (Toft, 1999, Juarez et al., 2008), MPH (Ritalin) was administered to 
these embryos and their % change in activity comparing 5 minutes of activity after 
treatment with 5 minutes of activity before treatment was assessed to investigate the 
effect of the drug on the hyperactivity phenotype.  Over the range of concentrations of 
Ritalin that were tested and a treatment time of one hour (that used by the Bally-Cuif 
lab to test their Lphn MO zebrafish) there was no dose at which the activity levels of 
the fih217/217 embryos decreased, suggesting either the need for further 
investigation or that a different mechanism is involved in the hyperactivity in these 
fih217/217 embryos, although the data is not shown.   
 
5.3 Loss of Fih causes alterations in metabolic factors compared to wild type 
Following on from the connection between activity and metabolism that were 
assessed by Zhang et al in their characterisation of Fih-/- mice and leading on from the 
observations of metabolic gene expression previously described in from the microarray 
data, several assays were attempted to assess metabolic parameters in the zebrafish. 
Increased presence of ATP and reductions in AMPK were observed in the Fih-/- mouse 
embryos, and a fluorescent plate reader assay called ATPLite, was tested in the 
zebrafish to assess total levels of ATP in the embryos, normalised to total DNA as a 
surrogate measure of cell number, see Figure 72.   
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Figure 72  Graph illustrates ATP levels in wt, fih217/217, vhl-/- and 
fih217/217;vhl-/- embryos 
Graph illustrates the results of a pilot attempt to assess total ATP levels in zebrafish 
embryos. Replicate samples of 40 embryos were utilised within the assay in order to 
provide an average. 
 
The vhl-/- embryos did not display an increase in total ATP compared to wild type 
embryos, however both the fih217/217  embryos and the fih217/217;vhl-/- embryos 
did and this could suggest a correlation between a high level of activity and the hyper-
metabolic phenotype in these embryos, while simultaneously correlating with findings 
from the Fih-/- mouse data.  Due to time constraints this assay has only been done 
once so further repeats are required. 
Another pilot test was attempted to assess total levels of cholesterol, as another 
feature of metabolism which was assessed in the investigation of the Fih-/- mouse.  
This utilised an enzymatic, colourimetric assay developed by Roche and used to assess 
cholesterol in blood samples.  The limitations of the assay include a statement that 
recovery is possible within ± 10% of initial values at a cholesterol concentration of 5.2 
mmol/L (200 mg/dL).  This meant that the assay required optimisation on sample 
preparation and number of embryos because the assay had been largely untested in 
zebrafish.  Large numbers of whole embryos (80+), homogenised in PBS, were required 
in order to provide a reading on this assay, see Figure 73.   
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Figure 73  Graph illustrates total cholesterol level in wt and fih217/217 embryos 
Roche Cobas enzymatic assay to quantify cholesterol concentrations in whole zebrafish 
embryos.  The units are provided by the assay, and indicate total cholesterol in mmol 
per litre of sample.   
 
Since the assays in the mouse and fish studies have used such different tissue samples 
It has impossible to compare the results directly, however, to put even this preliminary 
data into context the study of Fih-/- mice by Zhang et al was consulted and here a 
decrease in total cholesterol was observed, compared with wild type mice.  This 
remained true even when the mice were fed on a high fat diet (HFD) (Supplementary 
Table 3 (Zhang et al., 2010)).  In the mouse study, this was attributed to the Fih 
knockout mice exhibiting improved lipid homeostasis.  In this assay, an increase in 
cholesterol was observed in fih217/217 embryos at 5dpf.  The increase in cholesterol 
does correlate with the observation that there was an increase expression of fabp1a 
and fabp1b in the fih217/217 embryos.  The literature indicates a correlation between 
increased circulating levels of fabps and increased levels of 
cholesterol/triglycerides/LDL (Xu et al., 2007).  The difference in the findings between 
the two studies could be due to a difference in response to fabps or diet between the 
two animal models, see Table 17.  It would also be beneficial to investigate potential 
assays for assessing the differences in levels of TG, FFA, HDL, and LDL/VLDL, in order to 
interpret information regarding a more accurate profile of lipid homeostasis in the 
zebrafish, as well as look into the possibility of larger tissue samples using adult 
zebrafish or even adult serum. 
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Zhang et al proposed that FIH was involved in the regulation of respiration, energy 
balance and lipid metabolism in what they suggested might be a HIF independent way 
(Zhang et al., 2010).  The microarray that was performed in this study was utilised to 
assess the metabolic features of the transcriptome in the zebrafish embryos.  
However, simultaneous to these targeted searches, more general searches to look for 
any roles that Fih may play that were independent of Hif, involved the generation of 
heat maps to create a list of genes where expression was increased in the fih217/217 
embryos but not in the other mutants.   
Following the full annotation of this list, using the probe sequences and the Ensembl 
genome browser BLAST function, revealed that of the 26 genes that were isolated 
several were connected with membrane/matrix interactions.  These genes included 
integrin α2, glycoprotein A33 (transmembrane), phophatidylinositol glycan anchor 
biosynthesis, and SWI/SNF, matrix associated, actin dependent regulator of chromatin 
subfamily d member 1 (smarcd1).  The finding of increased expression of smarcd1 led 
to a targeted search through the microarray for other family members and identified a 
second probe to the same gene.  When the fold change was averaged across both 
probes the difference in expression between the different mutant groups was 
obscured, showing it to be two fold up-regulated in all three groups compared to wild 
type.  The SWI/SNF family has been connected with Fih function with ISWI expression 
resulting in repression of HIF target gene expression (Bnip3 and CA9).  It was also 
possible to assess other family members and identify the expression pattern of 
expression for smara5, which has been shown to be a homologue of the human ISWI.  
The expression of smara5 was not altered in any of the three mutant groups, however 
the expression of both bnip3 and cahz (the active zebrafish CA) is highest in 
fih217/217;vhl-/- embryos.  This can not rule out a connection between fih and smara5 
regulation of ca9 and bnip3, however this would require further investigation.  Aside 
from this connection this list yielded few potential targets that might indicate genes 
that might be causative for the phenotypes that had been observed up to this point.   
Following this, the same heat map was generated for those genes that were down-
regulated in the fih217/217 embryos and were un changed in the vhl-/- and 
fih217/217;vhl-/- embryos, see Figure 74. 
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Figure 74 Heat map illustrates genes down-regulated in fih217/217 embryos 
only 
Heat map illustrates the genes isolated by the venn diagram of up-regulated genes as 
being up-regulated specifically in the fih217/217 embryos and not the other mutant 
lines.  The list was annotated in excel since the annotation was low for this entity list. 
 
Many genes were not annotated, but of those that were immediately annotated, two 
pancreatic enzymes, amylase 2a (amy2a) and chymotrypsinogen (chymo) both 
appeared to be down-regulated in fih217/217 embryos and these genes appear not to 
be regulated in the other mutants.  For confirmation of these trends, qRT-PCR was 
used to validate the findings and further quantify the changes in expression in the 
different mutant embryos, see Figure 75. 
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Figure 75 Graphs demonstrate fold change in amy2a and chymo 
The quantification of the fold changes of both amy2a and chymo was validated by qRT-
PCR.  Both assays confirm that these genes are down regulated in the fih217/217 
embryos and either up-regulated (in vhl-/- embryos) or unchanged (in fih217/217;vhl-/-
).   
 
The qRT-PCR results for these two genes did not correlate with the microarray data, as 
had been the case for all previous genes tested.  This will need further repeats and the 
assessment of other genes in this entity list in order to confirm these data.   
A further assessment of the genes in the heat-map in Figure 74, using the probe 
sequences to search for the genes that were being assessed, revealed that 25% of 
genes were known to play roles in fat, sugar/carbohydrate or protein digestion and 
while these were not all validated by qRT-PCR, the trends have been shown in Figure 
76Figure 76.   
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Figure 76 Graphs indicate fold change in genes involved in metabolism 
The top left graph indicates the expression of genes involved in digestion, in the 
fih217/217 embryos, the top right graph indicates the same for the vhl-/- embryos and 
the bottom left graph indicates the same for the fih217/217;vhl-/- embryos. The left 
box highlights genes involved in fat digestion, the centre box highlights genes involved 
in sugar/carbohydrate digestion, and the right box highlights genes involved in protein 
digestion.  Abbreviations:- carboxyl ester lipase 1/2 (cel.1/2), carboxyl ester lipase like 
(cell), amylase2a (amy2a), chymotrypsin (ctrl), chymotrypsinogen B2 (chymoB2), 
elasetase-like (ela3l) 
 
Overall fih mutants appear to down-regulate several genes involved in fat, protein and 
carbohydrate digestion and to a greater extent than in the vhl mutants or the fih;vhl 
double mutants.   
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The investigation of the enzymes in the glycolytic pathway revealed few genes where 
the expression was significantly different in the fih217/217 embryos compared with 
wild type embryos.  However, following the annotation of the heat-map of genes that 
were down-regulated in the fih217/217 embryos, pyruvate dehydrogenase (lipoamide) 
alpha 1b (pdha1b) was significantly down-regulated.  Investigations of other family 
members showed that several other members of the family were also down-regulated 
in the fih217/217 embryos, see Figure 77.  Further investigation would be needed to 
ascertain whether these factors would influence cholesterol synthesis or simply its 
accumulation.   
 
 
Figure 77 Graphs indicate fold change in pyruvate dehydrogenase family genes 
The top left graph indicates the expression of pyruvate dehydrogenase genes, in the 
fih217/217 embryos, the top right graph indicates the same for the vhl-/- embryos and 
the bottom left graph indicates the same for the fih217/217;vhl-/- embryos. 
Abbreviations:- pyruvate dehydrogenase (lipoamide) alpha 1a/b (pdh1a/b), pyruvate 
dehydrogenase kinase, isoenzyme 2/3/3b (pdk2/3/3b) 
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Pyruvate dehydrogenase is a key component enzyme in the pyruvate dehydrogenase 
complex involved in converting pyruvate into acetyl-CoA.  The significant decrease in 
pyruvate dehydrogenase indicates a decrease in pyruvate to acetyl-CoA conversion, 
and this might potentially drive the conversion of pyruvate to lactate  
 
5.4 Investigation into expression of genes involved in glycolytic metabolism 
Entry of glucose into the glycolytic pathway is regulated by 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 3 (pfkfb3), see Table 13 and Figure 78.   
 
 
Figure 78 Fold change in Pfkfb3 
mRNA levels of expression 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 
(pfkfb3) were measured by microarray and also validated by qRT-PCR at 3dpf in 
zebrafish embryos.   
 
Expression of Pfkfb3 followed the trend seen in phd3 expression, highest in the double 
mutant.   
Hexokinase1 (hk1) is another glucose sensor (Table 13) and its expression levels were 
assessed in the microarray and one of the genes used for qRT-PCR validation, see Table 
15 and Table 16.   
Flux, or energy transfer, through the glycolytic pathway refers to the adjustment 
needed to respond to conditions inside and outside the cell, involving the rate of ATP 
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production and the levels of sugar in the blood, see Table 13.  Levels of LDH were 
assessed in the microarray to quantify the change in expression along with in situ 
hybridisation, see Figure 79. 
 
 
Figure 79 in situ hybridisation of LDH with microarray quantification of 
expression 
A) in situ hybridisation techniques (4dpf) were used to assess LDH expression patterns, 
Expression is visible in the liver, kidneys and head of the zebrafish embryos. These 
images are composite images stitched together.  B) mRNA derived fold changes in LDH 
quantified by microarray analysis (3dpf) in zebrafish embryos.  
 
The in situ indicated that there was little alteration in the level and location of LDH 
expression in the fih217/217 embryos compared to wild type embryos, the vhl-/- 
embryos do indicate an increase in expression and an expansion of the expression in 
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the brains of the embryos.  Levels of LDH are unchanged in fih217/217 embryos, but 
were increased in vhl-/- and further increased in the fih217/217;vhl-/- embryos in the 
microarray, these findings correlate in the fih217/217 embryos by in situ hybridisation 
and also the vhl-/- embryos, but not the fih217/217;vhl-/- embryos where the in situ 
hybridisation (4dpf) indicated a slight down-regulation.   
 
5.5 Investigating effect of loss of fih on genes involved in insulin homeostasis 
Components of the insulin and the gluconeogenesis pathway (the reverse process to 
glycolysis, the conversion of lactate to glucose) that were annotated in the microarray 
data-set, were assessed for expression in the fih217/217, vhl-/- and fih217/217;vhl-/- 
embryos, see Table 13 for references.  These data show that again fih results only in 
minor changes in expression of these genes, whereas gcga shows increasing 
expression going from vhl mutant to fih;vhl doubles, suggesting this gene is regulated 
via HIF.  The expression of pepck, a lyase enzyme in the gluconeogenesis pathway, 
providing the reverse step from pyruvate kinase (the 7th step in the conversion of 
glucose to pyruvate) was assessed by qRT-PCR, see Table 13 and Figure 80.   
 
  
Figure 80 mRNA levels of PEPCK were assessed by qRT-PCR at 3dpf in zebrafish 
embryos. 
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Expression levels of pepck (see Table 13) were elevated in the fih217/217 zebrafish to 
the same degree as had been found in the Fih-/- mice.  Preproinsulin levels, see Table 
15 and Table 16, were essentially unchanged or conceivably slightly decreased in the 
fih217/217 embryos, and increased only slightly in both the vhl-/- and fih217/217;vhl-
/- embryos.   
Glucose transport was assessed in the zebrafish embryos by looking at levels of glucose 
transporter 1 (glut-1/slc2a), see Figure 81.   
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Figure 81 in situ hybridisation of Glut1 with microarray and qRT-PCR 
quantification of expression 
A) Demonstrates the in situ expression pattern of Glut1 mRNA in the different mutant 
embryos at 4dpf.  These images are composite images stitched together. B) mRNA 
expression levels of Glut1 were quantified by microarray C) validated by qRT-PCR in 
3dpf old zebrafish embryos  
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The expression of Glut1 in the zebrafish at 3dpf by in situ did not show dramatic 
differences between the fih217/217 embryos and the fih217/217;vhl-/- embryos, and 
this lack of significant difference was quantified by the microarray and qRT-PCR data.  
Levels of glut1 can be confirmed as not to be significantly different across all three 
mutants, indicating that despite hypoxic regulation of the gene, its expression is not 
dramatically induced by the loss of either fih or vhl, or indeed by the loss of both.  
While there was no significant change in its expression at 3dpf these might become 
clearer over time, see Table 13.  When assessing genes involved in glucose 
homeostasis and insulin regulation one of the other genes where expression was 
elevated was fabp1a. 
In the fih217/217 embryos, only fatty acid binding protein (fabp1a) was up-regulated, 
to a significant degree and more of these genes were up-regulated in the vhl-/- and 
fih217/217;vhl-/- embryos.  Since fabp1a was elevated in all three of the fih217/217, 
vhl-/- and fih217/217;vhl-/- embryos, so further investigation was made into the 
expression of other members of the fabp gene family by searching through the 
microarray data set for other family members, see Table 13 for references.    
 
5.6 Investigating effect of loss of fih on genes involved in O2 consumption 
and CO2 evolution 
The link to mitochondrial roles in metabolism led to the assessment of some of these 
genes in the fih217/217 and vhl-/- zebrafish.  Increased O2 consumption can be caused 
by changes in uncoupled mitochondrial respiration and expression of mitochondrial 
uncoupling genes has been used as a surrogate for assessing this by Zhang et al (Zhang 
et al., 2010).  Here they found increased expression of Ucp1 and Ucp3 in the brown 
adipose tissue (BAT) of the Fih-/- mice.  The only uncoupling protein that was directly 
annotated in the zebrafish array was labeled ucp4.  Using Ensembl genome browser 
and the sequence of the probe on the microarray it was possible to see that this was 
mis-labeled in the microarray annotation and actually mapped to the zebrafish ucp1 
gene an orthologue of the human UCP1.  A further search found the slc25a27 gene, 
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using Ensembl it was possible to show that this was the zebrafish ucp4 gene.  See Table 
15 for the gene regulation of three of these ucp genes in the zebrafish embryos.  
Another gene that has been used both as a surrogate and in the direct assessment of 
CO2:O2 ratios and usage is carbonic anhydrase (CA), see Table 13  and Figure 82. 
 
 
Figure 82 Microarray derived Cahz expression in the fih217/217, vhl-/- and 
fih217/217;vhl-/- embryos at 3dpf.  
 
5.7 Relationship between apoptosis and hypoxia 
The connection between hypoxia and apoptosis has been a source of research and 
certain levels of uncertainty, Table 13.  In the analysis of Fih-/- mice the expression of 
BNIP3, a pro apoptotic/autophagic gene, was unaltered in the brains of these mice.  
The microarray in this study having been performed on whole zebrafish embryos 
provided an opportunity to assess the apoptotic pathway in a more global sense and in 
the whole organism, see Figure 83 for the findings. 
 
178 | P a g e  
 
 
Figure 83 Fold change of genes involved in apoptosis 
The top left graph indicates the expression of genes involved in apoptosis in the 
fih217/217 embryos, the top right graph indicates the same for the vhl-/- embryos and 
the bottom left graph indicates the same for the fih217/217;vhl-/- embryos.  
Abbreviations:- bcl-2 associated X protein (baxa/b), bcl2/adenovirus E1B interacting 
protein 3-like (bnip3l), B-cell leukemia/lymphoma 2 (bcl-2), bcl-2-interacting killer (bik), 
bcl-2 antagonist of cell death (bad), apoptotic protease activating factor (apaf1), bcl2 
associated athanogene (bag2), myeloid cell leukemia sequence (mcl1), bcl2 modifying 
factor 1 (bmf1), poly (ADP-ribose) polymerase family (parp), X-linked inhibitor of 
apoptosis (xiap), caspase (casp) 
 
In the zebrafish, there were changes in gene expression in several apoptotic genes 
investigated, both up-regulated (Bnip3l) and down-regulated (parp6a).  
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5.8 Discussion  
Furthermore we obtained data consistent with a metabolic phenotype as was 
proposed by Zhang et al for the Fih-/- mice.  To put the data linking the loss of FIH in 
both the mouse model published by (Zhang et al., 2010) and in the current study a 
summary table of the findings was collated, see Figure 15. 
 
 Fih-/- mice Fih217/217 zebrafish 
   (Zhang et al., 2010) Current study (Unpublished 
data) 
ATP Increased Increased (tentative) 
02 consumption and CO2 
evolution 
Increased   
Heart Rate Increased Increased 
Tidal Volume Increased   
Water and Food Intake Increased   
Activity Levels Decreased Increased 
Heat production Increased   
UCP genes Increased (1 and 3) No change UCP1, 4 or 5 
PGC1a level Increased No change 
Insulin sensitivity Increased   
RER No change   
AMPK Decreased   
Plasma EPO after hypoxia Decreased  No change in RNA by in situ 
Mass/body weight Decreased   
Adipocyte size and lipid 
droplet number 
Decreased   
Cholesterol and 
triglyceride 
Decreased Increased (tentative) 
Fed Insulin levels Decreased   
Weight gain on HFD Decreased   
Breathing Frequency No change   
Heart Size   No change 
Aortic Diameter   Increased 
Blood glucose No change No change in preproinsulin – 
surrogate marker as response 
to insulin stimulus 
Table 18 Table describes the correlation of findings between the current study 
and that of (Zhang et al., 2010)  in the Fih-/- mouse. 
 
Further investigation is needed before correlation between these two studies can be 
confirmed although Table 18 indicates common investigation directions from the two 
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studies and shows that similar phenotypes are observed in the two different models, 
mouse and zebrafish.  For example, since the fih217/217 embryos survive to 
adulthood, assessments could be made regarding body mass and indeed potentially 
into weight gain on a high fat diet, provided that clutches of embryos were raised at 
the same density under the same conditions.  Breathing frequency has not been 
checked in the fih217/217 zebrafish embryos, and this could be done.  Also new 
platforms are being developed for the observation of O2 consumption and CO2 
evolution in the zebrafish embryo (Stackley et al., 2011, Pei et al., 2010, Barrionuevo 
and Burggren, 1999, Makky et al., 2008).  Oil-Red-O and other stains can be used on 
frozen sections of zebrafish to assess lipid droplet size.  These would provide further 
connections between the findings in the different models and may elucidate 
differences that aid in species or indeed tissue specific findings.  
 
5.8.1 Metabolism 
Following the publication of the findings of Zhang et al on the characterisation of the 
Fih-/- mouse model displaying features consistent with altered metabolism, genes 
involved in regulating metabolism were assessed in the microarray.    This revealed 
that all of the enzymes involved in the conversion of glucose to lactate, which were 
annotated in the microarray, increasing numbers tended to be up-regulated to a 
greater extent in the fih217/217;vhl-/- embryos compared with fih217/217 embryos 
alone.  The expression levels of two enzymes at the extreme ends of the pathway, 
hexokinase and lactate dehydrogenase, were validated by qRT-PCR and in situ 
hybridisation, confirming the findings from the microarray.  This trend suggested that 
the loss of fih in the vhl-/- embryos played a part in increasing the activity within the 
glycolytic pathway; however this remains to be tested and confirmed.   
Since levels of pyruvate kinase, a rate limiting enzyme in the glycolysis pathway has 
also been shown to be influenced in obesity (Stolz and Martin, 1982), the level of 
expression of many of these enzymes was assessed using the raw microarray data.  
Levels of pyruvate kinase and other enzymes were not dramatically altered by the loss 
of fih, but many demonstrated elevated expression in the vhl-/- and fih217/217;vhl-/- 
embryos.  This suggests that these genes are regulated by HIF dependent signaling and 
that the loss of fih alone was not sufficient to induce their transcription, while the loss 
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of vhl or the dual loss of both fih and vhl was.  This correlated with published literature 
which has shown that glycogen storage and the induction of genes involved in 
glycolysis has been shown to be regulated by both HIF-1 and HIF-2 (Pelletier et al., 
2012) and the up-regulation of glycolysis enzymes in the fih217/217;vhl-/- embryos 
correlates with strong induction of glycolysis in these embryos.  Overall our data show 
only very mild effects on glycolytic enzymes in fih mutants and they are responsible 
metabolic phenotype in zebrafish fih mutants it is most likely the result of a very mild 
HIF activation rather than a unique HIF independent effect of fih.  The assessment of 
metabolism and its regulation in Chuvash mice/Chuvash patients could provide some 
indications of whether alterations in metabolism are HIF-dependent, if for example 
glycolytic enzymes were differentially regulated in response to the loss of vhl only as in 
these models.   
Similar results were obtained while assessing genes involved in glucose and fatty acid 
regulation in the microarray data-set igfbp-1 and fabp1a stood out in these sets and 
were shown to be unchanged or up-regulated in the fih217/217 embryos, further up-
regulated in the vhl-/- embryos and further up-regulated in the fih217/217;vhl-/- 
embryos, with the same expression pattern seen for several other family members of 
each gene.  Insulin growth factor binding proteins (IGFbps) perform regulatory roles on 
the IGFs mediating their functions.  IGFbp-1 has been shown to be increased in fetuses 
exposed to hypoxia and intrauterine growth restriction (Tazuke et al., 1998) and is an 
established HIF target (Kajimura et al., 2005, Tazuke et al., 1998). 
While assessing the connection between mitochondria and metabolism, as well as 
investigations concurrent with those in Fih-/- mice, the levels of mitochondrial 
uncoupling proteins (ucp) were investigated in the microarray.  Expression of ucp1 
showed the expression profile over the mutants that had been seen for other hypoxic 
targets, lowest/unchanged in fih217/217 embryos and highest in fih217/217;vhl-/- 
embryos.  The expression of UCP1 was shown to be significantly up-regulated in brown 
adipose tissue (BAT) in FIH nullizygous mice, along with levels of PGC-1α, while levels 
of UCP2 and UCP3 were similar between genotypes, along with PGC-1α in white 
adipose tissue (WAT).  Since BAT has not been characterised in the zebrafish and the 
microarray was performed on whole organisms rather than tissue specific sections, 
direct comparisons were not possible.  However it is possible to see that of the three 
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ucp genes that were annotated in the microarray (1, 4 and 5) none were up-regulated 
in the fih217/217 embryos, although ucp1 expression was up-regulated in the 
fih217/217;vhl-/- embryos.   
In order to investigate the regulation of the glycolytic pathway in the zebrafish 
mutants, the microarray data was searched for the enzymes known to be involved in 
the conversion of glucose to lactate.  All but a few (hexose diphosphate, fructose 
biphosphate aldose, phosphoenolpyruvate carboxykinase (pepck)) of the enzymes 
involved in the glycolytic pathway were annotated in the microarray and their 
expression was assessed in all three mutant groups.  Of all these glycolytic enzymes, 
the majority were not differentially regulated in the fih217/217 embryos but were 
strongly up-regulated in the fih217/217;vhl-/- embryos.   
The up-regulation of hk1 fits the trend in expression observed in other genes such as 
phd3, with a slight up-regulation in the fih217/217 embryos, a further up-regulation in 
the vhl-/- embryos and a further up-regulation in the fih217/217;vhl-/- embryos.  This 
correlates with the established connection between HIF-signaling and the glycolytic 
pathway and could be correlated with HIF target gene expression induced by the loss 
of FIH and/or VHL regulation.  The expression does not give a strong indication for a 
HIF independent role for fih in hk expression.   
Overall, these data do not give evidence that glycolytic enzymes are regulated by FIH 
rather than directly by HIF, which correlates with suggestions made by Zhang et al that 
while the Fih null mice exhibited an increased metabolic rate there was no observation 
of alterations in glucose homeostasis in these animals. 
The microarray was performed at 3dpf and the in situ needs to be repeated, at the 
same stage as the microarray and the qRT-PCR assays (3dpf) in order to assess the 
discrepancy that was seen in the results.  It may be due to possible proteasomal 
changes or via an impact on VHL/HIF interactions, see Table 13, this needs to be 
investigated further.   
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5.8.2 Insulin Homeostasis 
Expression of pepck was increased dramatically in the fih217/217;vhl-/-, not 
demonstrated in the Zhang paper, suggesting an attempt to reverse glycolysis and 
convert pyruvate back to glucose in these embryos.  The expression of pepck has also 
been shown, however, to be induced by the release of glucagons in cultured rat 
hepatocytes (Christ et al., 1997), and the expression levels of glucagons (data not 
shown) follows the same expression trend in these zebrafish embryos as that seen in 
Figure 80 for pepck.  The correlation of these findings leads to the suggestion that 
analysis of glucagon-pepck interactions might be an avenue of investigation worth 
pursuing.   
Conditional inactivation of von Hippel-Lindau-like (vhlh) in β-cells promoted diversion 
of glucose away from mitochondria into lactate production, inducing increased 
glycolytically derived ATP and the secretion of elevated levels of insulin at lower 
glucose concentration (Zehetner et al., 2008).  A targeted deletion of Vhlh pancreatic 
islet cells of mice allowed the assessment of responses to glucose, these mice exhibit 
diminished glucose stimulated changes in cytoplasmic Ca2+, electrical activity and 
insulin secretion, indicating impaired systemic glucose tolerance, which can be rescued 
in vhl-/-;hif-1α-/- mice (Zehetner et al., 2008).  The activation of preproinsulin in the 
fih217/217;vhl-/- embryos indicates that this process is being induced in these 
embryos and the slight activation seen at 3dpf could indicate that further increases 
might be seen at later stages.    The minor alterations in pepck and preproinsulin 
expression observed in the fih217/217 zebrafish indicate that control of glucose 
response is unlikely to be specifically regulated by FIH.   
Circulating levels of fabp can be shown to correlate with metabolic risk factors 
including central adiposity, dyslipidemia (increased serum triglycerides and decreased 
high-density lipoprotein (HDL) cholesterol), fasting glucose, insulin resistance and 
blood pressure (Xu et al., 2007).  These correlate with findings of increased expression 
of fabps, as well as with observed metabolic phenotypes in the Fih217/217 mice and 
suggests that similar characteristics may be present in the fih217/217 fish.  However 
the mice demonstrated a decrease in serum triglycerides and cholesterol even when 
fed on HFD (Zhang et al., 2010), indicating a discrepancy that will be discussed in 
Chapter 5.  
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One member of the FABP family to show consistent down-regulation, contrary to the 
others, in all three zebrafish lines in this study was fabp6 (data not shown).  Ileal-type 
fabp6, also known as gastrotropin or bile-acid binding protein (babp1), is dramatically 
down-regulated in all three zebrafish mutants being examined in this study.  Its over-
expression has been connected with cancer types as well as type2 diabetes (Fisher et 
al., 2009, Ohmachi et al., 2006).  Its expression in the zebrafish has been shown in the 
liver, heart, intestine, ovary and kidney of adult fish by qRT-PCR and in situ 
hybridisation (Alves-Costa et al., 2008).   The ligands of FABP6 are thought to be bile 
salts, indicating the involvement of FABP6 in their uptake from the ileal epithelium, 
and it has also been implicated in steroid metabolism (Alves-Costa et al., 2008).  its 
down-regulation in all three of the zebrafish mutants being studied in this project 
indicates a potential increase in the levels of free bile salts, the synthesis of which is a 
major route of cholesterol metabolism in most species besides humans (Hofmann and 
Borgstroem, 1964).  About 90% of excreted bile acids are reabsorbed by active 
transport in the ileum, potentially via fabp6, and recycled, moving them from the 
intestine to the liver and gallbladder (Hofmann and Borgstroem, 1964).  In a mouse 
model of cholangiocyte bile salt transporters, the functional state of FABP6, the 
expression of which was shown to be decreased by feeding a lithogenic diet (0.5% 
cholic acid, 1% cholesterol and 15% dairy fat) was thought to influence the uptake of 
bile salts (Liu et al., 2008).  The relationship between these findings and cholesterol 
production and metabolism could therefore be worthy of further investigation in the 
zebrafish. 
The data also indicated decreased expression in adiponectin, which is an insulin-
sensitising adipokine (biologically active molecule involved in maintaining 
cardiovascular homeostasis) with wide ranging implications in anti-diabetic, anti-
atherogenic, anti-inflammatory and cardio-protective mechanisms (Wang et al., 2008, 
Xu and Vanhoutte, 2012).  Expression of both adipo-like, adipo-like2  and 
adipoR1a/b/2 is, if anything, down-regulated in the fih217/217 zebrafish as well as the 
vhl-/- embryos, and further down-regulated in the fih217/217;vhl-/- embryos.  In Fih-/-
mice, adipocyte area and size has been shown to be decreased compared with wild 
type siblings (Zhang et al., 2010), which could correlate with the decreased expression 
of adiponectin seen in the fih217/217, vhl-/- and fih217/217;vhl-/- zebrafish.   
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5.8.3 O2 consumption and CO2 evolution 
The minor down-regulation of ucp1 in the fih217/217 embryos indicates is inconsistent 
with a predicted increase in expression, as was seen for ucp1 and 3 in the Fih-/- mouse 
brown adipose tissue (BAT) and skeletal muscle (SM) although ucp2 is slightly down-
regulated in the Fih-/- mouse BAT and slightly up-regulated in the Fih-/- SM (Zhang et 
al., 2010).  Ucp1 was up-regulated in vhl-/- and fih217/217;vhl-/- embryos, which does 
correlate with expected alterations in expression and could be used as a surrogate to 
infer increased energy expenditure in these embryos.  Ucp4 (slc25a27) and ucp5 
(slc25a14) are not differentially regulated in the fih217/217 embryos but could be 
considered to be slightly down-regulated in the vhl-/- and fih217/217;vhl-/- embryos.  
The zebrafish is an ectothermic species, i.e. they do not raise their body temperature 
above ambient by producing heat, so the presence of ucp homologues suggested that 
their role in the teleosts was not related to thermogenesis, as seen in mammals (Stuart 
et al., 1999).  Expression of UCP1 has been shown to be continuously expressed during 
differentiation and reduced total lipid accumulation, decreased glycerol and lactate 
output and increased glucose uptake (Si et al., 2007).  Up-regulation of ucp1 was 
proposed to reflect a down-regulation of fat synthesis, rather than an up-regulation of 
fatty acid oxidation, in vitro (Si et al., 2007), which ties this data in with altered 
expression seen for fabp family members as well as adiponectin.  Further investigation 
would need to be performed in order to draw conclusions as to the interaction 
between these gene expression changes and oxygen consumption and/or fatty acid 
metabolism.   
The elevated expression pattern, highest in the double fih217/217;vhl-/- embryos 
correlates with findings for Car9 expression in the study of Fih-/- mice performed by 
Zhang et al, which was used to propose their hypothesis that there are a selection of 
genes that are highly dependent on FIH derived control of HIF when VHL is absent 
(Zhang et al., 2010).  However we only found a very modest enhancement of 
expression suggesting differences in regulation at 3dpf, so further investigation of 
alternative stages, along with alternative assays to investigate O2 consumption and 
CO2 evolution would be necessary to draw further conclusions.  It would be 
informative to be able to assess respiratory acidosis, as had been performed in the 
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mouse, however the investigation of a method for how to achieve this in the zebrafish 
is ongoing.  
 
5.8.4 Apoptosis 
Of the biomarkers of apoptosis that were annotated in the microarray several 
exhibited the expression profile seen for other hypoxic targets, most were lowest or 
unaltered in fih217/217 embryos, which conforms with the mouse data, up-regulated 
in the vhl-/- embryos and further up-regulated in the fih217/217;vhl-/- embryos.  This 
included the Bcl2/adenovirus E1b 19kDa interacting protein 3a (Bnip3l), a hypoxia 
induced gene which has been shown to contain an HRE in its promoter region (Bruick, 
2000, Zhang et al., 2007).  Over-expression of BNIP3 reduces membrane potential of 
mitochondria, leading to dysfunction and the resulting caspase-independent apoptosis 
(autophagy) (Zhang et al., 2007).  It has been shown that the ablation of an autophagy 
mediator Beclin1, enhances cell death under hypoxic conditions and that the ablation 
of Bnip3 and/or Bnip3l also triggers cell death, implicating them in hypoxia-induced 
autophagy (Bellot et al., 2009).   
Expression of casp6l2 exhibited the same trend in expression in each of the three 
mutants as bnip3.  Caspase-6-like 2, was identified for its role in cleavage of nuclear 
lamins, as well as caspase-2, 3 and 8 and deemed an executioner caspase.   
In conjunction with the already established up-regulation of both pro- apoptotic 
markers by hypoxia based on the conditions, one of the other genes that showed the 
same expression pattern as bnip3 in the three mutants was mcl1. Mcl1 is one of 
several anti-apoptotic bcl-2 family member genes (Glaser et al., 2012).  The induction 
of both pro- and anti-apoptotic genes indicates the overall effect will be difficult to 
predict. 
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6 Regulation of Cardiovascular 
Development and Function 
The difference in the roles of both FIH and VHL with respect to regulation of HIF (see 
Figure 6) could be hypothesised to result in different effects on the transcription of HIF 
target genes.  The expression of HIF target genes, as assessed using microarray data, 
indicate that Fih exerts its effects on the transcriptome mainly through HIF as indicated 
in Figure 6.  The majority of the data from both physiological assays and the 
microarray at this point had indicated that the loss of fih in the zebrafish while 
affecting the phenotypes of the vhl-/- embryos, created no quantifiable physiological 
phenotypes compared to wild type siblings.   
 
6.1 Effect of fih on aorta and blood circulation 
6.1.1 Loss of fih causes an increase in aortic diameter compared to WT siblings 
Imaging studies of the vasculature in fih217/217, vhl-/- and fih217/217;vhl-/- zebrafish 
embryos compared with wild type siblings, described in Chapter 3, showed few 
measurable physiological differences between wild type and fih217/217 embryos.  The 
heart of the fih217/217 embryos was not measurably different compared with wild 
type embryos.  There were no changes in the number of ISVs or in the branching 
profile of the vessels in the fih217/217 embryos compared with wild type embryos.  
This was also true of the Fih-/- mice, where vascular branching phenotypes were 
assessed by imaging of the ears and no significant differences were observed. 
Closer inspection of images of the blood vessels from image deletion angiograms were 
analysed for vessel diameter and showed that the fih217/217 embryos had a small but 
significant difference in aortic diameter compared with WT siblings, see Figure 84.   
 
188 | P a g e  
 
 
Figure 84 Quantification of Diameter of Dorsal Aorta and Posterior Caudal Vein 
ImageJ was use to measure the internal diameter of the two major vessels, the dorsal 
aorta and the posterior caudal vein, of embryos imaged for Image-deletion-
angiograms.   
 
The level of change in the vessel diameter in these embryos remained small and 
because the angiogram data set required post-imaging genotyping, the number of 
embryos of each genotype was skewed.  Assessing the diameter of the dorsal aorta 
over time showed that the diameter of the aorta in fih217/217 embryos and WT 
siblings stayed constant between 2-5dpf.  The vhl-/- embryos had a significantly wider 
aortic diameter compared with fih217/217 embryos and WT siblings. The further loss 
of fih in the vhl-/- embryos resulted in a slightly wider aortic diameter compared with 
vhl-/- embryos up to 4dpf, see Figure 85Figure 85. 
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Figure 85  Assessment of diameter of dorsal aorta over time.   
Each point represents the average diameter from 3-12 embryos and the error bars 
indicate standard deviation.  
 
Since the fih217/217 zebrafish develop to adult hood, null animals can be isolated in 
tanks and in-crossed, allowing for increased numbers of embryos to be analysed 
without the need for post-analysis genotyping.  For this experiment careful staging was 
done to prevent age differences, wild-types were obtained from related individuals 
(LWT adults x fih+/- adults provide a clutch of fih+/+ and fih+/- embryos - see Materials 
and Methods).  The difference in the diameter of the dorsal aorta between the wild 
type and fih217/217 embryos, however, revealed the first measurable phenotype that 
distinguished the fih217/217 embryos from their wild type siblings, independent of the 
loss of vhl.   
 
6.1.2 fih217/217 embryos have increased blood velocity compared to WT siblings 
In the fih217/217;vhl-/- embryos blood flow along the aorta was observed to slow over 
time until it ceased between 4 and 5dpf.  The angiograms, in Figure 57, also 
demonstrate the loss of circulation in the tail.  High speed imaging of blood flow along 
the aorta was compressed into kymographs, in order to quantify the observed slowing 
of the blood flow in the fih217/217;vhl-/- embryos, see Figure 86.  Initially a software 
program called Correlator was used in order to convert the kymographs into traces, 
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however the software appeared to pick up movement of pixels even in images taken 
where circulation had ceased. 
Vibrations in the air and the table on which the microscope was mounted were 
hypothesised to cause the software to detect pixel movements where none were 
present in the embryo, making it impossible to use the software to quantify the 
slowing/cessation of circulation.  This lead to manual assessment of the kymographs, 
using ImageJ to draw and measure rate of movement over three traces per kymograph 
to achieve an average for each embryo.  Each trace within the kymograph tracks the 
progress of an individual pixel moving along the aorta within a rectangle with a 1 pixel 
width.  When the traces are stacked on top of each other they demonstrate time on 
the y-axis and distance traveled on the x-axis, depicted in Materials and Methods.  A 
level of subjectivity is present in placing the boxes around the heart beats, so the 
genotype of embryos within particular experiments would be blinded to prevent bias.  
ImageJ Software was used to measure the height and width of three rectangles, such 
as those imaged in Figure 33, for every kymograph and the speed of the blood flow 
was calculated for each embryo, the numbers were then collated and used to ascertain 
patterns in blood flow rates over time, see Figure 86Figure 86.   
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Figure 86  Graph showing quantification of blood velocity 
A) Illustrates blood velocity along the aorta over time.  Each point represents the 
average diameter from 3-12 embryos and the error bars indicate standard deviation. B) 
Indicates the fold change in blood velocity compared to wild type embryos  
 
Observation of the green line of the graph in Figure 86A confirmed and quantified the 
observation that had been made that by 5dpf the flow of blood along the aorta in the 
fih217/217;vhl-/- embryos had ceased, while the heart continued to beat.  What had 
not been directly observed before quantification was that there was an increase in 
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velocity in the fih217/217 embryos compared to wild type siblings, and that this was 
present throughout the first 5 days of development and that it was higher than that 
recorded for any of the other mutants.  Since vascular resistance to flow is related to 
path length and, inversely, to the fourth power of diameter (Wakhloo et al., 2005) the 
assessment of blood flow was assessed in the context of vessel diameter.  The data 
from measuring the diameter of the aorta, along with the blood velocity along the 
aorta were compiled and collated in order to lend statistical significance to the 
increased velocity and increased aortic diameter observed in these embryos, see 
Figure 87.  
 
 
Figure 87 Velocity along the aorta and aortic diameter compiled over multiple 
assays.   
 
In order to further ascertain the role of fih in the increase in blood velocity, two 
different novel compounds that were designed to be specific Fih inhibitors (C. 
Schofield, pers. Comm..) were administered to wild type embryos from the 1 cell stage 
through to 5dpf.  Kymographs were generated and the blood velocity and aortic 
diameter were assessed, in comparison with untreated wild type and fih217/217 
embryos at the same stage.  A range of concentrations of both of the two compounds 
were assessed, and the effects of the compound were measured using the high-speed 
imaging technique and assessing blood velocity as a way of assessing whether or not 
the compound was capable of phenocopying the fih217/217 embryo phenotype, see 
Figure 88. 
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Figure 88  Graph illustrating blood velocity in response to KKC-No-L-Phe 
Treatement 
Treatments with KKC-No-L-Phe at the doses tested did not result in increases in blood 
velocity compared with untreated wild type embryos. 
 
None of the concentrations of KKC-No-L-Phe that were assessed resulted in an 
increase in blood velocity to phenocopy that seen in the fih217/217 embryos.  
However, after optimising the dosage of the second compound (KKC396), beginning 
with the same range of concentrations used to test KKC No-L-Phe, it was possible to 
demonstrate that 1µM KKC396 treatment resulted in increased blood velocity and 
increased aortic diameter compared to untreated and DMSO controls (see Figure 89).   
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Figure 89  Graphs illustrate blood velocity and aortic diameter in response to 
KKC396 treatment 
Graphs demonstrate increased blood velocity observed in fih217/217 embryos 
compared with wt siblings and the increase in velocity following KKC396 treatment in 
wt embryos.  The same trend is observed in the aortic diameter. 
 
This compound had been designed to be a hydroxylase inhibitor that has specificity for 
Fih and, that being so It has possible to infer that observing the same alteration in 
velocity using this compound as that observed in the genetic null suggests that Fih 
plays a direct role in controlling the phenotype.  The increase in velocity did not reach 
the level of that observed in untreated fih217/217 embryos compared to untreated 
wild type embryos, which can be interpreted as the difference in penetrance of a 
genetic null and a chemical inhibitor of protein function.  The trend increase was 
significant and this indicated that the increase in blood velocity was dependent on a 
lack of Fih.  Further investigation into the effects of alternative doses and treatment 
times will need to be completed since increasing the concentration could demonstrate 
the relative specificity of the compound by potentially showing effects on other 
enzymes.   
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6.2 Effect of fih on cardiac function 
6.2.1 fih217/217 embryos have increased heart rate compared to WT siblings 
Hypoxia has been shown to induce multiple cardiovascular phenotypes, many of which 
can be investigated in the zebrafish, including cardiac output, stroke volume and end 
diastolic volume, along with increased ISV vascularisation index, see Table 13.  The 
increase in blood velocity along the aorta in the fih217/217 embryos compared with 
wild type siblings is almost certainly the result of altered cardiac function.  
High speed imaging of the heart of embryos at various stages was used to measure the 
heart rate of the various mutants.  The heart rate of the WT siblings was the lowest 
increasing steadily over time, the fih217/217 and vhl-/- embryos showed a higher 
heart rate compared to wt at 2dpf and remained higher until apparently stabilising at 
5dpf.  The fih217/217;vhl-/- embryos had a less clearly defined pattern, although 
higher than all other groups at 4dpf, see Figure 90.   
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Figure 90  Graphs illustrate heart rate over time 
A) Graph demonstrates average heart rate over time where each point represents the 
average diameter from 10+ embryos and the error bars indicate standard deviation.  B) 
Indicates the fold change in heart rate compared to wild type embryos over time. 
 
The correlation between the increase in velocity of blood along the aorta and the 
increase in the diameter of the dorsal aorta in the fih217/217 embryos compared with 
wild type embryos is possible only if there is a simultaneous increase in cardiac output.  
 
6.2.2 Loss of fih causes an increase in cardiac output compared to vhl-/- embryos 
Using the same images as had been used to count the heart rate of these embryos, an 
attempt was made to assess the cardiac output of the embryos, using ImageJ to draw 
around the inner wall of the ventricle and use the ‘Fit-to-ellipse’ algorithm in the 
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software to calculate the volume of the chamber at the beginning and end of the heart 
beat, see 
Figure 91. 
 
Figure 91  Graphs indicates fold change in cardiac output measured at different 
points through development.   
 
The greatest fold change in cardiac output compared to wild type was seen in the fih 
null embryos at 4 and 5dpf.   
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6.3 Renin-Angiotensin-Aldosterone System 
6.3.1 Expression 
The fih217/217 embryos phenotype has aspects that appear to be HIF independent, or 
at least much more strongly regulated by fih than by vhl.  From the microarray data, 
two genes that were immediately annotated as being down-regulated in the 
fih217/217 embryos independent of the other mutants were Angiotensinogen (Agt) 
and Angiotensin converting enzyme 2 (Ace2).  These are two components of the Renin-
Angiotensin-Aldosterone System (RAAS), a hormone system that is set up to 
homeostatically regulate blood pressure and water (fluid) balance, see Figure 92 for 
schematic representation of the pathway.   
 
 
Figure 92 The RAAS pathway 
The RAAS pathway is initiated by the production of angiotensinogen (agt) in the liver, 
which is cleaved by renin (produced in the kidney) to form angiotensin I (AngI).  AngI is 
further cleaved by angiotensin converting enzymes (Ace1 and 2) to angiotensin II 
(AngII) and other breakdown products to initiate sympathetic activity, Na+, Cl- 
reabsorption along with K+ excretion, this along with aldosterone secretion from the 
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kidney initiates H20 retention.  Arteriolar vasoconstriction results in increased blood 
pressure.  The system is in place to initiate water and salt retention, effective 
circulating volume increases along with perfusion of the juxtaglomerular apparatus, 
which in turn acts as a negative feedback on renin excretion from the kidney to turn off 
the process. More abbreviations:- Sodium (Na+), Chloride (Cl-), potassium (K+), water 
(H20), Prolyl-endopeptidase (Pep), neprilysin (Nep), angiotensin receptors (AT1AR, 
AT4AR).   
 
Having highlighted two genes from this pathway as significantly down-regulated in the 
fih217/217 embryos, the expression levels of various other genes involved in the RAAS 
pathway were assessed in the microarray data-set, see Figure 93. 
 
 
Figure 93 Graphs indicate expression of RAAS component genes 
The top left graph indicates the expression of the RAAS component genes in the 
fih217/217 embryos, the top right graph indicates the same for the vhl-/- embryos and 
the bottom left graph indicates the same for the fih217/217;vhl-/- embryos. 
Abbreviations:- angiotensinogen (agt), angiotensin converting enzyme (ace) 
angiotensin converting enzyme 2 (ace2), aldosterone synthase (cyp11b2), angiotensin 
receptor 1 (at1ar), apelin (apln), apelinrb (aplnrb).   
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When the expression of the different components of the RAAS pathway are depicted 
alongside each other for the different mutants, it is clear that agt, ace2, at1ar and apln 
are independently down-regulated in the fih217/217 embryos and not either the vhl-/- 
embryos or the fih217/217;vhl-/- embryos.  An exception would be aldosterone 
synthase (cyp11b2), the gene involved in synthesising aldosterone, which is a 
downstream effector of the RAAS and is down-regulated across all three mutant 
groups. In order to confirm the findings from the microarray and assess other 
components of the RAAS, qRT-PCR was used, see Table 15 and Table 16.   
The qRT-PCR data confirmed the microarray data for agt and ace2, lowest in the 
fih217/217 embryos, not altered in or even up-regulated in the vhl-/- embryos and 
then down-regulated to a lesser extent in the fih217/217;vhl-/- embryos.  The 
expression of ace1 was used as a control, having not shown altered expression in the 
microarray in any of the three mutants, and the qRT-PCR confirmed this too.  Agt is an 
α-2-globulin that is produced constitutively, with plasma levels increased in response 
to AngII.  It is down-regulated in the fih217/217 embryos, and not in the vhl-/- 
embryos, but where the qRT-PCR results differ from the microarray was that it is 
down-regulated, to a certain degree in the fih217/217;vhl-/- embryos.  This trend was 
also true of the Ace2 gene, confirming the microarray findings.  In order to assess 
other components and isolate these two genes, ace1, renin, aldosterone synthase 
(cyp11b2) and Angiotensin type 1 receptor (at1ar) were also assessed, see Table 15 
and Table 16. 
Ace1 showed no differential regulation in any of the mutants, and the microarray 
suggested that the same was true of Renin, however qRT-PCR showed that Renin was 
up-regulated and to a greater extent in both the vhl-/- and fih217/217;vhl-/- embryos 
compared with the fih217/217.  Slight discrepancies in the qRT-PCR confirmation of 
the microarray data for renin has made it difficult to confirm the microarray inference 
that renin expression was not altered in the fih217/217 embryos compared with wild 
type embryos.  The induction of the RAAS in the model therefore needs to be assessed 
using an alternative gene and/or alternative assays.  Aldosterone synthase, 
downstream effector of the RAAS was down-regulated in all the embryos, to a greater 
extent in the fih217/217 and vhl-/- embryos, inferring a decrease in activation of the 
pathway as the decreased expression of renin.  The Angiotensin receptor is down-
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regulated in the fih217/217 embryos and not the other two mutants, and this might 
connect with the down-regulation of agt/ace2.   
 
6.3.2 The effect of altering the RAAS by addition of chemical inhibitors 
In order to blockade different components of the renin-angiotensin pathway, two 
different RAAS inhibitors were used; Telmisartan (an angiotensin II receptor type I 
antagonist (AT1AR)) and Captopril (an ACE inhibitor).  Embryos were treated from 0dpf 
through to 4dpf at which point the blood flow rate along the aorta was analysed by 
high speed imaging.  Once the concentration of compound was optimised, the results 
were pooled in order to assess the trend, see Figure 94. 
 
 
Figure 94  Graphs illustrate blood velocity and aortic diameter in response to 
telmisartan treatment 
Results of treatment of wild type embryos with Telmisartan (AT1AR receptor 
antagonist) mimic the findings in fih217/217 embryos, embryos exhibit elevated blood 
velocity along the aorta, with a slight but not significant increase in the diameter of the 
aorta.   
 
Increases in velocity observed following treatment with telmisartan phenocopy the 
increase in blood velocity observed in the fih217/217 embryos.  This could be 
suggested to support the hypothesis that AT1AR is a significant receptor in the RAAS 
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and is also suggestive of this being causative in the development of the phenotype.  An 
increase in blood velocity, as shown, would most likely be caused by increased heart 
rate, it therefore follows that if phenocopies are parallel telmisartan also increases 
heart rate, and this would not be expected from a drug used to treat hypertension.  
Captopril is an ace inhibitor known not to directly influence ace2 (Table 13) and this 
was used to compare the results with those observed following treatment with 
telmisartan, see Figure 95.   
 
Figure 95  Graphs illustrate blood velocity in response to Captopril treatment 
Treatment of wild type embryos with the ace inhibitor, Captopril, demonstrated only 
minor effects on blood velocity at the lowest concentration used, to mimic the findings 
of the fih217/217 embryos. 
 
The data from this assay showed that over a range of concentrations none but the 
lowest were capable of inducing an increase in blood velocity along the aorta.  Given 
that the two different drugs have different mechanisms of action in inhibiting the 
RAAS, and that the data from each of the tests does not provide a coherent conclusion.  
The investigation was in to whether or not chemically inhibiting the RAAS has the same 
effect as that seen in the fih217/217 embryos, and without further experiments it is 
currently difficult to draw conclusions on the involvement of the RAAS system in the 
fih phenotype. 
The Kallikrein-Kinin system (KKS) has also been connected with glucose homeostasis, 
with bradykinin stimulation shown in isolated muscle or fat cells shown to improve 
insulin action and glucose uptake by promoting glut4 translocation to plasma 
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membrane .  Increased gluconeogenesis has been shown to be connected with 
increased expression of pepck and glucose-6-phosphatase (G6pase), and bradykinin 
has been shown to decrease hepatic mRNA expression of pepck.  The expression of 
pepck (Figure 70) and glucose-6-phosphate (Table 15) have been shown by qRT-PCR 
and the microarray data not to be dramatically altered in the fih217/217 embryos but 
in the fih217/217;vhl-/- embryos pepck expression is dramatically increased while 
g6pase is down-regulated.  Assessing the levels of bradykinin expression itself, along 
with the expression of pepck and g6pase in response to bradykinin administration in 
the zebrafish could aid in the assessment of the role of bradykinin in gluconeogenesis 
in this model. 
  
6.4 Discussion and Future Work 
6.4.1 Phenotype 
Gross morphological analysis, showed no phenotypes that distinguished fih217/217 
embryos from wild type siblings, and this is consistent with the fact that they are fully 
viable and fertile.   
6.4.2 Vascular Phenotypes and Function 
On the other hand fih mutants showed distinct phenotypes when in a vhl-/- 
background.  However, upon quantifying the features of the vessels in the image 
deletion angiograms, used to illustrate the branching phenotype of the vasculature in 
the vhl-/- embryos as well as the slowing of circulation in the fih217/217;vhl-/- 
embryos, an increase in aortic diameter was observed between the fih217/217 
embryos and wild type siblings.  In addition a surprising increase in the rate of blood 
flow along the aorta was observed in the fih217/217 embryos compared to wild type 
siblings, which could conceivably due to either a slight activation of HIF or a HIF 
independent effect of FIH.   The use of several novel compounds designed to act as 
specific fih inhibitors demonstrated that the same phenotype was observed with 
KKC396 treatment of wild type embryos as that seen in fih217/217 embryos, indicating 
a direct link between the loss of fih and the phenotype.  Since an increase in blood 
velocity could be related to an altered heart rate, this phenotype was also assessed in 
the embryos, and found to be elevated.  Our calculations from velocity and aortic 
diameter suggest cardiac output was elevated in the fih217/217 embryos, however a 
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direct measurement did not give reliable results as it failed to corroborate previous 
findings in the vhl-/- embryos and alternative methods will need to be investigated in 
order to confirm this.  A possible control for the specificity of the compounds would be 
to treat fih MZ mutants with compound, if they are totally specific for fih this should 
not result in any further increase as these embryos don’t have any fih anymore. 
Throughout the imaging for measuring the aortic diameter, blood velocity, heart rate 
and cardiac output of the embryos, the embryos were immobilised in 0.7% agarose 
made up in E3 embryo medium, with low dose tricaine.  This was necessary because 
the high speed imaging for the blood velocity required that the embryos be entirely 
immobile and not twitching throughout the imaging, even though this was only 
seconds in duration.  Tricaine is an anesthetic which is known to affect heart rate 
under long term exposure, slowing it down (Denvir et al., 2008).  For this reason the 
embryos were mounted in agarose in small batches and imaged immediately, ensuring 
that the effect of the tricaine was minimised and standardised across all of the 
embryos that were imaged.  This was an attempt to ensure that any differences that 
were observed between the measurements made in wild type embryos compared to 
fih217/217 embryos were affected to the same degree by the using of the anesthetic.  
Alternative assays which would allow for the quantification of these phenotypes 
without the use of the anesthetic would be worth investigating, such as those 
discussed by Chan et al (Chan et al., 2009).   
The cardiac output assay came across similar difficulties as when attempting to assess 
erythrocyte density, with the same caveats in the data.  The imaging required the mild 
and brief sedation of the embryos and mounting them on coverslips in low-melt point 
agarose.  If the mounting was slightly less than identical for each embryo this resulted 
in slight alterations in the angles at which the embryos were lying and slight changes in 
the focus around the ventricle of the heart as it was being imaged, resulting in built-in 
error, which over multiple embryos resulted in the data indicating changes in cardiac 
output that didn’t confirm data previously published for the vhl-/- embryos (van 
Rooijen et al., 2009).  Time scale for these assays only overlaps at 4 and 5dpf, however 
an fold increase in cardiac output is still indicated by Rooijen et al, which is not seen in 
the data from this study.  Alternative assays, such as laser scanning velocimetry 
(Malone et al., 2007) or the high-speed imaging technique optimised by Schwerte et al 
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(Schwerte et al., 2006), would be needed in order to further investigate the difference 
in cardiac output in these embryos.  Anesthetic immobilisation of the embryos, which 
is known to affect cardiac function and blood flow rates (Denvir et al., 2008), was still 
necessary for each of these assays, and would need to be taken into account to ensure 
consistency of the results.  
 
6.4.3 Lipid Metabolism 
Carboxyl ester lipase is a key regulator of lipid nutrient absorption.  Mice with null 
mutations in both carboxyl ester lipase and pancreatic triglycerate lipase gained a 
significant amount less weight on a high fat diet compared with wild type mice (Gilham 
et al., 2007).  This lack of weight gain was proposed to be due to their absorption of 
few calories from the high fat diet (HFD) resulting in less fat mass accumulation 
(Gilham et al., 2007).  The investigation of other genes involved in lipid and fatty acid 
regulation/transport, showed that adiponectin family genes were only slightly down-
regulated in the fih217/217 embryos, while fabp family genes were up-regulated in all 
the embryos (fih217/217, vhl-/- and fih217/217;vhl-/- embryos).  The significant down-
regulation of carboxyl ester lipase and the connection between the null-mutation in 
the mouse and HFD weight gain protection is suggestive of this gene playing a role in 
the HFD weight gain protection observed in Fih-/- mice, and could be worth further 
investigation.  Since the fih217/217 animals reach maturity, it would be possible to 
raise zebrafish, ensuring the same raising density and sex ratio, on normal and high fat 
diet and assess for such things as weight gain and lipid distribution using Oil-Red-O 
staining techniques, in conjunction with qRT-PCR to assess gene expression changes.  
6.4.4 Activity 
One of the phenotypes observed in the Fih-/- mice was a hypoactive phenotype during 
the dark cycles, when mice are characteristically more active.  The acquisition of the 
Zebralab system for observing and tracking zebrafish larvae movement allowed for this 
phenotype to be assessed in the fih217/217 fish, and several phenotypes were 
observed.  Surprisingly the activity levels of the fih217/217 embryos were higher than 
that in the wild type embryos.  Such short light:dark cycles during a normal “fish 
daytime” could be perceived as a predator shadows (Fleisch and Neuhauss, 2006, Li 
and Dowling, 1997), to assess the zebrafish larval behaviour in normal day:night cycle 
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the lights were adapted to simulate those in the aquarium 14hour light and 10 hour 
dark.  Instead of the decrease in activity seen in the Fih-/- mice, an increase both in 
duration of swimming and distance swum was seen in the zebrafish embryos, both in 
the light and dark compared with wild type embryos.  Given the proposal that the loss 
of Fih induces a hypermetabolic phenotype in the mouse (Zhang et al., 2010) the 
increase in activity profile is in keeping with the hypothesis, both in terms of total 
activity and the increase in activity in response to the light being switched off.  
However, the mouse study exhibited a hypoactive phenotype in their assay, lending 
discrepancies between the two models.  The preliminary assays to measure ATP and 
cholesterol also indicate corroboration for the hypermetabolic phenotype of 
fih217/217 zebrafish embryos; however both of these assays will need to be repeated 
to confirm the results.  As a potential explanation for the discrepancy in the mouse and 
fish activity data, the Fih null mice, assuming that they are hypermetabolic might not 
necessarily be in a position to use the excess energy as they’ve been shown to release 
more heat than their wild type siblings (Zhang et al., 2010), potentially explaining their 
not having an increased activity level.  The zebrafish being ectothermic means that 
excess energy produced isn’t released as heat and this could mean that their activity 
levels are more likely to correlate with excess energy than those seen in the mouse.   
6.4.5 Metabolism 
The connection between hyperactivity and metabolism has been made in the 
literature in multiple contexts and models, including a model of Pgc-1α-/- mice.  These 
mice exhibit constitutively active gluconeogenic enzyme activation and are 
paradoxically lean and resistant to diet induced obesity due to hyperactivity (Lin et al., 
2004).  These phenotypes are consistent with those that were observed in the Fih-/- 
mice, although no changes were observed in Pgc-1α in these animals (Zhang et al., 
2010).   
6.4.6 Blood Flow Rates 
An elevated blood flow velocity phenotype was identified, in fih mutants, with altered 
expression of RAAS genes agt and ace2.  In adult physiology the RAAS plays critical 
roles in cardiovascular control and therefore in cardiovascular disease pathogenesis 
(Basso and Terragno, 2001, Bader, 2010, Jacoby and Rader, 2003).  Angiotensinogen is 
produced in the liver and released and cleaved into active Angiotensin I by Renin, 
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which is produced in the kidneys (Bader, 2010), making renin the initial rate limiting 
enzyme in the pathway.  Angiotensin I is further cleaved by Ace enzymes 1 and 2 to 
release Angiotensin II and other breakdown products. These bind to Angiotensin 
Receptors in various tissues in order to exert various effects, such as the kidney 
(sodium retention, fibrosis), adrenal gland (aldosterone release), heart (inotropy, 
chronotropy, hypertrophy, fibrosis), vessels (constriction, hypertrophy) and brain 
(thirst, salt appetite, sympathetic activation, vasopressin release) (Bader, 2010).  In 
adult humans decreasing the activity of the RAAS results in decreasing tension of blood 
vessels and blood volume and an overall reduction in blood pressure as a result, a 
result that is achieved pharmaceutically with ACE inhibitors in the treatment of 
hypertension (Aronow, 2012).  Since fish embryonic circulation may be regulated quite 
differently (for instance there are no vascular smooth muscle cells around the vessels 
at 4dpf (Santoro et al., 2009)) wild type embryos were treated with various ace 
inhibitors in order to explore the connection between the down-regulation of agt and 
ace2 and the blood velocity phenotype in the fih217/217 embryos.   
Further investigation using both of these drugs (Telmisartan and Captopril) in 
combination with other drugs used in the regulation of the RAAS could provide further 
confirmation of the interactions between the loss of fih and the down-regulation of 
agt and ace2 in the zebrafish.  There is also the possibility of using these drugs and 
following up on other phenotypes that have been observed, such as the influence on 
activity levels.  The possibility of attempting to rescue the phenotypes by administering 
ace2 to fih217/217 embryos, or identifying a method for measuring the concentration 
of Ang(1-7) in the fih217/217 embryos, would also be worth pursuing.  Two classes of 
drugs were tested, an ace inhibitor and an ace receptor antagonist. Other drugs within 
these classes, as well as other drugs known to influence the pathway, need to be 
tested to further investigate these effects.   
Observation of the RAAS pathway diagram indicates that in the absence of Ace2 to 
convert AngI to Ang(1-9), AngI will instead be converted into AngII, due to the 
presence of Ace1.  However, the hypothesis that the aortic vasodilation that was seen 
in the fih217/217 embryos compared to wild type could be regulated by this pathway, would 
indicate that AngII (known to induce vasoconstriction through interactions with Agt1AR) is not 
being over-produced.  The pathway was assessed again and the alternative arm of the 
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pathway, for the conversion of AngI to Ang(1-7) (which induces vasodilation through 
interaction with Mas receptor) was assessed.  In the absence of Ace2, Pep is present to 
convert AngI to Ang(1-7) and that this breakdown product has been shown to signal 
through the Mas receptor and induce vasodilation, antagonising the AT1AR leading to 
increased NO production and an increase in blood flow.  This is the phenotype that is 
seen in the embryos, and so this correlates with the findings.  However, the increases 
in diameter and heart rate that have been shown in this study between the wild type 
and fih217/217 embryos is small and while increased NO has been shown to cause 
vasodilation in the zebrafish it has over time been shown to be stronger in vhl-/- 
embryos compared to fih217/217 embryos, indicating an alternative method of 
regulation (Rooijen E,. pers comm.).  In this case, it could be suggested that in vhl 
mutants, vessel diameter increases more strongly than fih mutants, while heart size 
remains similar.  The down-regulation of ace2 and agt together in the fih mutants 
could be affecting the conversion of angiotensin to Ang(1-7) more strongly than to 
AngII and might thus provide net vasoconstrictive effect in vhl mutants (albeit still 
vasodilated relative to wild type and explaining the vasodilation in the fih mutants).  
Sequencing studies have shown that the zebrafish do not have a Mas receptor 
homologue (Alenina et al., 2008), indicating that if Ang(1-7) is produced in the 
zebrafish it is likely to be signaling through a different receptor in order to induce 
these phenotypes, if indeed there is a connection.  The literature was assessed for 
studies of the effect of down-regulation or loss of these and other members of the 
RAAS.  The data from several of these studies has been summarised in Table 19. 
 
  Agt-/- mice AT2AR-/- mice AT2AR-/- mice 
 Author (Kim et al., 
2002) 
(Yvan-Charvet 
et al., 2005) 
(Kouyama et al., 
2005) 
02 consumption and CO2 
evolution 
  Decreased 
light 
Increased 
Water and Food Intake Increased No change   
Total energy expenditure   Increased   
Activity Levels Increased   Increased on HFD  
Lipid oxidation   Decreased   
Heat production     No change 
UCP genes Increased Increased   
Glucose clearance   Increased Increased 
Insulin sensitivity No change Increased Increased 
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RER     Increased 
RQ   Decreased Decreased 
Mass/body weight Decreased No change No change 
Fat mass Decreased     
Adipocyte size and lipid 
droplet number 
Decreased Decreased No change on NFD 
but Decreased on 
HFD 
Adipose tissue mass     Decreased 
Cholesterol and 
triglyceride 
Decreased     
FAS activity Decreased Decreased   
Fed Insulin levels   Decreased   
Blood pressure     Decreased 
Weight gain on HFD Decreased Decreased Decreased 
Blood glucose No change No change No change 
Table 19 Table describes a summary of findings from several studies of the 
individual knock-out of angiotensinogen (agt) and angiotensin type2 receptor (AT2AR) 
in mouse.   
 
Mouse knockout models of renin (Takahashi et al., 2007), ace (Jayasooriya et al., 2008) 
and ace2 (Niu et al., 2008) have also been investigated.  These studies, while 
investigating many of the same features as those indicated in Table 3, didn’t assess any 
of the same features as had been assessed in the fih217/217 zebrafish model, making 
interpretations between these difficult.  The increased activity level observed in the 
Agt-/- mouse does, however, correlate with observations in the fih217/217 zebrafish 
where agt is down-regulated.  This provides preliminary support for a hypothesis that 
the decrease in agt expression observed in the fih217/217 embryos was correlated 
with the phenotypes that have been characterised to differentiate the wild type 
embryos from the fih217/217 embryos, while leaving scope for further investigation 
into how this is achieved. 
Different axes of the RAAS have been shown to affect different outcomes and the 
Ang(1-7) breakdown product of angiotensin has been shown to signal through the Mas 
receptor.  Mas receptor knockout mice have been assessed for some of the same 
phenotypes as those from renin, at2r, ace and ace2 knockout mice.  The findings from 
two such Mas-/- mouse papers has been summarised in Table 20. 
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  Mas-/- mice Mas-/- mice 
  (Santos et al., 2006) (Lemos et al., 2005) 
Heart Rate   Decreased 
Activity Levels   Increased (anxiety) 
Glucose clearance Decreased   
Insulin sensitivity Decreased   
Mass/body weight No change   
Fat mass Increased   
Adipocyte size and lipid 
droplet number 
No change   
Cholesterol and triglyceride Increased   
Blood pressure   Decreased (male) 
Increased (female) 
Fasting glucose or insulin Increased   
Table 20 Table describes a summary of findings from several studies of the 
individual knock-out of mas receptor in mouse.   
 
Again the observations in these studies were into the same phenotypes as had been 
assessed in the Agt-/- mice, however the Mas-/- mice exhibits a decreased heart rate, 
the opposite to that seen in the fih217/217 zebrafish and making the hypothesis that 
this alternative RAAS axis was being utilised difficult to corroborate.  The increased 
cholesterol as well as increased activity levels does correlate, however, suggesting that 
further investigation, into targeted inhibition of the pathway might aid in further 
characterising the phenotypes directly connected with this.  After the Mas receptor 
was not found in the microarray and, using Ensembl genome database it was possible 
to investigate this and the Mas receptor does not have a zebrafish homologue (Alenina 
et al., 2008).  In this case, if Ang(1-7) was being produced following the loss of ace2, 
rather than producing increased levels of AngII due to the continued presence of ace1 
then the Ang(1-7) in the zebrafish could be seen to be interacting with an alternative 
receptor.  Investigation into selective knock-down of the different receptors of the 
RAAS, might elucidate the exact interactions, and which arm of the pathway, if any, is 
responsible for inducing the increased heart rate observed in the fih217/217 zebrafish.  
There are reports in the literature which connect the use of ACE inhibitors in 
hypertension and heart failure with increased levels of Ang(1-7) through bradykinin-
dependent mechanisms (Tom et al., 2003).  The direct mechanism of Ang(1-7)-
bradykinin induced vasodilation has been proposed to be that Ang(1-7) acts as a 
211 | P a g e  
 
localised synergistic modulator of kinin-induced vasodilation by inhibiting ACE and 
releasing NO (Li et al., 1997, Tom et al., 2001, Oliveira et al., 1999).  Further 
investigation specifically inhibiting individual components of the Kinin-Bradykinin 
pathways (using morpholinos, for example) would allow for the investigation of which 
receptor might be regulating downstream effects such as vasodilation and blood 
velocity.   
Angiotensin II (AngII) is the major effector of RAAS, and is a powerful vasoactive 
mediator associated with hypertension and renal failure.  The role of Vegf on the 
permeability changes in the vasculature have been described in Chapter 9, AngII has 
also been implicated in the permeability of the vasculature (Bodor et al., 2012).  AngII 
can stimulate the release of other vasoactive and pro-inflammatory cytokines, 
increased leukocyte rolling, adhesion and migration in rat mesenteric post-capillary 
venules (Bodor et al., 2012).  VEGF induces fenestrate formation in vivo and in vitro 
and increase in plasmalemmal vesicle-1 (PV-1), which has been shown to be correlated 
with disruption of blood-brain barrier in the ischemic brain and with micro-vascular 
leakage in diabetic retinopathy (Bodor et al., 2012).  Cell surface openings have been 
shown to increase in parallel with permeability and the development of fused vesiculo-
vacuolar structures or vaeolae or both.  AngII plays a role in regulating these cell 
surface openings through AT1AR and PV-1 protein synthesis in a p38 MAP kinase-
dependent manner (Bodor et al., 2012).  The connection between the RAAS and VEGF 
in regulating micro-vascular leakage indicates another avenue of investigation into the 
vessel competence in the fih217/217;vhl-/- embryos and suggests that vascular 
competence might be worthy of testing in the fih217/217 embryos.  If AngII is indeed 
being over-produced due to the loss of ace2 in the fih217/217 embryos and this does 
result in increased cell surface openings, then the injection of fluorescent dyes into the 
circulation may reveal this upon observation of the leakage of the dye from the 
vessels, an experiment which has not been performed at late states, to date.   
The ACE2 gene was identified from 5’ sequencing of a cDNA library of human heart 
failure patients.  It was shown to have a single matrix metalloproteinase (MMP) active 
site (with 42% homology with ACE) and a transmembrane domain, with more 
restricted expression than ACE (Donoghue et al., 2000).  As well as hydrolysing 
carboxyl terminal leucine from AngI to generate Ang(1-9), ACE2 also cleaves des-Arg 
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Bradykinin and neurotensin, but not bradykinin or several other vasoactive and 
hormonal peptides.  These findings along with those connecting the beneficial effects 
of ACE inhibitors with both a decrease in ACE and subsequent decrease in AngII with 
an increase in kinin levels and the levels of both B1 and B2 type bradykinin receptors 
(Erdos et al., 2010).  ACE inhibitors have been shown to potentiate bradykinin and ACE-
resistant bradykinin analogues through enhancing interactions on the cell surface and 
lead to elevated arachidonic acid and NO release in vitro (Erdos et al., 2010).  The 
connection between ACE and Bradykinin family regulation lead to the assessment of 
these family member genes in the microarray data set.  The literature indicates that a 
decrease in ACE leads to a subsequent increase in both kinin and both types of 
bradykinin receptor.  The microarray data however, indicate that any alterations in 
expression of bradykinin family members were small and seem unlikely to be relevant 
to phenotypes seen in this study.   
The data from this study supports several of the findings that were reported in the 
study by Zhang et al of the Fih-/- mouse.  They add information on the effect on blood 
velocity and vessel diameter, along with putting forward a possible mechanism for 
initiating these phenotypes (the RAAS).   
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7 Discussion 
The initial hypothesis was that the loss of fih alone would have no effect on the 
phenotype of the embryos compared with wild type, rather its loss in combination 
with vhl would further sensitise the system and enhanced features of the vhl null 
mutants.  This hypothesis was provided with support when features such as vascular 
branching and heart rate were exacerbated in the fih;vhl double mutants, compared 
with the vhl only mutants, where the fih null mutants showed no distinguishing 
features compared with wild type.   
The hypothesis, suggested by Lee et al, (Lee et al., 2003), that VHL is necessary in the 
formation of the complex between VHL, HIF and FIH, implied that the loss of fih in an 
individual that had lost vhl function, would result in no alteration in the phenotypes 
observed.  This hypothesis is not supported by the data from this thesis.  
FIH is an asparaginyl hydroxylase, characterised for its interaction with HIF and 
subsequently shown to have many more substrates.  The identification of the fihi217 
zebrafish mutant provided a tool for assessing the role of fih in HIF signaling, and also 
enabled the function of fih in other related pathways to be investigated.   
Preliminary hypotheses that the loss of fih and the loss of vhl would have distinct 
downstream effects on overall levels of HIF-signaling due to their different roles in Hif-
α regulation (inhibition of activity versus targeting for breakdown)(Lancaster et al., 
2004), were supported by the data from this study.  The homozygous loss of vhl in the 
zebrafish results in embryonic lethality before 15dpf, indicating that Vhl protein is 
essential to ensure HIF-α breakdown.  In the zebrafish embryo, the loss of vhl induces 
expression of HIF-signaling targets along with downstream effects such as increased 
buccal movement, cardiac output and heart rate as well as angiogenesis, and 
erythropoiesis (van Rooijen et al., 2010, van Rooijen et al., 2009).  However, 
homozygous fih null zebrafish are fully viable and fertile, confirming that the functional 
inhibition of Hif-α by fih provides a secondary mechanism of control that is most 
necessary only in the absence of vhl.   
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The direct interaction between HIF-α, FIH and VHL during HIF-α regulation has 
generated multiple modelling opportunities in vitro and these have agreed that it is at 
least possible, if not necessary, for the three proteins to interact.  In 2003 Lee et al 
proposed that a complex formed in hypoxia between the FIH dimer, VHL and HIF-α, 
with FIH acting as a bridge bringing together the association between VHL and HIF-α 
(Lee et al., 2003).  Later, in 2011, a secondary bridging model was proposed with HIF-α 
acting as a chaperone for FIH-VHL interactions, which in turn were proposed to allow 
FIH-HIF-α binding (Li et al., 2011b).  The proposal here is that in hypoxia the FIH-VHL 
complex disassembles, following stabilisation of HIF-α by VHL binding to the ODDD, 
decreasing FIH-TAD-C binding (Li et al., 2011b).  The fih and vhl mutant zebrafish 
provide a model for assessing the downstream HIF-signaling following the loss of 
either or both of these genes.  The loss of fih alone caused little increase in the 
expression of HIF target genes compared to wild type, the loss of vhl alone caused an 
increase in target gene expression, while the loss of both caused a further increase in 
expression.  If, as has been proposed by (Lee et al., 2003), FIH was a necessary 
chaperone for the interaction between VHL and HIF-ODDD, then its loss in the 
zebrafish could be thought to mimic that seen in the absence of vhl itself, which was 
not seen.  The model in Li et al (Li et al., 2011b) provides an alternative, suggesting an 
interaction that correlates more with the model in Lancaster et al (Lancaster et al., 
2004) that VHL provides the predominant control over HIF function, inhibiting FIH 
interaction with HIF-α (Li et al., 2011b).  The step-wise increase in HIF target gene 
expression in response to the loss of first fih then vhl then both makes it difficult to see 
how a model that would necessitate all three proteins interacting in order to inhibit 
HIF-α enough to induce signaling difficult to interpret, these data would rather suggest 
that fih and vhl are simply two levels of regulation. 
In the investigation of fih independent effects and through the early stages of the 
investigation there were no measurable differences between fih217/217 embryos and 
their wild type siblings, their overall shape, vascular patterning, endothelial cell 
number, and expression of classical HIF target genes were all consistent.  These 
features were altered, where fih was lost in a vhl background, and this would indicate 
that fih is acting predominantly on HIF and that other substrates are secondary.  One 
situation where the loss of fih did not exacerbate a previously observed phenotype of 
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the vhl-/- embryos was in the vascular patterning in the tail.  Instead, the loss of fih 
caused large extra loops of ISVs up and over the DLV to resolve to appear more like 
wild type.  The hypothesis that this might be regulated by flow rates in the vessels 
determining their arrangement and remodeling constitutes a separate and worthy 
area of study (Oliver. Watson. pers. Comm.).   
It has been shown that FIH has many more substrates besides HIF-α (Cockman et al., 
2009, Coleman et al., 2007).  There have been several studies to investigate the 
interactions of FIH, within and between the different pathways that these 
hydroxylation events potentially connect.  Models have been proposed to indicate that 
the multiple hydroxylation partners of FIH (including Notch (Zheng et al., 2008) and IκB 
(Shin et al., 2009)), have higher binding efficiencies, in comparison with FIH-HIF 
binding, and are therefore capable of sequestering FIH away from HIF.  The 
preferential binding of FIH to proteins other than HIF-α has been proposed as a 
mechanism of relieving FIH inhibition on HIF-α through the sequestering away to other 
proteins such as Notch/NICD.  The prevalence of FIH-binding partners, however, makes 
these models difficult to pin to one specific interaction in vivo.  There was no effect of 
the loss of either fih or vhl or both on the expression of IκB, NFκB or indeed those 
down-stream target genes that could be identified (which might have been supposed 
to increase in expression), to indicate a response.  However the effect of fih is 
suggested to be post-translational and therefore further investigation could elucidate 
interactions between the proteins in vivo. 
The proposed interaction between FIH and Notch/NICD provided an avenue of 
investigation since the Notch signaling pathway has been implicated in arterio-venous 
fate choice in the developing vasculature, as well as in the determination and 
maintenance of tip-cell/stalk-cell balance in the remodeling vasculature.  In the 
zebrafish, it had been shown that following inhibition of notch using chemical 
inhibitors such as DAPT, or morpholinos specific to dll4, the vasculature took on a 
hyper-branched appearance through the loss of lateral inhibition of tip-cells which is 
normally provided by dll4 (Leslie et al., 2007).  FIH hydroxylation of Notch is proposed 
to enhance signaling and so its loss should result in a decrease in efficiency and might 
therefore be expected to simulate, to some extent, the increased branching of the 
vasculature seen by Leslie et al.  This was not the case in the fih217/217 embryos, 
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however in the fih217/217;vhl-/- embryos the vasculature exhibited an increase in 
branching compared with vhl-/- embryos, indicating an effect of the loss of fih on these 
embryos.  This effect cannot be confirmed as being regulated by fih independent of 
alterations in Notch signaling as there is a concurrent increase in vegf family gene 
expression, and this will require further investigation to identify the independent roles.   
The release of the study describing the metabolic phenotypes of the Fih mutant 
mouse, published after the start of this current PhD project, provided an alternative 
avenue of investigation, and some surprising results (Zhang et al., 2010).  It was 
possible to assess several of the same features as those assessed in the mouse model, 
and find the correlations between the two data sets.  The role of Fih in regulating 
metabolic rather than HIF-regulated phenotypes had not been reported, and the 
investigation of heart rate and activity were within the scope of the zebrafish study.  
Following the investigation of the heart rate, vessel diameter and cardiac output in the 
zebrafish embryos, which followed that done in the vhl-/- embryos, the observation 
was made that the fih217/217 embryos exhibited an elevated heart rate and vessel 
diameter compared to wild type siblings.  This was found to be specific to the loss of 
fih by the use of a hydroxylase inhibitor which had been designed to be specific to fih.  
A tool that would provide alternative controls for this experiment along with others is 
the fih;pcs2+ construct.  This was not mentioned through the text as time constraints 
meant that it was not used during this project. It provides opportunities in the future 
for using it as an expression construct, for re-introducing fih into fih null embryos and 
observing the rescue of phenotypes, however, and this work will be ongoing.  The 
elevated heart rate, increased aortic diameter and hyperactivity provided observations 
that distinguished the fih217/217 embryos from wild type siblings, and a connection 
with the mouse study.  Zhang et al. suggest that Fih could provide a unique mechanism 
for regulating metabolism, which they imply could be independent of HIF signaling.   
The whole embryo microarray performed in the fih217/217 mutant zebrafish yielded 
two candidate downstream genes (agt and ace2), which were not identified in the 
mouse study.  The two genes were down-regulated only in the fih217/217 zebrafish 
and not the vhl-/- embryos or the fih217/217;vhl-/- embryos (at least not to the same 
extent as the single).  These genes provided a connection to one pathway, the renin-
angiotensin-aldosterone system, which plays roles in fluid homeostasis and as such 
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affects vascular tone (dilation/relaxation) as well as circulating fluid volumes.  While 
investigations into the exact connection between these genes being down-regulated 
and the increased vessel diameter and heart rate that have been seen in these 
embryos are preliminary it does suggest that the connection may be relevant and that 
one fih independent role is in regulating the RAAS.   
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